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ABSTRACT 
RNA interference (RNAi) is a highly conserved pathway in many eukaryotic organisms which 
has been recognised as a promising technique to suppress the expression of target genes in a 
sequence specific manner. Exogenous promoters such as the RNA polymerase III promoters 
can be used to express short hairpin RNA (shRNA) to induce RNAi. However, previous studies 
reported that the high levels of shRNA expression driven by strong exogenous RNA pol III 
promoters (for example U6 and H1) can lead to in vivo toxicity as a result of the over-saturation 
of natural micro RNA (miRNA) pathway. To date, very few studies have looked into the 
development of shRNA expression strategies that enable more natural levels of RNAi 
expression while retaining a high level of target suppression.  
This thesis examines the development of a “hitch-hiking” approach; which involves the 
assessment of parallel processing of an exogenous shRNA when positioned adjacent to a native 
miR-107 (microRNA-107). The miR-107 was identified as a universally expressed miRNA 
located in the intron 5/ of pantothenate kinase 1 (PANK1) gene. An adjacent site was selected 
and used to analyse the expression of individual shRNAs in different backbone structures in a 
plasmid construct containing the intron 5 of PANK1 with miR-107. Next, shRNAs targeting 
particular influenza genes were precisely integrated into one or both alleles of PANK1 locus 
using Zinc Finger Nuclease (ZFN) mediated and homology directed repair (HDR) in chicken 
fibroblast cell line DF-1. The shRNA expression and reporter based knockdown of 
corresponding gene targets was confirmed in ZFN modified DF-1 cells. The ZFN modified 
DF-1 cells with (single or double shRNAs) were tested for resilience to influenza infection in 
comparison to the unmodified DF-1 cells.   
A multi-war-head (MWH) system was engineered into intron 5/PANK1 gene to enable the 
insertion of three anti-influenza shRNAs. The characterisation of the MWH system was 
performed in both plasmid construct and by insertion into the chicken genome in DF-1 cells, 
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and the resilience to influenza infection was examined. Moreover, the Tol2 transposon system 
(Tol2) was used to deliver the hitchhiker constructs (intron 5 with shRNAs) into the chicken 
genome.  Initially, the Tol2-Intron constructs (single and MWH) were characterised in DF-1 
cells for shRNA expression and reporter based gene knockdown analysis. One of the Tol2-
Intron construct was then applied in vivo to assess the toleration of such expression in the germ-
line specific cells in the developing chicken embryo.  
In order to achieve the “hitch-hiking” expression of antiviral shRNAs in a living chicken, it is 
necessary to apply precision genome engineering (PGE) tools to bring about the accurate 
insertion of the shRNA sequences in primordial germ cells (PGCs). Evaluation of emerging 
PGE tools such as Transcription activator like effector nuclease (TALEN) and clustered 
regularly interspaced short palindromic repeat (CRISPR) CRISPR-associated (Cas9) systems 
in DF-1 cell line and primordial germ cells (PGCs) was performed by targeting a genomically 
integrated green fluorescent protein (GFP) gene. The creation of mutations and deletion of a 
section of the integrated GFP gene in the chicken PGCs was demonstrated. The HDR of the 
targeted GFP gene by red fluorescent protein (DsRed) gene was performed to calculate the 
efficiency knockout/in in DF-1 cells and PGCs. However, the CRISPR/Cas9 driven HDR in 
cultured PGCs was observed at very low efficiency. The re-migration of these modified PGCs 
into the embryonic gonad was confirmed by microscopy. In addition, the possibility of 
multiplex genome engineering by simultaneously targeting two genes (GFP & PANK1) in the 
chicken genome was demonstrated. 
In conclusion, this thesis has demonstrated a novel shRNA expression strategy by hitchhiking 
on the intronic miRNAs with minimal transgene insertion and that avoids the need for 
exogenous promoters. The study further demonstrates the successful application of 
CRISPR/Cas9 system in cultured chicken PGCs, which opens up many new opportunities in 
chicken transgenic research.
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CHAPTER 1:  LITERATURE REVIEW 
1.1. General introduction  
Transgenic animal technology is an exciting and emerging technology with the potential to 
counter a range of problems related to food production; particularly the diseases of the animals 
in those production systems. This study was instigated from the fact that existing technologies 
(for example RNAi) utilise large transgene constructs that contain multiple regulatory 
sequences that are randomly delivered into the genome of organisms, have toxicity issues. In 
addition, current transgenic technologies have significant downstream consequences affecting 
public and gene regulatory authority acceptance of genetically modified organisms (GMOs). 
Therefore, there is a need for the development of an efficient and reliable technology to acquire 
regulatory acceptance of transgenic animals used to feed a rapidly growing world population. 
While there has been approval of one food animal carrying a significant transgene (the 
AquaAdvantageTM Salmon), there is much debate in international forums regarding the 
relative acceptability of gene edited food animals compared to transgenic animals. This relates 
both to the regulatory approval and the public acceptance of these materials and is a complex 
issue that may take years, even, decades, to fully resolve. This study aims to develop novel 
strategies to mediate transgenesis by using minimal transgene (for example just the antiviral 
shRNAs) sizes through the precise genome engineering at specified locations using engineered 
nucleases. Additionally, the study also develops a unique approach to make use of the natural 
RNAi processing machinery for the parallel processing of anti-viral shRNAs that are positioned 
adjacent to a native miR-107 in the chicken genome. This is a unique approach in which the 
miRNA biology, RNAi and transgenic technology are brought together in a transgenic chicken 
model system, with an ultimate objective to generate a chicken that is resistant to viral disease, 
in this case avian influenza (AI) virus. 
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1.2. History and discovery of RNAi  
In the early years of molecular biology, the role of ribonucleic acid (RNA) in biological 
processes was considered as an intermediary molecule with the potential to decode the 
deoxyribonucleic acid (DNA) for functional protein synthesis through messenger RNA 
(mRNA) (Chamberlin and Berg, 1962). In addition, RNA molecules such as ribosomal RNA 
and amino acid (aa) transfer RNA catalyses the protein synthesis. However, prior to the 
development of advanced sequencing technologies, researchers have characterised several 
gene regulatory mechanisms at the RNA level which lead to the discovery of many influential 
tools in biology. For instance, in an attempt to enhance the intensity of coloured flowers, the 
chalcone synthase gene (CHS) was over-expressed in petunia plants. Surprisingly, the over 
expression of CHS gene had negative effects on the corresponding pigmentation and produced 
white coloured flowers through “co-suppression” (Napoli et al., 1990). Similar findings were 
observed on two other endogenous genes when homologous RNA sequences were introduced 
into the fungus Neurospora crassa, and described the biological effect as the “quelling” 
mechanism (Romano and Macino, 1992). A few years later, the first evidence of sequence 
specific gene silencing was observed in Caenorhabditis elegans by introducing either sense or 
anti-sense RNA against the par-1 gene. However, the authors were unable to conclude if it was 
the sense or anti-sense RNA that conferred the silencing (Guo and Kemphues, 1995).  
Building upon these reports, Fire et al. (1998) demonstrated the introduction of double-stranded 
RNA (dsRNA) can trigger the gene silencing mechanism by degradation of mRNA in a 
sequence specific manner. In addition, the authors reported the direct comparison of the 
silencing efficacies of the sense and anti-sense single stranded (ss) RNA compared to dsRNA, 
and showed that the ssRNAs (either sense or anti-sense) were less efficient than dsRNA in 
silencing the mRNA. This was the turning point for the discovery of the RNA interference 
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(RNAi) mechanism, often called post-transcriptional gene silencing or more simply “gene 
silencing” which has become a powerful tool to study genes in both animals and plants. This 
emerged as arguably the most important discovery in the field of molecular biology since the 
discovery of DNA.  Further studies have discovered that the RNAi mechanism plays a vital 
role in eukaryotic gene functions including viral defence (Obbard et al., 2009), heterochromatin 
maintenance (Hall et al., 2002; Volpe et al., 2002) and transposon control (Obbard et al., 2009; 
Sabin et al., 2013). The ease with which this RNAi mechanism can be utilised to target virtually 
any gene of interest (GOI) with high specificity has opened doors for the study and treatment 
of diseases that were previously considered as ‘undruggable’. Due to its potential to treat 
genetic, heritable and infectious diseases, up to 22 RNAi-based treatments have progressed to 
various stages of clinical trials (Burnett et al., 2011; Kanasty et al., 2013; Kubowicz et al., 
2013). 
1.3. RNAi mechanism   
The early characterisation of the RNAi pathway has been established such that the dsRNA 
molecules are the key source to trigger RNAi (Fire et al., 1998). However, the demonstration 
of RNAi pathway through 21-22 nucleotides (nt) small interfering RNAs (siRNAs) in plants 
(Hamilton and Baulcombe, 1999), Drosophila (Zamore et al., 2000) and mammalian cells 
(Elbashir et al., 2001) was one of the key breakthroughs in the field of RNAi. Since then, 
several studies focused on revealing the molecular mechanism by which siRNA induce targeted 
mRNA degradation.  
The mechanism of RNAi involves two critical steps; the initiation and effector steps (Fig.1.1). 
In the initiation step, the process begins with the recognition of dsRNA by a protein complex 
containing a dsRNA-binding protein; Rde-4 (Parker et al., 2008). This is followed by  
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Figure 1.1. Schematic representation of RNAi pathway. Modified and adapted from 
Cullen (2005).  
Endogenous RNAi begins with the transcription of hairpin RNA from genomic loci in the 
nucleus. This is subsequently processed by Drosha complex to generate pre-miRNAs. 
Similarly, artificial RNAi induction begins with transcription of shRNA or pre-miRNA mimics 
containing the artificial siRNA sequences from DNA vectors when introduced into the cells. 
The cellular machinery transcribes the shRNA sequences to form RNA hairpin transcripts. The 
hairpin RNA transcripts undergo cleavage by Drosha to produce pre-miRNAs. These pre-
miRNAs are then recognised by Exportin-5 (Xpo-5) and exported to the cytoplasm. In the 
cytoplasm, Dicer cleaves the pre-miRNA to produce miRNA duplex with 2 nucleotide 3' 
overhangs. The artificial synthetic siRNAs will enter into the RNAi pathway in this step. The 
siRNA’s are incorporated into RISC, followed by unwinding of siRNA strands by the helicase 
activity of RISC. The anti-sense strand incorporated in the RISC recognises and mediates the 
target mRNA degradation. 
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processing of the dsRNA by a multidomain ribonuclease, Dicer (Bergeron et al., 2010); a 
member of Ribonuclease III (RNase III) family which specifically cuts long dsRNA into 21-
22 nt small interfering RNAs (siRNA) (Ji, 2008). In the effector step, the siRNA duplex 
assembles with a ribonucleoprotein complex, called RNA-induced silencing complex (RISC) 
in two steps (a) RISC loading and (b) unwinding (Kawamata and Tomari, 2010). The siRNA 
duplex associates with Argonaute (Ago) family member to form ‘pre-RISC’ for target sequence 
recognition (Betancur and Tomari, 2012), and separated into two single strands; the guide 
strand and passenger strand (Rand et al., 2005). The unwinding of siRNA is an ATP-dependent 
reaction and occurs prior to the target recognition (Nykanen et al., 2001). Finally, the guide 
strand is incorporated into RISC and that directs it to the mRNA molecules containing 
complementary target sequence. Once loaded into the RISC, it directs the cleavage of the target 
mRNA and stops the synthesis of the protein (Cullen, 2005).  
1.3.1. RNAi - Natural activity  
In eukaryotes, the majority of the non-protein coding regions in the genome encode introns and 
other noncoding (nc) RNAs or nc small RNAs, and were known to have diverse cellular 
functions. Amongst these, the miRNAs are one of the abundant and widely studied endogenous 
nc small RNAs families that regulate gene expression (Hannon, 2002; Cullen, 2005). MiRNAs 
exhibit high tissue and developmental expression specificity. The schematic representation of 
miRNA biogenesis and RNAi pathway is shown in figure 1.1.  
Natural miRNAs are transcribed by RNA polymerase (pol) II (Lee et al., 2004) or RNA pol III 
promoters (Borchert et al., 2006) to produce primary miRNA (pri-miRNA) transcript with a 
characteristic stem-loop structure. Pri-miRNAs undergo endo-nucleolytic cleavage by RNase 
III enzyme Drosha and DGCR8 protein to produce ׽70-80 nt precursor miRNAs (pre-
miRNAs) (Denli et al., 2004; Meister and Tuschl, 2004). A single nucleotide polymorphism 
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(SNP) in the miRNA stem can significantly affect the Drosha processing step to produce pre-
miRNAs (Duan et al., 2007). Subsequently, the Xpo-5, a member of karyopherins proteins 
family will mediate the transportation of pre-miRNAs to cytoplasm for Dicer processing (Lund 
et al., 2004). The Dicer cleaves the pre-miRNAs to generate mature ׽22 nt siRNAs that are 
loaded into RISC, followed by sequence specific suppression of targeted mRNA.    
1.3.2. Artificial RNAi induction strategies  
The discovery and subsequent studies on miRNAs have revealed that these small RNAs have 
a crucial role in several biological systems. Therefore, knowledge about the miRNA associated 
endogenous RNAi pathway have significant impact on the development of artificial RNAi 
induction strategies (McBride et al., 2008; Boudreau et al., 2009). The use of chemically 
synthesised siRNAs, long dsRNA or shRNAs was demonstrated to target a wide range of genes 
both in vitro and in vivo. Chemically synthesised siRNAs can associate directly with RISC, 
however dsRNA and shRNA use the endogenous Dicer enzyme to chop the RNA molecules 
into mature siRNAs (Fig. 1.1). Therefore, each of the above described RNAi induction 
strategies enters at a different step of the RNAi pathway. The sections below were reviewed on 
the focus of using chemically synthesised siRNAs and shRNAs. In addition, the advantages 
and disadvantages of both siRNA and shRNA strategies were provided in table 1.1.  
1.3.2.1. Chemically synthesised siRNAs.  
The introduction of long dsRNA molecules to induce artificial RNAi was a widely used method 
in the early years of RNAi research (Baulcombe, 1999; Caplen et al., 2002; Meister and Tuschl, 
2004). However, long dsRNA molecules are known to trigger unwanted immune stimulation 
and protein kinase responses (Clemens, 1997), that can lead to substantial changes in gene 
expression pattern and sometimes potentially the initiation of apoptosis (Gil et al., 1999; 
Gantier and Williams, 2007). Hence, the utilisation of siRNA molecules less than 30 nt are  
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Method  Advantages Disadvantages 
shRNA expression 
from DNA vectors 
x Nuclear Expression  
 
x Local and systemic 
expression for some 
application    
 
 
x Reduced immune 
stimulation  
 
x DNA based work. No need 
to work RNAse free. 
 
 
x Cost effective for long term 
inhibition studies. 
x Cloning of small inserts 
can be difficult   
 
x Constitutive expression 
under strong endogenous 
promoter can be toxic for 
some cell types.    
 
 
 
 
 
 
Chemically 
synthesised siRNAs 
 
x Control over input dosage 
on cells or animal  
 
x Easier chemical 
modification of siRNA 
duplex 
 
x No cloning or plasmids 
involved  
 
x Easier, quick and efficient  
 
 
x Mass production of siRNAs 
with high quality is possible  
 
x No inducible expression.  
 
 
x Expensive to buy high 
quality siRNAs.  
 
x Low in vivo efficiency.   
 
 
x Low transfection and 
knockdown efficiency in 
primary or non-dividing 
cells.   
 
x Not useful for long term 
inhibition studies. 
 
 
Table 1.1.  A comparison of shRNA and siRNA mediated RNAi induction.  
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preferred to avoid cellular toxicity. The chemically synthesised 22 nt siRNA molecules with 2 
nt overhanging at 3’ end that mimics the product of Dicer processed pre-miRNAs was one of 
the most commonly used in vitro artificial induction strategies (Fig.1.2) (Bantounas et al., 
2004). Chemically synthesised siRNA can offer uniform distribution and also allow a range of 
possible modifications to improve the stability (Czauderna et al., 2003). For instance, the                      
chemical modifications like 2’–O methylation has increased the stability of siRNA (Whitehead 
et al., 2009). Initially, it was thought that any 22 nt sequence selected as a potential siRNA 
sequence would exhibit RNAi activity. However, only a few siRNA sequences were found to 
be effective for targeting. Therefore, development of optimal siRNA sequences is critical to 
achieve effective RNAi induction.   
A siRNA sequence is considered to be effective only if the sequence has minimal off-target 
effects and successful association with RISC at the targeted site (Overhoff et al., 2004; Ameres 
et al., 2007). For instance, Tuschl et al. (1999) reported a set of rules to design effective 
siRNAs, commonly known as the Max-Planck-Institute principles that includes GC content 
(approximately 50%) and symmetric 3' TT overhangs. Although these early empirical rules 
improved the designing process, there were still issues with prediction and validation of 
siRNAs (Tuschl et al., 1999; Yiu et al., 2005; Birmingham et al., 2009). For instance, Reynolds 
et al. (2006) selectively analysed 180 siRNAs targeting two independent genes; in which the 
experimental assessment coupled with algorithms has resulted in improved RNAi mediated 
targeting. According to this study, the siRNAs with G/C content of 30-50%, presence of an ‘A’ 
or ‘U’ at the positions 15-19, presence of an ‘A’ at positions 19 and 3, presence of a ‘U’ in 
position 10, absence of ‘G’ or ‘C’ at position 19 of the sense strand, and a ‘G’ at position 13 of 
the sense strand are considered to be the optimal rules for effective siRNA. Additional 
guidelines such as avoiding a repeat motifs, considering binding energy of the sequence and 
potential hairpin formations were also reported (Chalk et al., 2004).      
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Figure 1.2. Schematic of a synthetic siRNA design. Modified and adapted from 
Bantounas et al. (2004).  
The target region of 21 nucleotides in the mRNA is shown as underlined sequence. Typically, 
a siRNA molecule is 19-21 bp RNA duplex (sense and antisense) with 2 nucleotide 3’ 
overhangs (double uridine) on the both strands, with phosphorylated 5' ends and hydroxylated 
3' end.  
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Although these criterion improved the siRNA stability in vitro, there are issues with in vivo 
delivery of siRNAs into organisms. The high molecular weight and the negative charge of 
naked siRNA obstruct efficient penetration into the cell. Moreover, the intracellular distribution 
of siRNAs is very limited due to their short biological half-life and high vulnerability to RNase  
digestion (Yang et al., 2004). Therefore, siRNAs are often packaged into either ligands (Ikeda 
and Taira, 2006), liposomes (Sun et al., 2015) or polymers (Hinton et al., 2014) to mediate an 
efficient delivery. Despite the significant advantages and promising results gained by using 
synthesised siRNAs, their transient targeting nature was a huge limitation (Holen et al., 2002; 
Burnett et al., 2011). Therefore, it remains a priority to develop more advanced and alternative 
technologies to deliver siRNAs to establish RNAi as a viable therapeutic strategy. 
1.3.2.2. shRNA mediated RNAi induction  
 
A shRNA molecule is an artificial RNA transcript that folds into a ‘hairpin’ like structure with 
inverted repeat sequences connected by a loop sequence, that can be efficiently processed into 
~21-25 nt siRNAs by Drosha and/or Dicer (Brummelkamp et al., 2002; Paddison et al., 2002; 
Wooddell et al., 2005) (Fig. 1.3.A). The shRNA structures are usually expressed by polymerase 
(pol) II or III promoters with defined transcription initiation and termination sites from a DNA 
construct. The utilisation of the shRNA approach for RNAi induction offers a range of 
advantages and options over synthesised siRNAs in terms of longevity, efficiency and cost. For 
instance, the cloning of shRNA structure into DNA vectors and subsequent delivery of these 
vectors into cells will transcribe a large amount of RNA hairpin-like structures in the nucleus, 
and are transported into the cytoplasm to undergo sequential cleavages to process into mature 
siRNAs  (Cullen, 2005) (Fig. 1.1).  
Generally, the shRNA molecules are designed on the basis of algorithmic rules that are derived 
from knowledge about the various enzymes involved in the process of miRNA biogenesis. 
Hence, the studies on miRNA biogenesis have provided valuable contributions to the  
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(A)                                                                           (B) 
                           
 
(C) 
 
   
Figure 1.3. Diagram of various shRNA designing strategies. 
A shRNA molecule typically consist of the long stem (sense and antisense sequence) connected 
by an unpaired loop sequence. (A) The classic shRNA design that contains a perfectly paired 
duplex connected by a 9 nt loop (Brummelkamp et al., 2002) (B) The 2nd generation shRNAs 
to enhance the processing of shRNAs. The duplex sequence is connected by the loop sequences 
derived from natural miRNAs. (C) The artificial miRNAs in which the miRNA backbone is 
replaced by artificial siRNA sequence by introducing specific the mismatches and bulges at 
required position into the passenger strand of the duplex to most accurately mimic the original 
miRNA secondary structure.     
 
 
 
 
 
12 | P a g e  
 
development of shRNA mediated knockdown studies (McIntyre and Fanning, 2006; Fellmann 
et al., 2013). Unlike siRNAs, the effector sequence in a shRNA molecule can range from 19 to 
29 nt. The shRNAs can be classified into two major types based on their type of design.  First, 
the utilisation of classic design with 19 nt stem sequence and 4-9 nt loop sequence (Wise et al., 
2007) (Fig. 1.3.A). Second, the replacement of classic loop with native miRNA loop sequence 
(Hinton et al., 2008) (Fig. 1.3.B) or the natural pre-miRNA backbones (McBride et al., 2008) 
(Fig. 1.3.C) to insert siRNA sequences. The following sections will review the developments 
of different promoters and shRNA design strategies for artificial RNAi induction.    
1.3.2.2.1. Promoters to drive the shRNA expression.   
The first practical application of shRNA mediated gene knockdown under the control of the 
pol III promoter H1 was developed as a vector based shRNA delivery system called, the 
pSUPER system (Brummelkamp et al., 2002). Since then, the use of either pol II or pol III 
promoters has become one of the standard protocols to express shRNAs. Although, the use of  
RNA pol II promoters permits tissue or cell specific RNAi expression (Giering et al., 2008), 
the level of RNAi activity achieved by these promoters was relatively low compared to pol III 
promoters (Zeng et al., 2002; Xia et al., 2006). The Pol III promoters such as U6 (Lee et al., 
2002), H1 (Brummelkamp et al., 2002) and 7SK (Cummins et al., 2008) were found to be much 
more reliable for RNAi activity. In addition, the characteristic feature of RNA Pol III promoters 
to terminate the 3’ end with 4-5 thymidines in a row, allows the RNA hairpin transcript to be 
recognized by Xpo-5 and thus transported into the cytoplasm for cleavage by Dicer to produce 
the mature siRNA (Zeng and Cullen, 2004; Borchert et al., 2006). Furthermore, the short 
promoter sequence of pol III is easier to clone into vectors that can carry only limited DNA 
sequence (Giering et al., 2008).  
 
 
13 | P a g e  
 
In contrast, the Pol II promoters do not provide these defined nucleotide terminations, and 
therefore these need to be included during the construction of the expression cassette. The U6 
and H1 promoters were shown to be comparatively effective in terms of processing efficiencies 
(Seibler et al., 2005; Barichievy et al., 2007; Abrahamyan et al., 2009; Snyder et al., 2009).  
For instance, Wise et al. (2007) reported the use of chicken U6 small nuclear RNA (snRNA) 
promoters to achieve knockdown of the enhanced green fluorescent protein (EGFP) in chicken 
cells. In another study targeting the vascular endothelial growth factor gene in tumour cells, 
the use of H1 promoter to drive the shRNAs was much more efficient at inducing RNAi activity 
when compared to constructs using U6 promoters (Zhang et al., 2003). In contrast, Wooddell 
et al. (2005) reported that they did not find any significant difference in the level of knockdown 
efficiency using U6 and H1 in vitro experiments. However, this was not the case in vivo where 
they found that the U6 promoter has shown effective knockdown, but not the H1 (Wooddell et 
al., 2005). Therefore, variable levels of efficiency were reported in the literature based on the 
cell type and the experimental design. However, one disadvantage of using the U6 promoter is 
that the lack of control over the expression levels, which persists as a major limitation for the 
use of poll III promoters in some in vivo applications (Giering et al., 2008).   
1.3.2.2.2. Design strategies and optimisation of shRNAs.  
 
Since the initial report of the basic structure using a 19 nt siRNA sequence and a 9 nt loop 
sequence (Brummelkamp et al., 2002), several groups have reported variable levels of siRNA 
expression patterns by altering to this structure. For instance, alterations in the length of the 
stem (McIntyre et al., 2011), loop (Hinton et al., 2008) and flanking sequences (Boudreau et 
al., 2008) were shown to influence the expression of shRNAs. In their studies using an 
‘ineffective’ 19 nt stem length, increasing the stem length has been shown to cause knockdown. 
In contrast, increasing the length of an already effective 19 nt stem length hairpin does not 
increase its efficiency (Yu et al., 2003). In addition, Paddison et al. (2002) showed that any 
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shRNA with a stem length less than 22 nt was less effective compared to a shRNA with 25-29 
nt stem length in mammalian cells.  
Similar studies were performed on various loop sequences derived from a range of miRNA 
structures including miR-17 (Schopman et al., 2010), miR-26a (McManus et al., 2002), miR-
30 (Boden et al., 2004a; Hinton et al., 2008), miR-171 (Parizotto et al., 2004) (Fig. 1.3.B). 
Similarly, natural miRNA backbone structures were used to design the seed region of artificial 
siRNA sequences to study the impact on gene silencing efficacy (Fig. 1.3.C). The artificial 
shRNAs that mimic natural miRNAs are better substrates and lead to more efficient processing 
by endogenous RNAi enzymes. The miR-30 (Zeng and Cullen, 2003; Li et al., 2007; Liu et al., 
2013a; Liu et al., 2013b; Xu et al., 2015) backbone is perhaps the most widely used backbone 
compared to other backbones such as miR21 (Yue et al., 2010) and miR155 (Chung et al., 
2006) which have also been reported. A recent study showed that the addition of conserved 
elements at the 3’ end to systemically modify the miR-30 scaffold; termed as miR-30E, has 
increased the mature siRNA levels between 10 to 30-fold compared to the conventional miR-
30 structure (Fellmann et al., 2013). Therefore, a deeper understanding of miRNA biogenesis 
remains a priority, to determine the underlying mechanisms and rules that can be adapted to 
the current design systems being used for knockdown studies.  
1.4. Combinatorial RNAi (co-RNAi) 
 
While gene expression can be controlled by artificial RNAi induction using a single shRNA, 
for some practical applications such as the control of virus replication, a single shRNA may 
not be enough. For instance, some viruses can have antigenic drift due to their inability to proof 
read the genome during the process of replication. These mutations maximise the chances of 
escape mutants as a results of imperfect matching of the siRNA sequence (Grimm and Kay, 
2007; Liu et al., 2009; Zhang et al., 2012). This limitation can be overcome by simultaneously 
targeting multiple conserved locations in the viral gene of interest, or by targeting several genes 
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across the viral genome. Therefore, if a mutant virus emerges, one of the other siRNA would 
still knock down its target in the remaining viral mRNA (Choi et al., 2015).  
The major aim of developing co-RNAi is to multiplex the RNAi effector molecules to different 
conserved sequences of viruses to create an effective antiviral strategy (Akashi et al., 2005; 
Grimm and Kay, 2007; Liu et al., 2009). The combination of multiple shRNAs targeting highly 
conserved and essential genes was one of the most efficient approaches to block viral 
replication in vitro (Chang et al., 2005; Brake et al., 2008). For instance, the inhibition of foot 
and mouth diseases (FMD) virus using three shRNAs was shown to be very effective in vivo 
in a mouse model (Kim et al., 2010). To date, there are several optimised approaches developed 
to perform co-RNAi to target multiple endogenous and viral genes in range of species. These 
approaches can be classified into 2 major categories, single transcription unit (STU) and 
multiple transcription units (MTU).    
The use of a single pol II or pol III promoter unit to drive the expression of a set of shRNAs is 
termed as STU. The derived transcripts are transported into cytoplasm and undergo subsequent 
cleavages by Dicer to produce mature siRNAs. STU can be further described in two methods 
1.) Long hairpin 2.)  poly-cistronic miRNA cluster. The long hairpin based multiple expression 
system combines multiple shRNA units on top of each other and usually driven by pol III 
promoters (Barichievy et al., 2007; Liu et al., 2007; Saayman et al., 2010). This approach 
requires careful design considerations to avoid any imprecise RNA substrates for Dicer 
cleavage. The miR-30 structure has been widely used backbone to generate long hairpins in 
several studies (Zeng and Cullen, 2004; Sun et al., 2006; Snyder et al., 2009).  
To express more than one siRNA from a single RNA transcript, Liu et al. (2009) looked at 
processing of different stem lengths of single long hairpins and showed that a minimum of 51 
bp stem is required to process 2 functional siRNAs, and 66 bp stem length for 3 siRNAs. 
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However, in mammalian systems the utilisation of long hairpins for RNAi induction have been 
shown to induce unwanted interferon (IFN) stimulation (Sano et al., 2007). To overcome this 
limitation, Akashi et al. (2005) developed the concept of introducing specific point-mutations 
(such as G-U) for every 4-8 bp in the sense strand of long dsRNA molecules that were termed 
as modified hairpin-RNAs (mhRNAs). The mhRNAs were shown to stimulate lower IFN 
activity than normal long dsRNAs whilst achieving knockdown of Hepatitis C virus (HCV) 
(Akashi et al., 2005). Since some natural miRNA are transcribed from clusters under the control 
of pol II promoters with tissue specific expression, the generation of artificial poly-cistronic 
clusters with close structural proximity or using the natural backbone for artificial siRNA 
sequences was advantageous for in vivo tissue specificity and reduced toxicity (Aagaard et al., 
2008).  
In contrast, the MTU strategy for co-RNAi induction involves the expression of multiple 
expression cassettes, varying from two to seven ‘promoter-shRNA’ constructs (Boden et al., 
2004b; Hinton et al., 2008; Abrahamyan et al., 2009; Kim et al., 2010; Choi et al., 2015). The 
multiple shRNAs expression strategy has been successfully used to knockdown either multiple 
endogenous (Xu et al., 2009) or exogenous (Kim et al., 2010) cellular targets using either 
plasmid (Zhou et al., 2008) or viral vectors (Xu et al., 2015) to deliver the transgenes into the 
genome. The expression of multiple shRNAs from a single MTU construct to simultaneously 
target the viral genome and cellular co-factor genes to restrict viral replication is considered an 
effective approach (Ng et al., 2007). Furthermore, expression of multiple shRNAs from MTU 
constructs can be advantageous by targeting multiple spots in a single gene to enhance 
knockdown (Gonzalez et al., 2005). The utilisation of the MTU approach for shRNA 
expression is considered as a simple, quick, and cost-effective method for gene knockdown 
studies. In fact, this approach has dramatically expanded the spectrum for RNAi based 
therapeutics, particularly targeting infectious viruses.  
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1.5. shRNA associated toxicity  
Since the initial development of artificial RNAi induction strategies, unwanted IFN stimulation 
(Sioud, 2005; Reynolds et al., 2006) and off-target effects (Jackson et al., 2003; Hossbach et 
al., 2006) were considered as the serious safety issues for therapeutic applications. A few years 
later, Grimm et al. (2006) reported the shRNA associated in vivo toxicity through the saturation 
of endogenous miRNA pathway, as a result of high levels of shRNA expression. The authors 
delivered full strength U6 driven shRNA expression cassettes into the mouse genome, which 
caused death in 23 out of 49 mice. The authors concluded that the death of mice was due to the 
overloading of shRNAs into miRNA pathway which resulted in saturation of Xpo-5 (Grimm 
et al., 2006). A few years later, Grimm et al. (2010) reported that Xpo-5 was not the only 
determinant, but also the four Ago proteins have crucial roles in shRNA associated in vivo 
toxicity. In their experiment, the co-expression of Ago-2/Xpo-5 in adult mice showed 
decreased in vivo toxicity while achieving reliable RNAi mediated gene silencing. Similarly, 
toxicity in primary human lymphocytes was observed when the cells were transduced with 
lentiviral vector bearing weak (H1) and strong (U6) promoters for shRNA expression. The 
authors have observed significant knockdown of target genes using the U6 promoter, but with 
a tendency towards cytotoxicity. In contrast, the lentiviral vectors bearing H1 promoters 
showed low levels of cytotoxicity (An et al., 2006). In addition, shRNAs under U6 promoters 
used to generate transgenic mice lead to IFN stimulation and early lethality due to the 
production of high levels of dsRNA(Cao et al., 2005). Since then shRNA associated toxicity 
effects were reported in brain (van Gestel et al., 2014), neurons (Martin et al., 2011) and cardiac 
cells (Bish et al., 2011).  
Several optimisation strategies were implemented to reduce the shRNA associated cellular 
toxicity. One such strategy is the re-engineering of the conserved regions of strong promoters 
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with proximal sequence elements from low strength promoter sequences (also called hybrid 
promoters) to enable the attenuation of shRNA levels (Domitrovich and Kunkel, 2003; Suhy 
et al., 2012). Moreover, the utilisation of either weak pol III promoters such as 7 SK (Cummins 
et al., 2008), H1 (Grimm et al., 2010) or pol II promoter such as U1-pol II (Denti et al., 2004) 
were also developed for constitutive expression of shRNA with reduced toxicity. However, the 
attenuation of shRNA expression by using low strength promoters has been shown to 
compromise with the target gene silencing efficacy (Lebbink et al., 2011).   
To date majority of the transgenic animals that stably express shRNAs were produced using 
viral mediated transgenesis. As the viral vectors do not have any control over the number of 
copies of a transgene that integrates (Gao et al., 2002), the constitute expression of shRNA 
following multiple integrations could have a profound impact on the miRNA pathway (Grimm 
et al., 2006). Therefore, the development of novel RNAi expression systems by utilising the 
recent advances in the field of transgenic technology and PGE tools will offer significant 
improvements to the application of RNAi based strategies in transgenic animals.    
1.6. Transgenic technology   
Transgenic technology is a powerful tool that allows analysis of the biological functions of 
genes either by deletion of coding sequences or by the introduction of new DNA sequences 
into the genome of an organism. The crucial steps involved in the successful establishment of 
a line of transgenic animals  includes the identification of the gene sequence, cloning into a 
suitable vector with appropriate promoter to achieve expression, integrating the transgene into 
the genome and proper inheritance of the transgene. Typically, this technology involves the 
deliberate manipulation of an organism’s genome by deletion of coding genes or control 
sequences, reorganisation of genes, or addition of exogenous material to produce a detectable 
genetic and phenotypic effect. The objective is to retain overall genome expression with one 
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or a few deletions and additions into the genome. The technology enables researchers to make 
specific alterations to the genome that could be transmissible to the offspring (Clark and 
Whitelaw, 2003; Maga et al., 2006; Tyack et al., 2013; Proudfoot et al., 2015).  
This is an area of science with huge potential to accelerate and enable the practical application 
of recombinant DNA technology to create transgenic livestock animals with valuable traits. 
The knowledge of molecular genetics coupled with breakthrough techniques that enable the 
introduction of foreign DNA into animal’s genomes has huge potential in agricultural and 
biopharmaceutical biotechnology. The efficiency of transgene integration, success of transgene 
expression, and stable inheritance of the transgene by offspring are key aspects to the successful 
generation of transgenic model animals. Over the last two decades a range of transgenic 
technologies including modified integrating retroviruses and transposons have been employed, 
enhanced and refined in a range of animal models. These advances have presented significant 
opportunity for the modification and enhancement of food production animals however this 
approach has not been adopted by industry. New gene editing technologies, such as TALEN 
and CRISPR, present an opportunity to modify livestock for a variety of purposes (Golding et 
al., 2006; Lyall et al., 2011b; Carlson et al., 2012b; Schusser et al., 2013; Tan et al., 2013; Park 
et al., 2014; Proudfoot et al., 2015; Wei et al., 2015). These more precise and controlled 
techniques should increase the efficiency of the processes involved and may mean that the 
industry and the public understanding of safety of these products is improved.     
Since 1980, when the first stable integration using DNA microinjection was reported in mice 
(Gordon et al., 1980), the production of transgenic mice has become a very important tool to  
study various biological processes. Subsequently, the technique has been used in several farm   
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animals for biomedical (Carlson et al., 2012b), pharmaceutical (Schusser et al., 2013; Park et 
al., 2014) and agricultural research. A list of genetically modified mammalian livestock 
animals with improved or new traits is summarised in table 1.2. Due to the focus of this thesis, 
the current section concentrates on the development of avian transgenics. 
1.6.1. Transgenic technology in chickens   
The chicken is a well-established vertebrate animal model, with the benefit of access to the 
developing embryo and short generation interval (approximately 6 months). Therefore, the 
chicken is considered as an excellent model to for many research areas including embryonic 
development, physiology, immunology and hormonal regulation. In addition, chicken eggs can 
serve as a bioreactor for large scale therapeutic and pharmaceutical protein production (Sang, 
2004b). Furthermore, chicken meat and eggs are the largest source of animal protein 
worldwide. Their feed conversion efficiency and relatively small environmental footprint of 
poultry production in comparison to other livestock, e.g. cattle, sheep and pigs, also makes 
chicken a preferred candidate to meet the future demand for animal protein. The poultry 
industry is one of the largest food production systems globally, and therefore, has a huge 
commercial interest in improving the traits. Likewise, transgenic eggs which efficiently 
produce high levels of therapeutic proteins have great potential for pharmaceutical companies 
(Sang, 2004b). In addition, the development of disease resistant chickens to control diseases 
such as AI virus is of significant interest (Lyall et al., 2011a). Although the chicken genome 
project was completed a decade ago, the numbers of published reports on transgenic chickens 
are relatively low compared to mammalian animal models.  
The production of transgenic chicken and the successful transmission of the transgene to the 
next generation by using recombinant avian-leukosis virus were reported almost 3 decades ago 
(Salter et al., 1987). However, the authors reported a very low frequency of germ-line 
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transmission and transgene expression. To date, several transgenic techniques that are well-
established in mammals have been attempted in chicken to generate transgenic models. 
However experimentation has shown that these conventional mammalian transgenic 
techniques were either not applicable to chickens or inefficient in avian species due to the 
differences in their reproductive system. For instance, the micro-injection of exogenous DNA 
into pro-nuclei of fertilized zygote, a very convenient technique in mice, cannot be applied in 
the chicken due to difficulties associated with access to the zygote. In addition, the presence of 
a large yolk on the egg makes the visualization of the nucleus in the egg difficult. Love et al. 
(1994) microinjected exogenous DNA into chick zygotes prior to the first cleavage and used 
ex vivo culturing to derive transgenic chickens (Love et al., 1994). However, the technique is 
currently not being used in chickens due to inefficient DNA integration with poor hatching 
rate. Similarly, the application of somatic cell nuclear transfer (SCNT) is impractical in the 
chicken as the isolation of an enucleated oocyte is not possible. 
In chicken, the development of an egg begins with the formation of an ovum, and fertilization 
of the ovum occurs in the infundibulum by the fusion of the spermatozoa and the ovum. The 
fertilized egg slowly moves towards the magnum and isthmus for deposition of the albumen 
and shell membrane. The first cleavage of the fertilized egg occurs 5-6 hr after fertilization to 
form the zygote, and spends up to 22-24hr in the oviduct to form the shell around the zygote. 
During this time, the zygote undergoes vigorous proliferation, and by the time the egg is laid, 
the blastdisc comprises 50,000–60,000 embryonic cells. Therefore, obtaining a fertilized ovum 
often required sacrificing the hen, and reinsertion into the oviduct was considered as an 
inefficient technique (Love et al., 1994; Sherman et al., 1998; McGrew et al., 2004; Sang, 
2004a; Park et al., 2013). Although the electroporation of DNA constructs into the developing 
embryo is an alternative approach for the short-term gene function studies (Itasaki et al., 1999), 
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the technique can allow for the manipulation of only specific tissue, and the germ-line 
transmission of such modification is highly inefficient or not possible.   
The most widely used method for generation of transgenic chickens which transmit the 
transgene in the germ-line involve targeting the blastodermal cells using viral vectors 
(Bosselman et al., 1990; McGrew et al., 2004; Motono et al., 2010). As germ-line segregation 
in chickens begins at a very early stage of embryonic development (Sang, 2004a), targeting the 
blastodermal cells (containing small proportion of PGCs) at stage X results in high ratios of 
transgenic offspring via a first stage chimera chicken (McGrew et al., 2004; Motono et al., 
2010). The primary benefit of using viral vectors is their ability to rapidly infect and integrate 
the transgenes into the genome. Therefore the use of viral vectors such as avian leucosis virus 
(ALV) vectors (Salter and Crittenden, 1989), infectious non-replicating reticulo-endotheliosis 
virus (REV) (Bosselman et al., 1990), retrovirus vector (Lee et al., 2007) and lentivirus 
(McGrew et al., 2004) have been reported in chicken transgenesis.  
Although viral vectors have simplified chicken transgenics, issues such as genetic mosaicism, 
multiple integration sites and emergence of new viruses by recombination pose some concerns 
about  this technology (Denning et al., 2013). Therefore, the development of non-viral vector 
based transgene integration techniques has been a focus of research in chicken transgenesis. 
Transposable elements (TEs) are distinct mobile DNA sequences that can change their genomic 
locations and as a result they can be adapted for transgenesis (Miskey et al., 2005; Ivics and 
Izsvak, 2010). Unlike viral vectors, the non-viral vector such as such as Piggybac (Macdonald 
et al., 2012; Park et al., 2013) and Tol2 (Macdonald et al., 2012) do not readily integrate into 
the targeted cells when targeting the blastodermal cells. Therefore, it is essential to establish 
the culturing of germ-line competent cells followed by either transfection or electroporation of 
plasmids into the cells to allow stable integration of transgenes.  
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Primordial germ cells (PGCs), the progenitors of gametes, are considered an excellent 
candidate for germ-line transmission in avian species. It has been previously shown by multiple 
authors that the ability to isolate and culture the PGC whilst maintaining their germ-line 
competency is unique for avian species (van de Lavoir et al., 2006; Schusser et al., 2013). 
Hence, manipulating the chicken genome in PGCs using non-viral vectors technologies is 
considered an efficient approach to integrate novel genes into chicken genome (Macdonald et 
al., 2012; Park et al., 2013). In addition, the development of in vivo transfection of plasmids 
into the circulating PGCs in the blood stream of ED 2.5 embryos has simplified avian 
transgenic technology by providing an alternative to the use of cultured germ cells to introduce 
novel genes into chicken genome (Tyack et al., 2013). 
Despite these successes thus far in chickens; undefined insertions in the chromosomes could 
have unpredictable consequences on expression of endogenous genes and transgenes. 
Furthermore, these random genomic insertions add another factor that must be studied and 
proven to be safe to gain regulatory or consumer acceptance when seeking to translate the 
outcomes to improve commercial stock (Fahrenkrug et al., 2010; Carlson et al., 2012b). 
Therefore, it remains a major priority in animal agriculture to develop transgenic animals in a 
precise manner using minimal transgenes. The use of PGE tools in chickens to tailor the 
chicken genome at the single nucleotide level with absolute precision can offer significant 
advantages over conventional gene insertion technologies.  
1.7.  Precision Genome Engineering   
The ability to precisely modify the genome transformed biology in the late 1980s and early 
1990s. Inefficient transgenic methods hampered efforts to analyse and modify genetic traits to  
 distinguish the biological importance of the differences between species. Identifying and 
connecting a genotypic mutation to a phenotypic outcome is called forward genetics. In 
 
 
25 | P a g e  
 
contrast, mutating specific genomic loci and characterizing the phenotypic changes is termed 
as reverse genetics, and has emerged as a powerful tool to elucidate the biological and 
metabolic functions of an organism (Urnov et al., 2010; Carroll, 2011; Corrigan-Curay et al., 
2015). However, conventional gene targeting relies on homologous recombination (HR), a 
mode of gene targeting with very low efficiency, presenting difficulties in large scale 
applications.  
The advance of DNA sequencing technology to the level of generating whole organism genome 
sequences has augmented our understanding and ability to rationally select ‘sites of interest’ in 
virtually any living organism. The development of PGE tools such as ZFN (Kim et al., 1996), 
TALENs (Bedell et al., 2012) and CRISPR/Cas9 (Cong et al., 2013) nucleases have 
revolutionised the genome engineering field and enable researchers to introduce precise 
modifications in a wide variety of cell types and model organisms. Gene targeting efficiency 
can be enhanced by provoking the repair of genomic locus with targeted double strand breaks 
(DSBs), which can be repaired by the error prone non-homologous end-joining (NHEJ) 
pathway or HDR (Lin et al., 2014). The following sections will review the rapidly emerging 
PGE technologies and their application. The chronology of major discoveries, developments 
and a few applications of PGE tools is summarised in figure 1.4.  A detailed side by side 
comparison of the three nuclease systems is provided in table. 1.3.    
1.7.1. Zinc Finger Nuclease  
The structural features of zinc finger DNA binding proteins were first elucidated as protein 
motifs, containing conserved cysteine and histidine ligands that make tandem contacts with 
DNA molecules with an intense interaction to facilitate stability in DNA (Miller et al., 1985). 
The characteristic structure of a C2H2 zinc finger protein array is a highly complex architecture 
with multiple motifs, with each individual motif called a module. A single zinc finger module  
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(ZFM) comprises of an anti-parallel beta ribbon and an alpha helix synchronised by a zinc ion 
(Cathomen and Joung, 2008). The zinc ion plays a key role in folding the two cysteines at 3-ribbon 
region of beta sheet and histidines at the COOH-terminal portion of alpha helix forming a compacted 
structure, the residues of alpha helix can recognise and binds to 3 bp of DNA with high specificity 
(Fig. 1.5) (Lee et al., 1989; Pavletich and Pabo, 1991; Kim et al., 1997). Each ZFM is connected to 
the next one with a highly conserved linker sequence TGEKP or a few closely related linker 
sequences to fold in a definite manner, providing significant binding energy in the DNA - ZFP 
complex (Choo and Klug, 1993; Laity et al., 2000).    
The first demonstration of using ZFMs for development of site specific nuclease was reported by the 
fusion of a non-specific nuclease domain (FokI type II) to a DNA binding domain (Kim et al., 1996).  
ZFNs create heterodimer like DSBs, with each multi-unit monomer binding a very specific 9-12 bp 
on either side of DNA strand (Fig. 1.5) (Xiao et al., 2013). The ZFNs for genetic engineering involves 
the alterations in target gene by either NHEJ or HR mediated exchange between the target locus and 
a donor construct. In 2002, the first successful germline transmission of a ZFN induced mutation 
was reported in Drosophila melanogaster (Bibikova et al., 2002). Since then, several reports have 
been published the use of ZFNs for targeted genome engineering for diverse range of applications. 
For instance, Urnov et al. (2005) reported highly efficient replacement of the human interleukin (IL)-
2Rγ gene with donor sequence when targeted with ZFNs. Similarly, the homozygous deletion of the 
CCR5 gene in CD4+ cells (a major co-receptor for HIV-1), was shown to provide resistance to HIV 
infection (Cannon and June, 2011). Furthermore, the combination of SCNT with ZFN technology 
was used to produce peroxisome proliferator-activated receptor-gamma heterozygous KO (mono-
allelic disruption) pigs with 4 times increment  in mutation rate, when compared to traditional HR 
mediated SCNT (Yang et al., 2011).  
Having proven to be successful in editing the genomes of several organisms, many attempts have  
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Figure 1.5.  The structure and design of ZFN system. Modified and adapted from Cathomen 
and Joung (2008).  
 
The schematic of a pair of ZFNs bound to its target DNA to create a DNA double strand break (DSB); 
each subunit of ZFNs contain three zinc-fingers (ZFs, 1-2-3) to specifically recognise 9 base pairs 
on either side of target sequence in an inverted orientation in order to dimerize and produce a DSB. 
The nuclease domains, the FokI endonuclease domain (brown) dimerize and cut the spacer sequence 
of DNA. A short linker sequence connects the two domains to form an active ZFNs system. 
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been made to further improve the targeting efficiency of ZFN systems. For instance, Doyon et al. 
(2010) reported that applying  transient hypothermic culture conditions (30 °C or “cold shock”) to 
the cells delivered with ZFN plasmids enhanced the gene disruption efficacy (Doyon et al., 2010). 
Likewise, the use of surrogate reporter system to isolate targeted cells has dramatically improved the 
efficiency of ZFNs (Kim et al., 2011). The development of zinc-finger nickases, by inactivating 
catalytic activity of one monomer in a ZFN dimer to reduce off-target effects, has shown to be a 
powerful approach to create strand-specific nicks to stimulate HDR (Ramirez et al., 2012).   
Despite the successful use of ZFNs in various organisms, the wider application of ZFNs was 
hampered due its limited modularity, requiring the design and assembly of multiple ZF domains to 
routinely engineer the ZFNs (Ramirez et al., 2008). For instance, the Oligomerized Pool Engineering 
strategy to design new ZFN targets can offer very limited number of combination i.e. one ZFN 
combination for every 200 bp in the genome (Maeder et al., 2008; Foley et al., 2009). Furthermore, 
the assembly of ZF domains for new targets was laborious, expensive and often leads to failures in 
cutting DNA.  
Therefore, the limitations inhibiting rapid design and evaluation of a series of ZFNs at a targeted 
location remains a major disadvantage for ZFNs. Moreover, the lack of specificity among few ZF 
domains has shown cellular toxicity as a result of unwanted DSB at off-target sites (Pruett-Miller et 
al., 2009). These limitations with ZFNs have driven researches to develop more reliable PGE 
technologies to modify the genome with high targeting efficiency and precision.   
1.7.2. Transcription activator like effector nucleases.   
In 2007, for the first time Romer et al (2007) identified a unique binding mechanism by special type 
of proteins derived from bacterial plant pathogen Xanthomonas campestris infection. The authors 
termed this unknown mechanism in the infected plants as “Promoter Activation” (Römer et al., 
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2007). Two years later, two other groups on similar studies reported a novel class of a large group 
of a highly conserved bacterial proteins, produced during the infection of bacterial strains of 
Xanthomonas sp. and coined the term, Transcription activator-like (TAL) proteins, and revealed a 
DNA binding recognition code associated with the TAL proteins (Boch et al., 2009). The TALEs are 
capable of recognising specific promoter sequences in the nucleus to transcriptionally activate the 
genes that contribute to bacterial colonization (Bedell et al., 2012). The TALEs are highly conserved 
and repetitive regions in the middle of proteins that contain many tandem repeats. Each repeat 
contains 33-35 amino acid sequence motifs and that determine the biological specificity. However, 
the last repeat contain only 20 aa and thus called as “half repeat”. Most importantly, the identities at 
residues 12 and 13 positions, known as the repeat variable di-residue (RVD) are associated with base 
recognition preference. The repeat within a specific RVD will define nucleotide specificity with high 
precision. For example, the RVD ‘NI’ recognizes adenine, ‘HD’ recognizes cytosine, ‘NN’ 
recognizes G/C guanine/cytosine and ‘NG’ recognizes thymine (Fig. 1.6) (Boch et al., 2009; Moscou 
and Bogdanove, 2009; Deng et al., 2012; Li et al., 2013a). The sequence array of such TAL effectors 
repeats can be customized to bind to virtually any DNA sequence. Therefore, the knowledge of 
TALE protein functionality has turned the attention of many scientists to develop of the concept of 
engineering the TALE proteins for targeted genome engineering (Carlson et al., 2012a; Stower, 
2014). Unlike ZFNs, TALENs offer reasonable possibilities to design new genomic targets that are 
not possible with ZFN architecture. However, the only described consensus and limitation for 
TALEN design is the requirement of a 5’ T at the start (Miller et al., 2011; Stower, 2014) 
In 2010, the first successful demonstration of artificial TALE proteins coupled with FokI catalytic 
domains introducing DSBs at the intended cleavage site was reported (Christian et al., 2010) A year 
after, the TALEN technology was recognised as method of the year by Nature methods (2012b). 
Similar to TALENs, a new class of tools called the chimeric TALE recombinases (TALERs), where  
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(A) 
 
 
 
(B) 
 
 
 
Figure 1.6.  Schematic of TALEN design and their specificity to bind DNA. Modified and 
adapted from Miller et al. (2011).   
(A) Diagram of TALE repeats (shown as blue boxes) that mediate DNA recognition. The TALE 
amino acid terminal and C terminal domains are the key determinants for DNA recognition and 
activity. A single TALE repeat was highlighted to show the RVD, that determines the binding 
specificity of in a TALE repeat. The recognition of nucleotides based on the RVD (top row of letters) 
change in the repeat. (B) Sketch of a pair of TALENs bound to its target sequence. The cleavage 
domain FokI (shown in brown colour) mediates the site specific DSBs at the spacer sequence.    
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the TALE domain is linked with catalytic domain from recombinases was also reported (Mercer et 
al., 2012). The TALEN expression plasmids are delivered as pairs that contain the repeat sequences, 
a nuclear localization signal, N-terminal domain, and the FokI catalytic domains. Once in the 
nucleus, each TALEN binds at the intended site of plus and minus DNA strand with appropriate 
spacer sequence ranging from 12-30 bp (Fig. 1.6). The fused FokI domain of each protein dimerizes 
and mediates the DSB within the provided spacer sequence (Sander et al., 2011; Joung and Sander, 
2013).  
Although TALENs offer more flexibility than ZFNs, the repetitive nature of TALE DNA binding 
domains often presents technical challenges for cloning into desired expression vectors (Sander et 
al., 2011; Reyon et al., 2012; Burgess, 2013). Therefore, a prerequisite to explore the modularity of 
TALE proteins is the ability to precisely synthesise the TALEs for the desired sequence. Several 
methods were developed for fast and reliable generation of new targets. Currently, the Golden gate 
method that permits fusion of many DNA fragments in a single reaction is a widely used approach 
(Cermak et al., 2011). The application of TALENs to induce gene alteration has been demonstrated 
in wide range of species such as yeast (Li et al., 2011b), zebrafish (Sander et al., 2011), chickens 
(Park et al., 2014), rabbits (Wang et al., 2014), pigs (Tan et al., 2013), cattle (Wei et al., 2015) and 
human somatic and pluripotent stem cells (Mussolino et al., 2011; Ding et al., 2013). Furthermore, 
due to ease of designing new targets and increased efficiencies and specificity compared to ZFNs, 
TALENs have been readily adopted by many researchers for gene therapy applications to correct 
genetic disorders such as Epidermolysis Bullosa (Osborn et al., 2013) and sickle cell disease (Zou et 
al., 2011).   
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1.7.3. Clustered Regularly Interspaced Short Palindromic Repeats   
The CRISPR locus in the bacterial genome was first identified as repeats that are interspaced 
with 32-33 bp spacer sequences adjacent to the isozyme alkaline phosphatase gene in the 
bacterial genome almost two decades ago (Ishino et al., 1987). Subsequent studies have 
revealed that CRISPR was one of the most highly conserved genes in the bacterial genome. 
Viruses that infect bacteria (bacteriophages) are arguably the most abundant and diverse family 
of organisms on the planet, and are a constant threat to bacterial survival (Breitbart and Rohwer, 
2005). Through adaptive evolution, bacteria have evolved various multifaceted innate “phage 
resistance” mechanisms to combat invasion of exogenous genetic material (Abedon, 2009; 
Labrie et al., 2010).    
CRISPR is one such remarkable adaptive immunity system, found in most archaea and bacteria, 
and can target a huge diversity of bacteriophages and plasmids (Pourcel et al., 2005; Al-Attar 
et al., 2011). The defining features of the CRISPR system are the clustered set of CRISPR-
associated (Cas) genes and the identical short repeat arrays that are interspaced by highly 
variable and unique spacer sequences of similar length (Marraffini and Sontheimer, 2010; 
Wiedenheft, 2013). The repeat sequence forms a hairpin like structure due to the palindromic 
sequence. These spacer sequences are a form of “prokaryotic immunological memory” of 
CRISPR. The proto-spacers are often derived from viral sequence or plasmids typically with a 
short (2–5 nt) conserved protospacer adjacent motif (PAM), and are incorporated into the 
CRISPR loci. Within the CRISPR loci, sequences upstream of repeat-spacer contain two 
critical components. 1) The Cas genes are located upstream to the CRISPR array and provide 
diverse functionality at various steps of CRISPR mediated immunity. 2) The leader sequence, 
which is an AT rich 400-500 bp genomic region and functions as a promoter for the 
CRISPR/Cas9 system. More than 45 different types of Cas genes have been identified based  
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Figure 1.7. Schematic of CRISPR/Cas9 system. Modified and adapted from Jinek et al. 
(2013).  
 
Creation of site specific double-strand DNA breaks at the target locus by sgRNA attached to 
the target sequence at NGG sequence. Target DNA sequence (shown in black). The Cas9 is the 
nuclease (shown in light brown colour ovals) that guided by sgRNA to mediate the cleavage 
of specific DNA sequences  
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on their amino acid sequence similarity. Among those, Cas1 and Cas2 have proven to be 
universal as they play critical role in spacer acquisition (Fineran and Charpentier, 2012). Based 
on the signature Cas3, Cas9 and Cas10 genes, the CRISPR/Cas system has been classified into 
type I, II and III. The Type II CRISPR system from Streptococcus pyogenes with Cas9 genes 
was one of the widely characterised Cas genes. The Cas9 protein contains two nuclease 
domains, one at the N terminus (RuvC-like nuclease) and an HNH (McrA-like) nuclease 
domain that mediates the endonuclease activity at the target region (Jinek et al., 2012; Anders 
et al., 2014).      
The simplicity of CRISPR/Cas9 system to recognise and cut virtually any DNA sequence has 
encouraged the customizing of this system for genome editing. Jinek et al. (2012) purified the 
Cas9 protein from either Streptococcus thermophilus or Streptococcus pyogenes and carried 
out the critical biochemical characterization and demonstrated the targeted cleavage of DNA 
by Cas9 and crRNAs (Jinek et al., 2012). By 2013, the type II CRISPR/Cas9 system has been 
programmed to target the genome in mammalian cells by to stimulate NHEJ or HDR mediated 
gene editing (Mali et al., 2013b). In this study, the U6 snRNA Pol III promoter was used to 
transcribe the crRNA-tracrRNA to guide the Cas9. Cong et al. (2013) demonstrated a further 
flexible and simple design by the fusing the crRNA and tracrRNA structures to generate one 
single guide RNA (sgRNA) for Cas9 target recognition and cleavage. A pictorial representation 
of the CRISPR/Cas9 mechanism on target DNA sequence is shown in figure 1.7. Following 
those successful demonstrations, coupled with the ease  of designing new targets, the 
CRISPR/Cas9 system has been explored in wide range of species to induce NHEJ, HDR, 
generate large deletions, and inversion-mediated gene targeting (Chen et al., 2014; Hai et al., 
2014; Kabadi et al., 2014; Lin et al., 2014; Suenaga et al., 2014; Price et al., 2015).         
In addition, the ability to simultaneously target multiple genes in a cell is another unique and 
advantageous feature. CRISPR/Cas9 based genome editing has tremendous advantages over 
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ZFN and TALENs, as it requires only 20 nt short RNA sequence, which is easier to generate 
for new genomic targets. There are now commercially available plasmids, which contain the 
universal Cas9 sequence and a site to clone in your desired sgRNA,  which are also suitable 
for high-throughput and multiplex gene targeting for variety of species (Cong et al., 2013; Mali 
et al., 2013a).    
1.8. Targeting viral diseases by transgenic RNAi  
Historically, the emergence of new viruses has posed a significant threat to both human and 
animal health globally. This is particularly true for RNA viruses where the antigenic mutations 
to form new subtypes occur up to 107-fold more rapidly than DNA viruses (Drake et al., 1998). 
This constant antigenic drift often leads to a lack of efficacy of current anti-viral vaccines and 
drugs to new and emerging viral strains. Since the first evidence of nucleotide sequence specific 
silencing, investigating the feasibility of RNAi as a therapeutic tool has drawn significant 
interest in the scientific community. Moreover, the evidence of viral suppressors in plants 
(Voinnet, 2001), insects (Galiana-Arnoux et al., 2006) and recently in mammals (Li et al., 
2013b) has encouraged researches to develop RNAi based antiviral therapeutic strategies. 
RNAi presents numerous advantages over other drug development strategies including the ease 
of design for new targets, efficient knockdown at low dosage, applicability for diverse cell 
types and achievement of stable gene silencing through shRNA-transgenic approaches. 
Theoretically, all RNA viruses and viruses that have RNA intermediates during the 
transcription of genes can be targeted by an RNAi based strategy. In addition, RNAi can be 
used as an indirect approach by silencing the host genes that are essential for replication of a 
virus (Zhang et al., 2004; Xue et al., 2007).  
The demonstration of potent and durable inhibition of HIV in cultured cells has opened the 
door for many other applications. This strategy has been successful in targeting a number of 
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viruses such as FMDV (Kim et al., 2010), HBV (Snyder et al., 2009), HCV (Akashi et al., 
2005), HIV-1 (Konstantinova et al., 2006; Zhang et al., 2012) Human Papilloma Virus (HPV) 
(Butz et al., 2003; Hall and Alexander, 2003) influenza virus (Ge et al., 2004), Severe Acute 
Respiratory syndrome (SARS) virus (Lu et al., 2004), dengue virus (Adelman et al., 2002), 
Human Para-Influenza Virus (HPIV) (Bitko et al., 2005), West Nile Virus (WNV) (McCown 
et al., 2003) and Vesicular Stomatitis Virus (VSV) (Barik, 2010) etc.  
To date, the use of viral vectors to stably integrate the shRNA expression constructs is one of 
the widely used approaches for transgenic RNAi applications in animals (Arrighi et al., 2004; 
Chen et al., 2006). For instance, a line of transgenic chickens that are resistant to AI virus were 
generated using the combination of decoy RNA technology and viral transgenesis. Although 
these transgenic chickens efficiently suppress virus transmission (Lyall et al., 2011a), the use 
of viral vectors as gene delivery vehicles may present limitations to commercialization. As 
viral vectors tend to integrate randomly in the genome without any control over the number of 
transgene copies (Grimm et al., 2006), their practical application to production animals such as 
chicken may raise significant safety concerns. There is a need to develop novel RNAi induction 
strategies to circumvent current limitations of this technology for in vivo application.    
1.9. Aim of this study  
 
The literature relating to RNAi has clearly identified toxicity related issues in vivo when using 
strong exogenous promoters in several animal models, and this is reflected in unpublished 
observation from our own laboratory in chickens. To date no one has reported successfully 
making transgenic chickens that constitutively express RNAi molecules.   
The aim of this study is to design and develop novel anti-viral RNAi induction strategy in 
chickens to control gene expression. With generating a scientifically valuable chicken in mind 
and having a measurable system to indicate successful control of gene expression, a virus 
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infection model, AI, was selected. The design of the system involves the introduction of 
exogenous siRNA into the natural RNAi pathway. This was approached in a way that would 
ensure that the natural miRNA pathway was not overloaded, which is known to have the 
potential to cause toxicity. ZFN-mediated gene targeting in the chicken had not been reported 
at the start of this PhD project in 2012. In the first instance, this ZFN was used to bring about 
precision insertions of anti-influenza (anti-flu) shRNAs in the genome of a chicken fibroblast 
cell-line (DF-1), which can then be tested for resistance to influenza virus infection. To achieve 
these aims it was essential to develop the methods and determine the efficiencies by applying 
the PGE tools (particularly TALEN and CRISPR/Cas9) to generate a precision edited chicken.  
The final step in this thesis aims to develop and validate a multiplex method to generate 
chickens with precisely modified genomes. These methods are applied to the technical aim of 
generating a chicken expressing anti-viral RNAi through the hitch-hiking principle of precise 
placement of shRNAs sequences adjacent to a natural miRNA.   
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This research was therefore structured to focus on three key areas as follows:  
 
Chapter 2: General material and methods  
 
Chapter 3: Hitch-hiking on miRNA pathway using precision genome engineering:  
In this chapter, the parallel processing of one/multiple shRNAs by hitch-hiking on the miRNAs 
was examined. ZFN technology was utilised to generate a series of transgenic DF-1 cell lines 
that were modified with anti-influenza shRNAs adjacent to a native miR-107. The ZFN 
modified DF-1 cell lines were challenged with influenza virus to evaluate the resilience to the 
infection.     
 
Chapter 4: Characterisation of hitch-hiking approach using transposon mediated genetic 
engineering: For this chapter the Tol2 transposon system was utilised to mediate the 
transgenesis of hitch-hiker constructs into chicken genome in DF-1 cell line. One of the 
Tol2_hitch-hiker constructs was used to evaluate the tolerance in PGCs by injecting the 
construct into ED 2.5 chicken embryos. The chickens (G0) with Tol2_hitch-hiker construct 
were raised to sexual maturity and the transgene in the semen was quantified by qRT-PCR.   
 
Chapter 5: Evaluation of precision genome engineering tools in chicken PGCs:  
This chapter evaluates the emerging PGE tools such as TALEN and CRISPR/Cas9 system in 
cultured chicken PGCs by specifically targeting a stably integrated GFP gene.   
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CHAPTER 2: GENERAL MATERIALS AND METHODS 
2.1. Continuous cell lines 
2.1.1. Cultivation and sub-culturing of cell lines 
DF-1 cell cultures were passaged at ~95 % confluency. Briefly, cells were harvested by 
removing the old media and washed twice with phosphate-buffered saline (PBS) followed by 
incubation with 1 % trypsin (trypsin in PBS) for 5 min at 37°C. The cells containing flask was 
gently shacked, and the cells were resuspended growth medium and spun for 5 min at 1200 
rpm. The growth medium was removed and the pellet was resuspended in growth medium, and 
a cell count is performed using a haematocytometer. To count the viable cells, cells suspensions 
were diluted at 1:1 ratio with trypan blue and the number of viable cells were determined based 
on the number of trypan positive and negative cells. Cells diluted to a count of 1x106 cells/mL 
were transferred into new flask with growth medium and incubated at 37°C with 5% CO2 and 
subcultured twice a week.  
2.1.2. Seeding the cells in plates 
Seeding was performed after cell passaging, using the remaining cell suspension with 
1x106cells/mL. The cells were seeded in the 96, 24, or 6 well tissue culture plates by pipetting 
the desired volume (100 to 500 μL) of the cell suspension in each well and incubated at 37°C 
and 5% CO2. The cells were generally ready for transfection 24 hr post seeding.   
2.1.3. Transfection of cells 
Transfection of plasmid DNA into the cell lines was performed using Lipofectamine 2000 
reagent (Invitrogen) following manufacturer’s protocols. Briefly, transfections were performed 
on cells at 80-90% confluence. The plasmid DNA (1.5 μg to 4 μg) was diluted in 250 μL 
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OptiMEM (Invitrogen) and mixed with 250 μL of Opti-MEM containing 7-10 μ of 
Lipofectamine 2000 (L2000) (Thermo Fisher Scientific) and incubated at room temperature 
for 20 minutes and then carefully added to the wells. The cells were incubated at 37°C with 
5% (v/v) CO2.   
2.2. Primers and oligonucleotides  
All the primers used in this study meet general primer designing consensus i.e. 18-24 nt length, 
40-60% GC content, 50-65°C melting temperature, 1-2 nt GC 3’ clamp, maximum 
polynucleotide repeats (N)=4. Primers were designed using either clone manager or NCBI 
primer designing tool, and were purchased from Gene works, Australia. Primers were 
resuspended with nuclease free water at 100 μM stock. Working primers were further diluted 
from original stock to a concentration of 5 μM concentration for quantitative real time PCR 
(qRT-PCR) and 10 μM for end point PCR experiments. The list of primers used in this study 
was provided in Appendix B  
2.3. Polymerase Chain Reactions (PCR)  
 PCR amplifications were conducted using the Hot Start Polymerase supplied with 2X Green 
GoTaq reagent (Buffer (pH 8.5) according to manufactures protocols (Promega, USA). The 
reaction was performed in a final volume of 25 μL containing the following components: 12.5 
μL of goTaq polymerase, 9.5 μL water, 1 μL of forward (Fwd) primer (stock: 10 μM), 1 μL of 
reverse (Rev) primer (stock: 10 μM) and 1μL of DNA template in a 0.2 mL PCR tube. The 
PCR amplification was conducted using an Eppendorf Mastercycler Epgradient S (Eppendorf, 
USA) machine.  The PCR conditions were as follows; the initial denaturation step for 2 mins, 
followed by 35 cycles of denaturation (95o C for 15-30 sec), annealing (55o C to 60o C for 15-
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30 sec), and extension (72o C – 1 min/kb) steps. A final extension step at 72 o C for 1 - 5 mins 
was performed.    
2.4. Cloning    
Custom vectors used in this study were generated by modifying existing base plasmid 
backbones. Cloning DNA constructs involves the sequential application of the techniques of 
PCR amplification, restriction digestion, ligation and transformation of a close circular DNA 
construct into E.coli, isolation, growth and extraction of DNA from a single clone and the 
characterization of that DNA construct. Primers flanking a region of interest which incorporate 
restriction sites were used to generate suitable fragments for sub-cloning. PCRs were 
performed using GoTaq® Green Master Mix (Promega, USA) or Platinum PCR supermix 
(Invitrogen, USA) following manufacturer instructions. Restriction maps of plasmids and 
inserts were generated and analysed using the software tool Clone Manager Professional v9.0. 
Restriction digestion experiments were done using specific restriction enzymes (RE) 
(Promega, USA) following manufacturer instructions. To ligate the desired fragments, a 
dephosphorylation step was performed when required to prevent plasmid re-circularization, 
using Thermosensitive Alkaline Phosphatase (Promega, USA) following manufacturer 
instructions. Details of specific plasmids were described in each chapter.     
2.4.1. Gel extraction and purification  
An agarose gel electrophoresis was used to determine the amplified PCR products based on the 
size of amplicon. The PCR amplicons less than 500 bp were analysed on 2 % agarose gel. 
While PCR amplicons greater than 500 bp were analysed on 1-2% agarose gel.  The isolation 
of DNA following DNA gel electrophoresis was performed using the QIAquick Gel Extraction 
Kit (Qiagen), according to the manufacturer’s instructions. 
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2.4.2. Ligation of PCR products 
PCR products were cloned directly into the pGEM®-T Easy (Promega) vector by following 
manufacturer’s instructions. Briefly, Ligation reactions were carried out in a final volume of 
10 μL, which contains 1 μL of ligase buffer (10x stock), 1 μL of T4 DNA ligase (3U/μl) and 8 
μL by following 1:3 molar ratios of insert and vector. The final concentration of the DNA 
fragments in the ligation mix was 50 ng. The reaction is incubated at room temperature for 4hr 
and stored at 4 °C.     
2.4.3. Ligation of shRNA oligonucleotides 
 The two complementary oligonucleotides were annealed to form a hairpin. Each nucleotide at 
of volume 2 μl of fwd primer (stock conc. 1 μg/mL) and 2 μl of rev primer (stock conc. 1 
μg/mL) were resuspended using 46 μl of annealing buffer (pSilencer™ Kit, Ambion) in a 1.5 
mL microfuge tube. The tube was placed at 90°C for 3 min in a heat block prior to the block 
being removed from the apparatus and allowed to cool at room temperature for 1 hr. The 
annealed oligos were diluted at 1 in 10, prior to use in ligation with peGFP-N1_intron. The 
reaction is performed in a final volume of 10 μL, containing peGFP-N1_intron (plasmid DNA; 
100ng), 1 μL of T4 DNA ligase (3U/μL) and 1 μL of T4 DNA buffer (10X stock) with 
respective shRNA’s and incubated at overnight.    
2.5. Bacterial strains, media and growth  
The plasmids generated in this study were transformed into commercially available (electro-
competent) ElectroMAX™ DH5α-E™ Competent Cells (Life Technologies). Bacterial cell 
cultures were grown in sterile Luria Bertani (LB) broth and on LB agar plates with 100 μg/mL 
of penicillin or 50 μg/mL of kanamycin antibiotics. The choice of antibiotics was based on the 
antibiotic resistant gene in the plasmid being used. Liquid cultures were grown in LB broth 
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containing respective antibiotic in a shaking incubator 37°C with shaking (250 rpm) in a 
Gallenkamp Orbital Incubator (Sanyo, UK). Cells plated on LB agar plates and incubated 
overnight at 37°C.         
2.5.1. Bacterial - Transformation of plasmid DNA into E. coli   
The transformation of competent E. coli cells with desired plasmids was done using 
electroporation. Cells stored at -80oC were removed and placed on ice and allowed to thaw. An 
aliquot of 30 μL of cells were mixed 10 ul of 10% glycerol, followed by mixing 2 μL of ligation 
mix and immediately transferred to cold 0.2 cm cuvettes (BioRad, USA).  E. coli cells were 
electroporated at 25 μF, 2.25 V and 200 ohms resistance in a Gene pulser transformation apparatus 
(Biorad). Cells were then immediately recovered with LB broth and incubated at 37oC for 1 hr. The 
recovered bacterial cells were gently spread on LB agar plates and incubated at 37°C overnight.  
2.5.2. Plasmid DNA purification from E. coli cultures  
The plasmid DNA isolation from the transformed E. coli cells was performed by using QIAprep 
Spin Miniprep Kit (Qiagen, Germany) for small scale plasmid DNA isolation and QIAprep 
Spin Maxiprep Kit (Qiagen, Germany) for large scale plasmid DNA by following manufacturer 
instructions.  
2.5.3. Measurement of DNA & RNA concentrations 
The spectrophotometer (NanoDrop ND-1000 3.3 Spectrophotometer, NanoDrop Technologies, 
USA) was used to measure the concentration DNA and RNA. 1 μL of elution buffer was used 
to correct the spectrophotometer base reading (blank), followed by measuring the nucleic acid 
concentration in 1 μL of the sample.   
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2.5.4. Glycerol Stocks 
E. coli colonies found to be positive for an insert or particular construct design were frozen 
down in glycerol by adding 500 μL of glycerol to 500 μL of overnight culture and stored at –
80oC. 
2.6. Restriction digestion  
All restriction enzymes used in this study were purchased from Promega.  Restriction maps of 
vectors were generated and analysed using clone manager software. Restriction digestion 
reactions were carried out in 20 μL final reaction containing 1 μL restriction enzyme, 2 μl 10x 
buffer (specific to the enzyme), 100-500 ng plasmid DNA, and H2O to a final reaction volume 
of 20 μL. Samples were incubated for 4 hr at 37°C. If required the dephosphorylation of 
digested DNA fragments was performed using Thermosensitive Alkaline Phosphatase (TSAP) 
(Promega) following manufacture’s instruction.  
2.7. RNA extraction, cDNA synthesis and qRT-PCR  
The RNA extractions and qRT-PCR in this study was performed by following the protocol 
described by (Bannister et al., 2011). Briefly, the RNA extraction procedure was carried out 
using Trizol Reagent (Invitrogen, USA). The extraction of small RNAs was performed using a 
modified version Trizol method (Invitrogen, USA). DF-1 and other derivative transformed 
cells were subjected to homogenisation by adding 1 mL of trizol reagent and incubated at room 
temperature for 5 min. This was followed by the addition of 200 μL of chloroform and gently 
mixing the tubes for 15 sec then centrifuging at 12,000 g max for 15 min at 4°C to create phase 
separation. The aqueous phase was carefully removed into an Ambion RNase-free microfuge 
tube (Applied Biosystems, USA) and 1 μL glycogen (stock: 10 μg; Invitrogen) was added to 
the aqueous phase, followed by 500 μl of isopropanol per 1 mL of Trizol used. The solution 
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mixture was carefully mixed and incubated at room temperature for 10 minutes to precipitate 
the small RNAs. Next, the samples were centrifuged at 12,000 g max for 15 min at 4°C. The 
supernatant was removed and the small RNA pellet was washed in 1 mL of ethanol per 1 mL 
of Trizol used and centrifuged at 7,500 g max for 5 min at 4°C. The ethanol was removed 
without disturbing the pellet and air dried for 10 min in a fume hood. The pellet was 
resuspended in 50 μL water and incubated at 55°C for 5 min. RNA samples were quantified 
using NanoDrop as described in the section 2.5.3.  
The quantitative analysis of small RNAs (polymerase basic (PB1), nucleoprotein (NP), non-
structural (NS-1), miR-107 or 5S) in the study was carried out by qRT-PCR Polyadenylation 
method. Therefore the total RNAs extracted in the previous step were subjected to RNAse-free 
DNAse prior to Polyadenylation step according to the manufacturer instruction. The 
Polyadenylation of small RNAs was performed in a 20 μL reaction volume that consisting of 
1 μg total RNA (8 μL), 4 μL of 5x PAP buffer, 0.25 μL (150 U) of yeast poly (A) polymerase 
(PAP: catalogue no. 74225; USB corporation) and 1 μL of 10 nM rATP (Ambion) and 
Nuclease free (NF) water (Promega). Reactions were incubated at 37 oC for 30 min and then 
95 oC for 5 min and stored at -20 oC. Next, the synthesis of first-strand cDNA template was 
performed by using Superscript III (Superscript III First-Strand Synthesis Supermix; Catalog 
number: 18080-400, ThermoFisher scientific, USA). Briefly, 4 μL polyadenylated RNA (from 
previous step) was annealed with 3 μL of primer (miR-PTA) at 25 mM and 1 μL of annealing 
buffer in a final volume of 8 μL, mixed and incubated at 65°C for 5 min and then placed on ice 
for 1 minute. A reaction containing 2 μL of enzyme mix (includes SuperScript III RT and 
RNaseOUT) and 10 μL of 2X RT Reaction Mix (includes oligo (dT) 20 (2.5 μM), random 
hexamers (2.5 ng/μl), 10 mM MgCl2 and dNTPs) was mixed with 8 ul annealed polyadenylated 
total RNA to final volume 20 μL to synthesis of first-strand cDNA. The contents were gently 
mixed and incubated at 50°C for 50 min, then 85°C for 5 min and stored at -20°C.  
 48 | P a g e  
 
The quantitative hairpin expression profile from the plasmids or transgenic cell lines was 
examined by qRT-PCR analysis using StepOnePlus real-time PCR system (Machine and 
Software; Applied Biosystems). The universal reverse primer PAM-URP recognises the    
complementary sequence in the miR-PTA sequence used to generate the cDNA, while the 
forward sequence is choosen to recognise the small RNA of interest. The chicken ribosomal 
small RNA (5S rRNA) was used as control sample. The reactions were performed in 96 well 
optical reaction plates in triplicates, with a 20 μL final volume, containing 10 μL of SYBER 
green PCR Master Mix (Applied Biosystems, Life technologies) 2 μL cDNA diluted 1:30 in 
water, 0.8 μL of each primer (stock concentration 5 μM) and 6.4 μL of NF water. The reaction 
was run under the following conditions: 1x cycle 50˚C for 30 min followed by 95˚C for 10 min 
(1 cycle), 95˚C for 15 sec and 60 ˚C for 1 min (40 x cycles) followed by 60˚C for 1 min. The 
melt curve Melt curve was 95qC, 15 sec; 60qC, 1 min; ramp 0.3qC/sec; 95qC, 15 sec (one 
cycle). The fold expression and statistical significance were calculated using 2 -∆∆ Ct method    
The data analysis for qRT-PCR was performed using 2-delta-ΔCt (2-ΔΔCt) method (Livak and 
Schmittgen, 2001). This generates an expression profile for the target that is normalised against 
a reference gene. The qRT-PCR data analysis was performed calculated by 2-(ΔΔCt) method 
as follows: the target (mature siRNA sequence e.g PB, NP or NS) refers the sequence being 
detected. The “reference gene” (endogenous control; i.e 5S gene) used to normalise expression 
to the control sample (untransfected or wildtype). The relative expression level was calculated 
as fold differences between treatment and control samples. The “Ct” value represents the cycle 
threshold value to refer expression level. The difference between the Ct of the target and the 
Ct of the reference gene represents the“delta-Ct” (ΔCt), while the difference between the ΔCt 
of the sample and the ΔCt of the reference sample is “delta-delta-Ct” (ΔΔCt). The fold 
difference is calculated as 2-(ΔΔCt). For all qRT-PCR results in this thesis, expression levels 
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are shown as a fold difference relative to the level in a selected reference sample, where the 
fold difference in the reference sample has a value of 1.  
2.8. Luciferase assay.   
To generate luciferase reporter constructs, the target sequences of PB1 (553 bp section), NP 
(551 bp section) and NS1 (531 bp section) were amplified by influenza reverse genetics 
plasmids (kind gift from John Stamba’s group, CSIRO AAHL) genes. The primers used for 
PCR amplification of target section of influenza genes were listed in the Appendix B. The 
amplicons were then cloned into NotI and XhoI restriction sites of psiCHECK-2 dual luciferase 
reporter plasmid (C8021; Promega, USA) to generate the psiCHECK-2_PB, psiCHECK-2_NP 
and psiCHECK-2_NS1.    
The knockdown analysis of plasmid based experiments on DF-1_WT cells using peGFP-Intron 
plasmid; the constructs were transfected into DF-1_WT cells at a concentration of 3 μg/well 
(1.5 μg peGFP-Intron + 1.5 μg psiCHECK-2) unless otherwise stated. For knockdown assays 
on ZFN or Tol2 modified DF-1 cells with siCHECK-2 plasmids, as the cells stable produce 
shRNA by genomic integration of hitch-hiker fragment, an empty vector (pUC-DNA – 1.5 μg) 
plasmid was supplemented along to match the total DNA load. Therefore, 1.5 μg psiCHECK-
2 (PB, NP or NS) plasmid and 1.5 μg pUC-DNA were used to on these cells. At 48 hr post-
transfection, cells were harvested and the levels of Firefly luciferase (Fluc) and Renilla 
Luciferase (Rluc) were measured using a dual luciferase reporter assay (Promega, USA) as per 
manufactures instructions. Briefly, the transfected DF-1 cells were lysed in 500 mL of passive 
lysis buffer. The luminescence was measured in a 96-well format with 20 mL of each sample 
using Luminescence Micro plate Reader (BioTek Instruments). First, 100 μL of Luciferase Assay 
Reagent II was added to the sample and luminescence was measured. Next, 100 μL of Stop & 
Glo Buffer was then added to measure Rluc activity. The normalised renilla luminescence was 
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calculated as the quotient of Rluc/Fluc luciferase reading to examine the knockdown of target 
gene.   
2.9. Microscopy. 
To determine the confluency of the continuous cell lines, the cells (in wells or flask) were 
routinely observed in bright field microscope (Leica microsystems, D-35578 WETXLAR). To 
determine GFP fluorescence, cells were observed using fluorescence microscope (Leica) with 
excitation (470/440) and emission filter (525/50). Similarly, DsRed positive cells were 
observed using the excitation filter (545/30) and emission filter (610/75). The images were 
taken at 20x, 50x or 100x magnification  
2.10. Statistical analysis. 
 The statistical significance calculation was performed using the GraphPad Prism 6 package 
(GraphPad Software, Inc., USA) with One-way ANOVA followed by the Dunnett post-test to 
attain P-value unless otherwise stated. The data represent the mean ± SD of three biological 
replicates and was representative of 3 individual experiments. The statistics were determined 
as significant when (P < 0.05).   
2.11. Experimental Animal Care.  
The work undertaken here to introduce the Tol2 constructs into the chicken genome was 
approved by the Australian Animal Health Laboratory Animal Ethics Committee under the 
protocol number 1724. This research was conducted in accordance with the guidelines of the 
Office of the Gene Technology Regulator, with the approval of the local Institutional Biosafety 
Committee as a Notifiable Low Risk Dealing, approval number NLRD 11/2013 
AAHLIBC/2013/12.   
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The birds used in the experiments were maintained according to the standard animal 
management protocols at Werribee Animal Facility (WAF). All experiments that include 
embryo injection, manipulation and dissection were performed by following the standard 
operating procedures of Tim Doran’s Chicken laboratory at AAHL.  
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CHAPTER 3: HITCH-HIKING ON THE MiRNA PATHWAY USING 
PRECISION GENOME ENGINEERING 
 
Abstract  
RNAi has emerged as a powerful experimental tool and an opportunity for the control of 
important traits in production animals. However, it has been observed that overloading of 
natural miRNA pathway with exogenous shRNAs can have serious toxicity issues. The advent 
of PGE technology has provided the tools to allow us to induce RNAi by a method of 
transgenesis that can enable tissue/timing specificity of gene silencing and that can alleviate 
the issue of toxicity. In an attempt to achieve the natural non-toxic levels of RNAi activity, 
shRNAs targeting avian influenza virus were positioned adjacent to a constitutively expressed 
miRNA (miR-107) residing in the intron-5/PANK1 gene to “hitch-hike” the native miRNA 
processing pathways. The parallel processing of shRNA by hitch-hiking on miR-107 was first 
demonstrated using an artificial intron system by transfection into chicken fibroblast DF-1 cell 
line. Next, to incorporate the shRNAs adjacent to miR-107 in the genome context, ZFN driven 
HDR of single/multiple shRNAs into either one or both PANK1 alleles was achieved in DF-1 
cell line. For all of the cell lines generated precise placement of the very small transgene has 
been confirmed.  The RNAi activity of these shRNAs has been assessed by qRT-PCR and 
luciferase reporter assays. Furthermore, the ZFN modified DF-1 cells were challenged with 
AIV and displayed a reduction of viral titre up to 2 to 7-fold compared to DF-1 wildtype cells. 
Taken together, these results provide a novel strategy for the development of disease resilient 
animals by combining RNAi technology and emerging PGE tools in the chicken model.     
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3.1. Introduction      
Avian Influenza (AI) virus present a significant threat to global poultry industry and human 
health, particularly due their propensity to undergo unpredictable genome re-assortments 
which create new and highly pathogenic strains such as H5N1 and more recently H7N9 (Capua 
and Alexander, 2007; To et al., 2013). In young birds, these highly pathogenic avian influenza 
(HPAI) virus strains have high virulence and often lead to 100% mortality (Alexander, 2000). 
Direct contact of birds infected with some HPAI viruses facilitate transmission of the infection 
to humans (Webby and Webster, 2001; To et al., 2013). Despite extensive efforts, the current 
vaccination programme to control for AI virus in poultry is either ineffective or have limited 
value (Capua and Marangon, 2007; Barik, 2010; Suarez, 2012; Swayne et al., 2014). Therefore, 
there is a need to develop new strategies against AI virus to protect the global poultry industry. 
A specific example for this could be the use of RNAi, which has been recognised as a potential 
therapeutic strategy for viral diseases.    
RNAi is an evolutionarily conserved eukaryotic cellular mechanism that mediates sequence-
specific blocking of mRNA from translation often by degradation. The introduction of 
exogenous RNAi effectors in the form of siRNA, shRNAs or artificial miRNAs to harness the 
endogenous RNAi machinery is a powerful tool to silence gene expression. Although the 
introduction of siRNAs can exhibit potent gene knockdown effect in vitro (Andersen et al., 
2007; Abrahamyan et al., 2009; Chang et al., 2012), their practical application in vivo pose 
several limitations. Furthermore, some application such as inhibition of virus replication, 
sustained targeting of multiple genes that are highly conserved and essential are required.   
To promote stable shRNA expression, pol III promoters such as H1 and U6 are widely used 
promoters to drive the shRNA following their integration into the host genome. Previously, our 
laboratory (Wise et al., 2008) and others (Ge et al., 2004; Jiao et al., 2013) demonstrated the 
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inhibition of AI virus replication in the transgenic mice expressing anti-influenza shRNAs. 
Despite these seminal data, the high levels of shRNA expression and random genomic 
integration of constructs often lacks spatial and temporal regulation expression, which is 
arguably, a significant limitation for in vivo RNAi applications. For instance, Grimm et al. 
(2006) observed in vivo toxicity in mice as a result of over-loading of RNAi pathway by pol 
III driven shRNA constructs regardless of the sequence or length of shRNA used. Although, 
utilisation of pol II promoters attenuates these negative effects to a certain extent, the low 
shRNA levels shRNA of targeted knockdown was observed compared to Pol III promoters 
(Xia et al., 2006; Giering et al., 2008). Therefore, there is a need to develop safe and efficient 
in vivo RNAi induction approaches to reduce the pol III-shRNA associated toxicities whilst 
maximising the knockdown effect.   
The advent of PGE tools such as ZFN, TALEN and CRISPR/Cas9 system allows precise 
manipulation of genome at defined locations, and offers tremendous potential to improve the 
weaknesses of current transgenesis methods (Gaj et al., 2013; Joung and Sander, 2013). During 
the start of this thesis, the application of PGE tools to introduce the shRNAs into the chicken 
genome was not reported. In this study, ZFN technology was used to engineer the chicken 
genome to precisely locate coding sequences of anti-influenza shRNAs (single and multiple) 
adjacent to a natural miRNA (miR-107) to achieve parallel processing of shRNA by hitch-
hiking the miRNA expression pathway. Once expressing and processing of exogenous shRNAs 
was confirmed, resilience to AI virus infection was examined.   
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3.2. Materials and Methods  
3.2.1. Cell culture and viruses  
DF-1 Chicken Fibroblast Cell Line (DF-1: American Type Culture Collection (ATCC) 
number: CRL-12203) were obtained from the CSIRO AAHL tissue culture laboratory. DF-1 
cells were maintained in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 
10 mM Hepes, 1.5% (w/v) sodium bicarbonate, 100 U/mL penicillin and 100 μg/mL 
streptomycin. The cells lines were passaged twice in a week and grown at 37 oC and 5% CO2 
in an incubator.   
Madin-Darby Canine Kidney (MDCK) cells (ATCC CCL-34) were maintained in Roswell 
Park Memorial Institute medium (RPMI) supplemented with 10 % (v/v), foetal calf serum 
(FCS), 2 mM L-glutamine, 1.5 % (w/v) sodium bicarbonate, 100 U/mL penicillin and 100 
mg/mL streptomycin.   
3.2.2. Cloning of shRNAs into peGFP-Intron plasmid.  
The peGFP-Intron plasmid (manuscript in preparation) was a generous gift from Kristie 
Jenkins from CSIRO-AAHL, Geelong. Briefly, the intron-5 of PANK1 gene harbouring the 
miR-107 was PCR amplified including the splicing acceptor and donor sides, and cloned into 
the coding of GFP sequence of peGFP-N1 to generate the peGFP-Intron expression plasmid. 
The successful transcription of this plasmid will facilitate the intron splicing and joins the two 
eGFP coding sequences to produce GFP. In addition, two restriction enzymes (BamHI and 
KpnI) were generated to facilitate the insertion any hairpin downstream of the miR-107 
sequence.  
The siRNA sense strand sequences used in the study were previously shown to be effective in 
silencing influenza A subtype HINI. The sequences were used to insert into the classic BK and 
the miR-30 adapted shRNA structures with compatible restriction enzyme site sites (BamHI 
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and KpnI) (Appendix B). For the MWH plasmid construction (bulge-miR-30_MWH or loop-
miR-30_MWH, the native intron sequence loops or bulges were engineered with miR-30 
structure shRNAs containing PB, NP and NS siRNA sequences. The engineered sequences of 
bulge_MWH (465 bp long) or loop_MWH (466 bp) with BamHI and KpnI RE overhangs were 
synthesised as oligonucleotides (Life Technologies, Australia), and cloned into peGFP-Intron 
to generate peGFP-Intron-Bulge_MWH or peGFP-Intron-Loop_MWH plasmids respectively 
(Appendix B).  
3.2.3. ZFN and HDR constructs  
Custom designed ZFN plasmids that targets intron-5/PANK1 gene were purchased from 
Sigma-Aldrich. The design, cloning, and validation of the ZFNs were performed by Sigma-
Aldrich. The ZFN-PANK1 pair targets sequence upstream to the miR-107 within the intron-5; 
the cut region is shown in bold: 5 ′TACTCCAGACACCTACattgttTTTGTGAGGTACGGCT 
3’ in the intron-5 of genomic pantothenate kinase 1 (PANK 1) (Gene ID: 423792) in 
chromosome 6 of the chicken genome. The nuclease activity of ZFNs at the PANK1 site was 
tested by surveyor nuclease assay by Sigma Aldrich. To generate HDR template for shRNA 
insertion, a part of the modified intronic region (approximately 1655 bp) in the peGFP-Intron 
plasmid was amplified using primers (listed in appendix B), and cloned into pUC18 vector to 
generate the base HDR vector; the pUC-Intron vector. The oligonucleotides for miR-30_PB, 
miR-30_NP or loop-miR-30_MWH were cloned into BamHI and KpnI RE sites in the pUC-
Intron vector. For shRNA knock-in in DF-1 cells, pUC-Intron construct with desired shRNA 
(single or multiple) and ZFN plasmid pair were co-transfected at a ratio of 1:1:1 (1 μg: 1 μg: 
1μg = pUC-Intron: ZFN1-PANK1: ZFN2-PANK1) using 8 ul of L2000 (Invitrogen, Thermo 
Fisher Scientific).   
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To detect HDR mediated genomic integrations, PCR and sequencing analysis was performed 
on the genomic DNA extracted from ZFN modified cells. The screening was performed using 
two strategies of PCR screening (Fig. 3.3.A). For PCR strategy 1, the forward primer binds in 
the genomic region outside homology region of HDR template and the reverse primer was 
designed specifically bind to the shRNA (either NP or PB specific primer). Only through 
precise integration of shRNAs at intron-5 will produce the PCR amplicons. For PCR strategy 
2, both the forward and reverse primers amplify across the target site and this determines the 
number of alleles modified. The modified allele will produce a 300 bp PCR amplicon, while 
the unmodified allele produce a 500 bp at intron-5 of PANK1 gene. For sequencing analysis, 
PCR amplicons were gel purified using Qiagen Gel Extraction Kit and cloned into pGEM-T 
easy vector.  
3.2.4. Virus titration   
The propagation of influenza A/WSN/33 H1N1 (will be termed as WSN from now) was 
performed in the allantoic fluid of pathogen-free embryonated chicken eggs (stage E9) at          
37 oC for 48 hrs. The allantoic fluid was harvested, aliquoted and stored at −80 oC for 
inoculations.  
The ZFN modified DF-1 cells were seeded at 2 x 105 cells per well and infected with WSN 
viruses at MOI of 0.01 in the presence of DMEM media (5% FCS). After adsorption for 1 hr, 
the virus inoculum was removed and replaced with DF-1 maintenance media and cells were 
incubated in incubator at 37°C, 5% CO2. The viral supernatants were harvested from six 
replicates at 24 hr and 48 hr post-infection (hpi), and stored at -80 oC to perform the plaque 
assay.   
To determine the virus titre, a plaque assay was performed on MDCK cells in a 6 well plate as 
previously described (Takeda et al., 2002). Briefly, cells were washed with serum-free MDCK 
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maintenance media to remove all the traces of serum and dead cells. The viral supernatants 
were serially diluted at 10-fold in the serum-free MDCK maintenance media. The serial log 
dilutions prepared in were added to ~ 90% confluent MDCK monolayers cells following the 
aspiration of culture media. The virus adsorption was carried out for 1 hr, during which the 
plates were gently rocked for every 15 mins to prevent the monolayer from drying-out and to 
ensure an even spread of diluted virus inoculum. After the virus adsorption period, the virus 
inoculum was removed and the MDCK monolayers were overlaid with 3 mL of media 
containing 1% agar and incubated at 37°C with 5% CO2 until clear plaques were formed 
(approximately 3 days).  To analyse the plaques, the cells were fixed by adding 3 mL of 5 % 
formaldehyde in PBS on top of the agarose and gently rocked for 1 hr. The solidified agarose 
was carefully removed from the wells and washed with distilled water and left to dry. The 
plaques were visualised by staining with crystal violet, and the PFU at the indicated dilution 
was calculated.  
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3.3. Results  
3.3.1. MiR-107 conservation and vector construction.  
Supporting data to make decisions about construct design was provided by Mark Tizard and 
Kristie Jenkins (CSIRO-AAHL, Geelong, Australia). The peGFP-Intron plasmid was 
constructed by Kristie Jenkins. Mark Tizard’s group carried out deep sequencing of miRNAs 
in the chicken embryo, and identified that miR-107 is one of most highly expressed miRNAs 
(Glazov et al., 2008). Consistent with the majority of miRNAs, miR-107 is an intronic miRNA, 
located in the intron-5 (size: 3.5 kb) of the gene encoding pantothenate kinase 1 (PANK1) 
(Gene ID: 423792), a gene involved in the biosynthetic pathway from pantothenate to 
synthesise Coenzyme A (CoA) (Fig. 3.1.A). CoA is an essential co-factor that plays central 
role in metabolism of carboxylic acids (Rock et al., 2002). Due to its higher levels of 
expression, miR-107 was chosen as the candidate to examine the possibility of achieving 
parallel processing of an exogenous shRNA (in this case anti-flu siRNA sequence), when 
positioned adjacent to miR-107 (Fig. 3.1.B).  
The intron (~3.5 kb) containing miR-107 was PCR amplified including the acceptor and donor 
sites, and cloned into eGFP coding sequence in the peGFP-N1 plasmid to generate peGFP-
Intron plasmid with RE sites for shRNA insertion. The constructed plasmid mimics the native 
gene transcript environment as it was organised as ‘exon-intron-exon’ for the cloned PANK1 
intron-5 (Fig. 3.1.B). The transfection of the peGFP-Intron plasmid into DF-1 cells resulted in 
the expression of GFP indicating the successful splicing of the intron from the two eGFP exons 
to produce a single eGFP transcript (Fig. 3.1.C). Therefore, this system provides an opportunity 
to analyse the expression of miR-107 and shRNA during splicing from the eGFP exons. The 
qRT-PCR analysis for miR-107 levels has found that the expression of miR-107 was up to 3-
fold higher and that was statistically significant (p<0.0001) compared to either negative control 
or untransfected cells (Fig. 3.1.D).     
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(D) 
 
Figure 3.1. Characterisation of miR-107 in the peGFP-Intron plasmid.  
(A) Sequence conservation of the PANK1 genomic location among various species using the 
‘University of California, Santa Cruz’ (UCSC) genome browser web tool. The graphical view 
of comparison this comparison from the UCSC website shows the high conservation of miR-
107 across different species. (B) Schematic of peGFP-Intron plasmid with restriction enzyme 
site (in blue colour; BamHI & KpnI) for shRNA insertion downstream to miR-107 (not drawn 
to scale). (C) Detection of fluorescence after peGFP-Intron transfection into DF-1_WT cells. 
Bright field (top row) and fluorescence (bottom row) images (magnification 50x) after 48 hr 
post transfection with respective plasmids. In comparison with cells with peGFP-N1, a 
proportion of cells in the peGFP-Intron transfection group also turned the cells to GFP positive. 
As expected, the negative control (untransfected) cells do not show any GFP expression.          
(D) DF-1_WT type cells were transfected with either pUC_DNA or peGFP-Intron (no 
shRNAs) or left untransfected. The cells were harvested at 48 hr post-transfection for qRT-
PCR analysis of miR-107 expression. The miR-107 expression was normalised to 5S reference 
gene and made relative to the untransfected control to calculate the fold difference. MiR-107 
expression was quantified on 3 independent transfections and analysed in triplicate. Results are 
representative of three separate experiments. Error bars show ±SD. Asterisks indicate statistical 
significance: *** P<0.0001.  
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3.3.2. Characterization of NP shRNA in peGFP-Intron plasmid.  
Previously, our laboratory has developed a novel way to express the anti-influenza shRNA 
(PB1-2257; will be termed as PB from now) targeting basic polymerase (PB) gene using hitch-
hiking on native miRNA processing machinery by positioning the shRNA sequence adjacent 
to a natural miRNA (miR-107) in the peGFP-Intron plasmid (Jenkins et al., manuscript in 
preparation). Here, a similar approach has been implemented to express another anti-influenza 
siRNA sequence (NP-1498; will be termed NP from now) that targets nucleoprotein (NP) gene 
of influenza virus. The NP siRNA sequence was used as the effector sequence to incorporate 
into the classic BK and miR-30 structures with mis-matches and bulges, and cloned into the 
BamHI and KpnI sites of peGFP-Intron plasmid (Fig. 3.1.B). The insertion of shRNA (either 
BK_NP or miR-30_NP) into the intronic region does not altered the predicted RNA fold of 
intron (Fig. 3.2.A).  
The constructs were transfected into DF-1 cells and the splicing of the intron from the two 
eGFP exons was confirmed by the presence of GFP in the transfected cells at 24 hr post-
transfection. As expected, the negative control group that was transfected with pUC-DNA did 
not show any fluorescence. To confirm the successful processing and expression of NP and 
miR-107 after splicing, qRT-PCR analysis was performed. DF-1_WT cells cannot express 
NP_shRNA and thus qRT-PCR analysis cannot generate a threshold cycle value (Ct value) to 
provide a reference point to calculate relative expression levels. Therefore small RNA was 
extracted from DF-1_WT cells transiently transfected with the BK_NP intron plasmid. This 
was used as a standard reference against which to calculate relative levels of expression of 
NP_shRNA. As shown in figure 3.2.B, the qRT-PCR has detected approximately 2.5-fold 
increased NP siRNA levels using miR-30_NP structure when compared to the levels obtained 
by BK_NP structure. Furthermore, the miR-107 expression levels were examined using qRT-
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PCR analysis. As expected, the miR-107 levels were significantly higher in the groups that 
were transfected with plasmids (intron alone, +BK_NP or +miR-30_NP) compared to 
untransfected group. However, within the comparison between different transfected groups, a 
1.5-fold decreased miR-107 levels was observed in miR-30_NP group; which is statistically 
significant (P<0.001) compared with peGFP-Intron alone (Fig. 3.2.C).  
Furthermore, the RNAi knockdown activity of the influenza NP gene was evaluated by co-
transfection of psiCHECK-2_NP (containing a 551 bp section of the NP gene) with BK_NP or 
miR-30_NP in peGFP-Intron construct with appropriate controls. The Rluc and Fluc levels 
were measured after 48 hr post-transfection to determine the knockdown efficiency. As shown 
in the figure. 3.2.D, the transient expression of miR-30_NP from the intron has significantly 
inhibited the Rluc expression (p value P<0.0005) compared to either intron alone plasmid 
(negative control) or BK_NP plasmid.     
(A) 
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Figure 3.2. Characterization of NP siRNA sequence in the peGFP-Intron plasmid.  
(A) The RNA secondary structure prediction for natural intron (small part) and intron-5 with 
shRNA insertion. The miR-107 sequence is highlighted in red colour and the shRNAs were 
highlighted with arrow in purple. (B) The analysis of NP shRNA expression from peGFP-
Intron in two different structures (BK_NP and miR-30_NP) using qRT-PCR. The expression 
levels from the treatments samples were normalised to the 5S gene (reference control) and 
calculated as a fold difference relative to the BK_PB. ShRNA expression was quantified on 3 
independent transfections and analysed in triplicate. Error bars show standard deviation (±SD). 
Asterisks indicate statistical significance: ***p<0.0003. (C) The expression levels of miR-107 
after the transfection of peGFP-Intron plasmid was examined by using qRT-PCR. The miR-
107 expression was normalised to 5S (reference control) and calculated as a fold difference 
relative to the untransfected control. Results are representative of three independent 
experiments performed in triplicate. Error bars show ±SD. Asterisks indicate statistical 
significance: **p<0.001. (D) Comparison of knockdown efficiency of different NP_shRNA 
structures in the peGFP-Intron constructs using dual luciferase reporter system. The 
knockdown of a section of NP gene containing the target site were analysed following co-
transfection of plasmids. Values are the mean ratios of Rluc: Fluc ±SD from n=3 and 
representative of 3 independent experiments. Asterisks indicate statistical significance: 
***P<0.0007.       
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3.3.3. Precision engineering of shRNAs into the chicken genome.  
Having successfully demonstrated the expression of miR-30_PB (Jenkins et al., manuscript in 
preparation) and miR-30_NP (in this study; Fig. 3.2.B) by hitch-hiking on miR-107 expression 
pathway in a plasmid system, the expression of shRNA when positioned adjacent to miR-107 
in the genome was examined. A pair of ZFNs targeting the intron-5 of PANK1 locus were used 
to facilitate the HDR of hitch-hiker constructs containing anti-influenza shRNAs (Appendix 
A, Fig. A.1). The HDR template does not contain the ZFN active site and that avoids the 
nuclease “self-targeting” of intronic sequence in the HDR template or after integration into 
genome (Appendix A, Fig. A.2). To confirm the ZFN driven HDR of shRNA constructs into 
the genome, two PCR strategies have been implemented. The PCR strategy 1 (at the insertion 
site) was performed by shRNA specific reverse primers (Rev_PB primer for miR-30_PB 
shRNA & Rev_NP primer for miR-30_NP) and the forward primer binds to a region located 
outside the homology arms (Fwd_Screen-7). The PCR strategy 2 was performed by the primers 
spanning across the insertion site (Fwd_Screen_1and Rev_Screen_4) to determine the type of 
allelic (mono-allelic or bi-allelic) modification (Fig. 3.3.A). The clonal isolation and 
establishment of pure population of mono-allelic and bi-allelic cell lines was shown in 
Appendix A (Fig. A.4) 
As the HDR template does not contain any antibiotic or fluorescent genes, it was necessary to 
use clonal isolation and expansion of cells from transfection positive cells by PCR screening, 
through limiting dilution and expansion (Appendix A, Fig. A.3). To establish DF-1_PB cell 
line, clones from limiting dilution are grown, and the genomic DNA from these cells was used 
to analyse the integration miR-30_PB HDR template into the genome by PB specific primers. 
Similarly, to generate DF-1_NP, out of 67 colonies tested, 2 clones were positive for the miR-
30_NP HDR template insertion. Additional rounds of screening limiting dilution and expansion 
was performed to establish pure transgenic lines (Appendix A, Fig. A.3). To generate a bi-
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allelic cell line that harbour’s two different shRNAs from two alleles, co-transfection of ZFN 
pair (ZFN1 & ZFN2) and pUC-Intron_miR-30_NP was performed on the DF-1_PB (mono-
allelic) cell line. Prior to perform the limiting dilution to isolate the clonal population, the 
genomic DNA from cell pool was used to determine the integration of miR-30-NP in these 
cells. Using PCR strategy-1, 2 positive clones were obtained out of 93 clones tested. Additional 
rounds of screening was performed on one of the positive clone, and expanded to establish the 
pure population of DF-1_PB-NP cell line.  
Using the primers; outside the HDR template Fwd_Screen-7 and Rev_PB (Fig. 3.3.B, lane 1 
to lane 4), the genomic DNA of DF-1_PB; mono-allelic cell line (Fig. 3.3.B, lane 2) and DF-
1_PB-NP; bi-allelic cell line (Fig. 3.3.B, lane 4) have derived expected PCR amplicons 
expected sizes as a result of miR-30_PB insertion at intron-5/PANK1 gene. No PCR amplicons 
were produced using the genomic DNA of DF-1_WT; negative control (Fig. 3.3.B, lane 1) and 
DF-1_NP (Fig. 3.3.B, lane 3) using this primer combination. Similarly, using primer outside 
the HDR template Fwd_Screen-7 and Rev_NP (Fig. 3.3.B, lane 5 to lane 8), the DF-1_NP; 
mono-allelic cell line (Fig. 3.3.B, lane 7) and DF-1_PB-NP; bi-allelic cell line (Fig. 3.3.B, lane 
8) have produced expected PCR amplicons as a result of miR-30_NP insertion at intron-
5/PANK1 gene. No PCR amplicons were derived using the genomic DNA of DF-1_WT; 
negative control (Fig. 3.3.B, lane 5) and DF-1_PB (Fig. 3.3.B, lane 6).  
The PCR strategy 2 (spanning across the insertion site) to determine the type of allelic (mono-
allelic or bi-allelic) modification, the genomic DNA from DF-1_WT cells has produced a 
single WT PCR amplicon with expected size (Fig 3.3.C, lane 1). The mono allelic modified 
DF-1 cells engineered with either miR-30_PB (DF-1_PB) (Fig 3.3.C, lane 2) or miR-30_NP 
(DF-1_NP) (Fig 3.3.C, lane 3), the PCR product has been split into 2 DNA bands, unmodified 
bands with 500 bp and modified allele with 300 bp. In contrast, the bi-allelic modified DF-1 
cell line (DF-1_PB-NP) with two modified alleles with both miR-30_PB and miR-30_NP 
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shRNAs has produced a single mutant PCR amplicon (300 bp) across the insertion site (Fig 
3.3.C, lane 4).  
 
 (B)                                                                                                (C) 
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Figure 3.3. Precision engineering of shRNAs into the chicken genome.  
 
(A) To clonally isolate the transgenic cells with shRNA insertion after HDR, two PCR 
strategies were devised to confirm the successful integration (PCR strategy-1) and to ensure 
the modification is either mono or bi-allelic (PCR strategy-2). In the PCR strategy-1, the 
forward primer (Screen_7_Fwd; shown in black colour) was designed to start amplification 
from genomic DNA region (outside the homology region in HDR template) and the reverse 
primer was designed to specifically bind the shRNA (NP or PB shRNAs; Rev_PB or Rev_NP 
respectively). Upon successful integration the PCR strategy-1 will produce approximately 
1000 bp PCR amplicon and confirms the integration. For PCR strategy-2, the primers were 
designed to hybridize the intronic region, spanning the predicted integration site for ZFN and 
amplify products with variable sizes that distinguish that either one or both alleles of PANK1 
gene were modified. (B) PCR analysis of genomic DNA extracted from DF-1-WT and ZFN 
modified DF-1 mono-allelic (DF-1_PB and DF-1_NP) and bi-allelic (DF-1_PB-NP) cells using 
the PCR strategy 1; for miR-30_PB insertion (lane 1 to lane 4) and miR-30_NP insertion (lane 
5 to lane 8). (C) PCR analysis for HDR of hitch-hiker constructs on genomic DNA extracted 
from DF-1_WT and the ZFN modified DF-1 mono-allelic (DF-1_PB and DF-1_NP) and bi-
allelic (DF-1_PB-NP) cells. The primers spanning across the predicted integration site (PCR 
strategy 2) were used to amplify genomic DNA extracted from DF-1 WT (lane 1) and ZFN 
modified cells (lane 2 to lane 4) and negative control (lane 5). The agarose gel picture shown 
here is a representation of each cell line that was characterised in the downstream 
characterization studies.  
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3.3.4. Characterisation of ZFN modified cells for shRNA expression and knockdown.  
 
The expression levels of PB and NP shRNAs in ZFN modified cell lines was analysed by qRT-
PCR analysis by making relative to corresponding shRNA levels derived from transient BK 
plasmid as previously described in the section 3.3.2. The expression of both PB (black bars) 
and NP (white bars) shRNAs were detected in the corresponding ZFN modified cells, whilst 
PB was not detected in DF-1_NP cells and NP was not detected in DF-1_PB. In contrast, both 
PB and NP shRNAs expression was detected in the bi-allelic modified DF-1_PB-NP cells (Fig. 
3.4.A and Fig. 3.4.B).   
To examine the RNAi activity in the ZFN modified DF-1 cells, siCHECK-2 plasmids 
harbouring the gene section containing the target sites of PB or NP shRNAs were transfected 
with appropriate controls. The knockdown efficiency of ZFN modified cells in comparison 
with DF-1_WT cells was analysed at 48 hrs post-transfection. As seen in the figure. 3.4.C, a 
significant reduction of Rluc activity (p<0.0001) was observed when the siCHECK-2_PB was 
transfected on to corresponding cells with miR-30_PB (DF-1_PB or DF_PB-NP). The 
reduction of Rluc activity was not observed when the psiCHECK-2_PB plasmid was 
transfected on either DF-1_WT (negative controls) or DF-1_NP (Fig. 3.4.C). Similarly, a 
significant reduction Rluc activity was observed when the psiCHECK-2_NP plasmids were 
transfected into corresponding cells with miR-30_NP (p<0.02) (Fig. 3.4.C). As expected the 
bi-allelic cell line (DF-1_PB-NP) has shown the reduction of Rluc activity with both PB and 
NP genes in psiCHECK-2 plasmids (Fig. 3.4.C and 3.4.D). The reduction of Rluc activity was 
not observed when the psiCHECK-2_NP plasmid was transfected on either DF-1_WT 
(negative controls) or DF-1_PB (Fig. 3.4.D).   
The expression levels of native miR-107 in ZFN modified cells was quantified by qRT-PCR 
analysis. As seen in the figure 3.4.E, the expression of miR-107 was not affected in mono-
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allelic cells. While the miR-107 levels were slightly decreased in the bi-allelic modified cells, 
the decrease was not statistically significant.   
(A)                                                                             (B) 
(C)                                                                              (D) 
 
(E) 
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Figure 3.4. Characterisation of ZFN modified DF-1 cells.  
 
The ZFN modified DF-1 cell lines (DF-1_PB, DF-1_NP and DF-1_PB-NP) were characterized 
for shRNAs and miR-107 expression using qRT-PCR analysis. Cells were harvested and small 
RNAs were extracted prior to cDNA synthesis. (A & B) The expression levels of (A) PB (black 
bars) and (B) NP (white bars) shRNAs in ZFN modified DF-1 cells was quantified by qRT-
PCR using PB or NP specific qRT-PCR primers. The shRNAs expression was normalised to 
5S reference gene and made relative to BK_PB or BK_NP transient expression (positive 
control) to determine the fold difference. Results are representative of 3 independent 
experiments analysed in triplicate. Error bars show ±SD. Asterisks indicate statistical 
significance: ***P<0.0001. (C & D) The reporter mediated knockdown of (C) PB (black bars) 
and (D) NP (white bars) shRNAs using ZFN modified DF-1 cells in comparison with DF-
1_WT cells. To analyse the knockdown effect of a section of PB or NP genes using dual 
luciferase system, cells were transfected with psiCHECK-2_NP and psiCHECK-2_PB with 
appropriate controls in triplicate. Cells were harvested two days post-transfection to calculate 
the knockdown efficiency. Values are the mean ratios of Rluc: Fluc ±SD from n=3 and 
representative of 3 independent experiments. Asterisks indicate statistical significance: 
*P<0.02, **P<0.005, ***P<0.0005. (E) The miR-107 expression levels after engineering one 
shRNA (mono-allelic; DF-1_PB or DF-1_NP) or two shRNAs (bi-allelic; DF-1_PB-NP) was 
analysed by qRT-PCR analysis. The miR-107 expression was normalised to 5S reference gene 
and made relative the levels of DF-1_WT to determine the fold difference. Results are 
representative of three independent experiments performed in triplicate. Error bars show ±SD.  
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3.3.5. Expression of multiple shRNAs by hitch-hiking on intronic miRNAs.  
Targeting three or more viral genes is desirable to avoid the emergence of virus escape mutants. 
Therefore, the possibility of simultaneous expression of three shRNAs (PB, NP and NS in miR-
30 backbone) by hitch-hiking approach was examined by a multi-war-head (MWH) system. In 
contrast to the single shRNAs expression system, the MWH system was developed by 
engineering the intronic ‘bulge’ or ‘loop’ sequences by inserting three anti-influenza shRNAs 
downstream to the miR-107. The design of optimal insertional locations with-in the intron for 
shRNAs could maintain the secondary structural integrity of the whole intron. The major 
objective to retain the secondary structure is to avoid any tertiary folding that can potentially 
form helices and obstructs the shRNAs to form substrate for Drosha/DGCR8. For loop 
modification, the shRNAs were positioned in the order of PB-NP-NS with a distance of 204, 
270 and 332 bp downstream to miR-107 without any disturbance to the predicted secondary 
structure of the intron-5/PANK1 gene (Fig. 3.5.B). However, the modifications at bulge 
sequences to insert PB-NP-NS shRNAs at the positions 172, 219 and 249 distorted the 
predicted secondary structure of intron-5/PANK1 gene (Fig. 3.5.A).  
The qRT-PCR analysis was carried out to assess the shRNAs expression from the peGFP-
Intron construct with either loop_multi-war-head (loop_MWH) or bulge_multi-war-head 
(bulge_MWH) designs. The levels of anti-influenza shRNAs were made relative to a U6-MWH 
construct transfected sample expressing three BK_shRNAs (PB, NP & NS) under the  
attenuated low strength U6 promoter (kind gift from Tim Doran’s lab). As seen in the figure 
3.5.C; the expression of PB (black bars) NP (white) and NS (line bars) shRNAs in the miR-30 
backbone from the bulge and loop design constructs was confirmed using qRT-PCR analysis; 
and the levels were statistically different compared to the attenuated promoter driven MWH in 
BK structures (Fig. 3.5.C). In comparative analysis of expression levels between the bulge and 
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loop MWH constructs, the levels of PB were slightly higher in bulge_MWH construct 
compared to the loop_MWH (3.5.C; black bars). However, the expression levels of NP (Fig. 
3.5.C; white bars) and NS (Fig. 3.5.C; line bars) observed relatively higher in the loop modified 
construct. The qRT-PCR analysis on miR-107 expression have shown decreased expression 
pattern after the transfection of either bulge_MWH or loop_MWH plasmid constructs. 
However, the levels were still higher compared to the untransfected control (Fig. 3.5.D).  
The reporter mediated knockdown of PB, NP and NS genes containing the target sites that were 
cloned into psiCHECK-2 reporter plasmids was observed with both bulge and loop MWH 
systems with decreased levels of Rluc expression compared to the intron by itself. As seen in 
the figure 3.5.E, a significant knockdown of Rluc activity with psiCHECK-2_PB was observed 
using bulge_MWH (p< 0.0001), which is slightly more than loop_MWH construct (p< 0.0001), 
in comparison with intron by itself (Fig. 3.5.E; black bars). However, a significant reduction 
of Rluc activity was observed when psiCHECK-2_NP was co-transfected with either 
loop_MWH (P<0.0001) or bulge (p<0.05) in comparison to peGFP-Intron alone (Fig. 3.5.E; 
white bars). Similar, results were observed with the knockdown of NS in psiCHECK-2_NS in 
which a significant reduction of Rluc activity was observed with loop_MWH construct, which 
is slightly stronger than bulge_MWH when compared to the intron alone (Fig. 3.5.E; line bars). 
These results suggest that it is possible to express multiple shRNAs with biological 
significance, by incorporating the siRNA sequences into the genomic loop or bulge sequences 
adjacent to a miR-107 by the hitch-hiking approach. However, due to its consistent and 
relatively higher reporter mediated knockdown activity of more than one influenza gene, the 
loop_MWH design was chosen as the candidate MWH construct to integrate into chicken 
genome.  
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Figure 3.5. Design and characterization of MWH system in the peGFP-Intron plasmid.   
  
(A) The RNA secondary structure prediction for natural intron (small part) has been zoomed 
to highlight the bulges (in red colour oval), in which the anti-influenza shRNAs are positioned 
downstream from the miR-107. The predicted structural distortion in comparison to natural 
intron structure can be seen in the after bulge modification (B) The selected loop sequences 
downstream to miR-107 to replace with miR-30_PB, miR-30_NP and miR-30_NS were 
highlighted in red colour oval. The comparison of predicted secondary structure of intron 
with/with-out the MWH modification was shown. (C) DF-1_WT cells were transfected with 
MWH plasmids (either bulge_MWH or loop_MWH) with appropriate controls. The 
quantification of PB (black bars), NP (white bars) and NS (line bars) expression levels from 
peGFP-Intron was performed using qRT-PCR analysis. The shRNA levels were normalised to 
the 5S (reference control) and calculated as the fold difference relative to the U6_BK_MWH. 
Results are representative of three independent transfection experiments in triplicate. Error bard 
show ± SD. Asterisks indicate statistical significance: *P<0.01, **P<0.001, ***P<0.0005. (D) 
The miR-107 expression levels was examined by qRT-PCR.  DF-1 cells were transfected with 
intron alone or intron with shRNAs (bulge or loop) or left untransfected. The miR-107 
expression was normalised to 5S (reference control) and calculated as a fold difference relative 
to the untransfected control. The miR-107 levels were examined in three independent 
experiments in triplicate. Error bars show ± SD. Asterisks indicate statistical significance: 
**P<0.001, ***P<0.0004 (E) Comparison of knockdown efficacy between two the MWH 
plasmid systems. DF-1 cells were co-transfected with psiCHECK-2_PB, psiCHECK-2_NP or 
psiCHECK-2_NS with one of the modified peGFP-Intron plasmids (bulge or loop) or peGFP-
Intron alone. The cells were harvested two days post-transfection and a dual luciferase reporter 
assay was performed to analyse the knockdown effect. Values are the mean ratios of Rluc: Fluc 
±SD from n=3 and representative of 3 independent experiments. Asterisks indicate statistical 
significance: *P<0.01, **P<0.001, ***P<0.0001.   
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3.3.6. Precision engineering and characterization of loop_MWH in DF-1 cells.  
 
To engineer the intron-5/PANK1 loci with the loop engineered (containing shRNAs) intron 
sequence, the sequence was cloned into the previously described base HDR template. The 
PANK1_ZFN pair was co-transfected with the pUC-Intron_loop_MWH into DF-1_WT cells; 
and limiting dilution was performed to screen and isolate the positive clones. Out of 74 clones 
screened, 1 clone contained the loop_MWH insertion (Fig. 3.6.A). A series of screening, 
limiting dilution and expansion was performed on the transgenic clone to establish a pure 
population of DF-1-loop_MWH (from now termed as ‘DF-1-MWH’).   
The PCR strategy-2 (Fig. 3.3.A) using the primers across the targeted region of DF-1_MWH 
has produced two bands; the upper band with a size of ~700 bp represents modified allele with 
three shRNAs and the lower band represents the unmodified allele (Fig. 3.6.A, lane 2). The 
genomic DNA from DF-1-WT has produced a single band that represents the two wild type 
allele (Fig. 3.6.A, lane 1). Likewise, the PCR strategy-1 using Rev_PB (PB specific; lane 5 & 
lane 7) and Rev_NP (NP specific; lane 6 & lane 8) and Fwd_Screen-7 (primer outside the 
homology region) has produced the expected sized amplicons only by the genomic DNA of 
DF-1-MWH (lane 7 & lane 8), but not using the genomic DNA of DF-1-WT (lane 5 and lane 
6).  
The expression of each shRNA from the DF-1-MWH cell line were determined by qRT-PCR 
and made relative to the transient transfection positive control using peGFP-Intron-MWH, 
previously shown to express all the three shRNAs from the intron. As seen in the figure 3.6.B, 
the DF-1-MWH cell line has showed stable expression of three shRNAs that were precisely 
modified into the chicken genome with significantly higher than the transient plasmid 
transfection shRNA levels. Quantification of miR-107 expression levels showed that the hitch-
hiking of three shRNAs had a small effect on expression levels of miR-107, but the effect was 
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not statistically significant. Furthermore, the RNAi mediated silencing of influenza genes was 
confirmed by the inhibition of Rluc from the psiCHECK-2 vector harbouring a section of gene 
segments (PB, NP or NS), that were transfected on the DF-1-MWH cell line. These 
observations suggest that the expression of multiple shRNAs is possible by hitch-hiking on the 
native miR-107 both in plasmid and genome context.  
(A) 
 
 
(B) 
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Figure 3.6. Precision engineering and characterization of loop_MWH construct.   
 
(A) The PCR strategy 2 (lanes 1 to lane 3) using the primers spanning the predicted integration 
site (expected product ~500 bp). Lane 2; DF-1_WT cells without any genomic modification, 
has produced a single WT PCR amplicon with expected size (~500 bp). Lane 3, mono-allelic 
modified DF-1 cells with loop _MWH shows two bands, unmodified bands of ~500 bp and 
modified allele of ~700 bp. Lane 3; no template control has not produced any PCR amplicons. 
The PCR strategy 1 (lane 5 to lane 8) using Fwd_Screen-7 and Rev_PB (lane 5 & lane 7) or 
Rev_NP specific (Lane 6 & lane 8). The PCR amplicons derived from genomic DNA of the 
DF-1-MWH using Rev_PB and Rev_NP (lane 7 and lane 8; ~1050 bp and ~1195 bp 
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respectively) and DF-1_WT (negative control; lane 6 and lane 7) were shown. (B) The 
quantification of PB (black bars), NP (white) and NS1 (lines) expression levels from DF-
1_MWH cell line using qRT-PCR analysis. The levels of shRNAs were normalised to the 5S 
(reference control) and calculated as a fold difference relative to the transient expression of 
peGFP-Intron-loop_MWH on DF-1_WT cells. Results are representative of 3 independent 
experiments analysed in triplicate. Error bars show ±SD. Asterisks indicate statistical 
significance: ***P<0.0001. (C) The levels of miR-107 in DF-1_loop_MWH or DF-1_WT 
were quantified by qRT-PCR. The miR-107 expression was normalised to 5S (reference 
control) and calculated as a fold difference relative to the untransfected control. Results are 
representative of three separate experiments. Error bars show ±SD. Asterisks indicate statistical 
significance. (D) The knockdown efficacy between DF-1_WT and DF-1_MWH. Cells. The 
cells were harvested two days post-transfection and subjected to dual luciferase reporter assay 
system to analyse the knockdown efficiency. Values represent mean ratios of Rluc: Fluc. 
Values are the mean ratios of Rluc: Fluc ±SD from n=3 and representative of 3 independent 
experiments. Asterisks indicate statistical significance: Student t-test two-tailed. Asterisks 
indicate statistical significance: *P<0.0102, **P<0.0017, ***P<0.0007.       
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3.3.7. Inhibition of influenza virus in ZFN modified DF-1 cells.  
As the luciferase assay have indicated that the shRNAs expressing from intron-5/PANK1 are 
functional and show target specificity, the ZFN modified cells were next tested for resilience 
to influenza virus infection. The DF-1_WT and ZFN modified cells were infected with WSN 
virus with the MOI of 0.01, the supernatant from respective treatment and control groups was 
collected at 24 hpi (white bars) and 48 hpi (black bars), to analyse the viral kinetics up to 48 
hpi, and the plaque assay was performed to examine the viral titres. As seen in the figure 3.7., 
the plaque assays revealed that the ZFN modified cells containing shRNAs against influenza 
showed significant reduction in viral titre ranging between 2 to 7-fold compared to DF-1_WT. 
The mono-allelic (DF-1_PB) cell line showed inhibition of AI virus replication up to 5-fold at 
24 hpi (Fig. 3.7.A) and 3-fold reduction at 48 hpi (Fig. 3.7.B). Similarly, the DF-1_MWH cell 
line has shown up to 8-fold reduction of viral titre at 24 hpi (Fig. 3.7.A), while only 4-fold 
reduction of viral titre was observed at 48 hpi (Fig. 3.7.A). In contrast, the biallelic cell line 
(DF-1_PB-NP) expressing different shRNAs from two alleles showed the virus inhibition up 
to 7-fold at both 24 hpi and 5-fold 48 hpi respectively, compared to the DF-1_WT.  
(A)                                                                              (B) 
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Figure 3.7. Inhibition of influenza virus replication in ZFN modified cells.  
ZFN modified DF-1 cells (with single or double or MWH) were infected with WSN virus at 
an MOI of 0.01. The supernatants were collected at (A) 24 hpi (B) 48 hpi and assayed for virus 
titre (PFU) by plaque assay on MDCK cells. Results are representative of three separate 
experiments in triplicate. The error bars represent ± SD (n=6).  Asterisks indicate statistical 
significance compared to DF-1-WT cells: *P<0.01, **P<0.001, ***P<0.0001  
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3.4. Discussion 
 
The stable integration of shRNA expression cassettes into the genome offers an efficient RNAi 
induction approach for durable gene knockdown. However, previous studies (An et al., 2006; 
Grimm et al., 2006), including our laboratory (unpublished data) have demonstrated that the 
utilisation strong promoters (for example U6) to drive stable shRNA expression can have 
deleterious effects. For instance, Grimm et al. (2006) reported that these toxicity issues were 
the resultant of overloading of exogenous shRNAs into the natural miRNA pathway, and 
subsequent competition for the cellular enzymes involved in the RNAi pathway. In an attempt 
to minimise these toxicity issues, parallel processing of shRNAs (without any regulatory 
elements) by hitch-hiking on a highly expressing miRNA (miR-107) in the chicken genome 
was examined. The miR-107 was chosen as the location since hitch-hiking with its processing 
will result in wide ranging tissue expression of the anti-influenza shRNA, which is essential to 
meet the aim of producing a fully disease resistant animal. Moreover, hitch-hiking approach 
will eliminate the need for foreign promoters, regulatory sequences and buffer sequences, and 
thus greatly reducing the transgene size from few thousands of base pairs to less than 100 base 
pairs. In addition, the utilisation of PGE tools to precisely locate the anti-influenza shRNAs in 
an intronic sequence will be viewed much more favourable for transgenic animals for food 
production by regulatory agencies and perhaps even by the general public.   
To assess the parallel processing of an exogenous shRNAs from intron-5/PANK1 gene (Fig. 
3.1.A), previously published siRNA sequences targeting the AI virus were selected to 
incorporate into shRNA structures (Wise et al., 2008; Zhou et al., 2008; Hinton et al., 2014). 
As the processing efficiency of shRNA was one of the critical factors to determine the RNAi 
activity, the NP sequence was examined in two shRNA structures (BK and miR-30) that were 
cloned adjacent to miR-107 in the peGFP-Intron plasmid. The BK structure is equivalent to the 
structure that is commonly used in U6 driven expression of shRNA; i.e. perfectly matched stem 
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containing the active RNAi sequence connected by Brummelkamp loop sequence 
(Brummelkamp et al., 2002). The miR-30 structure is based on the native secondary structure 
of miR-30 in which the miR-30 sequence will be replaced by the RNAi effector sequence (NP 
siRNA). The NP expression levels obtained from the miR-30_NP construct were have 
significantly higher compared to the BK structure (Fig. 3.2.B). Moreover, significant 
knockdown of NP gene was observed in the luciferase assay when the miR-30 backbone used, 
but not with BK from the peGFP-Intron plasmid (Fig. 3.2.D). These comparative results 
between miR-30 and BK structure correlate with the findings of several studies, in which the 
miR-30 structure has been shown to serve as a good substrate for RNAi enzyme recognition 
and siRNA processing (Boden et al., 2004a; De Rienzo et al., 2012; Liu et al., 2013a). For 
instance, Boden et al. (2004b) observed a significant increase (up to 80%) in the level of target 
gene knockdown using the miR-30 structure compared to the conventional shRNA structure. 
Furthermore, McBride et al. (2008) observed decreased toxicity when the siRNA sequence was 
positioned in a miRNA backbone without any negative effects on gene silencing efficacy. 
Therefore, the date obtained in this study suggests that it is important to make use of the miRNA 
adapted structures, when using weak (attenuated) promoters or a system like ‘hitch-hiking’ that 
relies on native miRNA pathway for reliable RNAi activity.  
The transfection of peGFP-Intron plasmid (with/without shRNAs) has elevated the miR-107 
expression levels between 2 to 4-fold compared to untransfected control. Interestingly, a 
significant reduction of ‘elevated’ miR-107 levels was observed in the cells transfected with 
intron containing miR-30_NP compared to either intron containing BK_NP or intron alone 
(Fig. 3.2.C). One possible explanation is that there was competition for the native miRNA 
pathway between the elevated miR-107 and miR-30_NP from the peGFP-intron transcript. 
Similar expression patterns was observed in previous studies with PB1-2257 sequence in miR-
30 backbone structure (un-published data; personal communication with Dr. Kristie Jenkins). 
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These results demonstrate that the elevated miR-107 levels from the peGFP-Intron plasmid 
were slightly affected when an exogenous shRNA in miR-30 structure was positioned nearby 
native miR-107, regardless of the siRNA sequence used.  
The observation of knockdown activity by the shRNAs expressed from the peGFP-intron 
plasmid has prompted the engineering of a “pure hitch-hiker shRNA” construct (without any 
reporter; just the shRNA sequence and homology arms on either side) into intron-5/PANK1 
gene using ZFNs. The HDR integration of shRNAs using ZFN was achieved at very low 
frequency which is consistent with many other studies (Orlando et al., 2010; Remy et al., 2014). 
In an extensive series of clonal isolations, a bi-allelic modified cell line with the desired shRNA 
insertion was not obtained. Therefore, a two-step targeting approach was performed utilising 
the mono-allelic cell line (DF-1_PB) (Fig. 3.3.C, lane 2) to modify the second allele by 
transfection of ZFN pair and miR-30_NP shRNA. In this way the bi-allelic cell line (i.e. DF-
1_PB-NP) harbouring individual shRNAs in each of the two alleles was established (Fig. 3.3.C, 
lane 4).  
The qRT-PCR analysis for the shRNA expression and luciferase assay for knockdown have 
demonstrated the RNAi activity in the ZFN modified cells. The expression of PB and NP was 
observed in the cells with either mono-allelic (PB or NP) or bi-allelic modifications (PB and 
NP) (Fig. 3.4.A and Fig. 3.4.B). Moreover, high on-target gene knockdown was observed in 
the ZFN modified cells in the reporter knockdown assay. The mono-allelic cell lines (DF-1_PB 
or DF-1_NP) were shown to have decreased Rluc on only the corresponding siCHECK-2 
plasmids (test); but not the mismatching (control) psiCHECK-2 plasmids. The bi-allelic cell 
line showed the decreased Rluc levels of both PB (Fig. 3.4.C) or NP (Fig. 3.4.D) siCHECK-2 
plasmids, confirming the successful and specific reporter mediated gene knockdown. In 
addition, the expression of one (mono-allelic) or two (bi-allelic) shRNAs from intron-
5/PANK1 gene did not significantly affect the native levels of miR-107. However, a decreased 
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trend of miR-107 levels was observed in the bi-allelic cell line (DF-1_PB-NP), but the decrease 
was not statistically significant (Fig. 3.4.E). The possible reason for the differential expression 
pattern of miR-107 in plasmid transfection (3.2.C) and ZFN modified cell lines (Fig. 3.4.E) is 
the fact that the miR-107 expression levels from the engineered cells that was quantified are 
the endogenous levels. Therefore, miR-107 levels in the ZFN modified cells are measured after 
a single (mono-allelic) or double (bi-allelic) shRNA insertions in the genome, while the miR-
107 levels in the plasmid experiment were over-expressed.  
The use of combinational RNAi to successfully target multiple viral genes to avoid escape 
mutants has been proposed in several studies (Chang et al., 2005; Aagaard et al., 2008; Brake 
et al., 2008; Kim et al., 2010; Chen et al., 2011). For instance, it was experimentally shown 
with HIV that it required less than 25 days for the virus to become resistant against mono-
therapy RNAi by viral mutation and expansion (Boden et al., 2003; Das et al., 2004). Therefore, 
the current study has explored the possibility of parallel processing of three shRNAs (targeting 
PB, NP and NS1 genes) by positioning shRNAs adjacent to miR-107 in two distinct approaches 
(by modifying the bulge or loop sequences in the intron) (Fig. 3.5.A & Fig. 3.5.B). To ensure 
efficient Drosha/Dicer mediated cleavage for miR-107 and the three exogenous shRNAs, care 
was taken to avoid any potential secondary structure distortions that could have potential 
implications in downstream RNAi cleavage steps (Fig. 3.5.A). In contrast to single shRNA 
insertion adjacent to miR-107, differential pattern of qRT-PCR expression levels of three 
shRNAs were observed when comparing the loop and bulge constructs (Fig. 3.5.C). Although 
the predicted secondary structure was affected after shRNA insertion in bulge-based constructs 
(3.5.A), high levels of PB shRNA were detected in the cells transfected with bulge_MWH 
compared to loop_MWH (3.5.C, black bars). However, the higher levels of NP (white bars) 
and NS (line bars) were detected in the loop_MWH, but not the bulge_MWH (Fig. 3.5.C).   
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The differential processing efficiencies of the multiple shRNAs from the MWH system (loop 
and bulge modification) have correlated with findings of the processing efficiencies of 
miRNAs observed from pri-miR-17-92a cluster. The RNA secondary structures of the pri-miR-
17-92a cluster often forms altered secondary or tertiary folds with suboptimal Drosha-DGCR8 
recognition and processing sites (Chaulk et al., 2011; Chakraborty et al., 2012). Consequently, 
those altered clusters potentially process the pri-miRNAs that lack a single-strand-double-
strand junction (Michlewski et al., 2010), a key requirement for Drosha-DGCR8 binding (Han 
et al., 2006). These findings from the pre-miR-17-92a cluster in comparison to the  minimal 
predicted secondary structure distortion in the loop_MWH construct may be an explanation of 
the elevated PB expression and high levels of NP & NS shRNAs, compared to the bulge_MWH 
design which causes more obvious changes in the predicted secondary structure of the intron 
(Fig. 3.5.A).  
Although elevated miR-107 levels were observed as a result of peGFP-Intron_MWH (bulge or 
loop) transfection, significantly decreased levels of miR-107 were seen in both designs 
compared to peGFP-intron alone (without MWH), but more so in bulge_MWH (Fig. 3.5.D). 
The reason for this is not clear, but, two potential factors could have mediated the effect on 
miR-107. First, the dramatic secondary structure distortion in the bulge modification of the 
intron could possibly have higher negative impacts on the RNA scaffold and accessibility of 
enzymes to process miR-107. Second, the location of first shRNA (miR-30_PB) is closer to 
miR107 and may be more accessible for the RNAi enzymes to efficiently process the PB 
shRNA when hitch-hiking on the miR-107 expression from this construct. The engineering of 
the loop_MWH into the chicken genome showed the expression of all three shRNA molecules 
(Fig. 3.6.B), and subsequent knockdown of reporter genes when co-transfected on DF-1-MWH 
cell line (Fig. 3.6.D). In contrast to the elevated miR-107 levels of plasmid transfection 
experiment, significant reduction of natural miR-107 levels in the DF-1_MWH cell line was 
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not observed (Fig. 3.6.C). The demonstration of precise insertion of shRNA by ZFNs into the 
chicken genome offers the proof of concept to justify testing emerging technologies such as 
CRISPR/Cas9 and TALENs to introduce novel shRNA sequences into any intended location. 
Future extension of this work could include the insertion of shRNAs alongside miRNAs with 
tissue specific or inducible expression.   
 AI virus infection is considered a very dangerous diseases due to its rapid replication and 
ability to mutate and generate new and virulent strains, for which the effectiveness of 
vaccination is limited (Stephenson et al., 2003; Capua and Marangon, 2007; Abdelwhab and 
Hafez, 2012). Previously, shRNA transcribed from pol III promoters, either transient plasmid 
expression (Abrahamyan et al., 2009) or integrating vectors for stable expression (Chen et al., 
2011), was shown to be effective at reducing AI virus replication in chicken cells. Here, 
following the confirmation of luciferase mediated knockdown, the resilience of ZFN modified 
cells against WSN strain of AI virus was examined. The ZFN modified cells expressing the 
anti-influenza shRNA (either one or two or three) were shown to have resistance against WSN 
compared to the DF-1_WT cells at 24 and 48 hr post infection. The mono-allelic (DF-1_PB) 
and bi-allelic (DF-1_PB-NP) cell lines were shown to have reduced viral titres from plaque 
assays performed on viral supernatants from the 24 hr time point (Fig. 3.7.A). The results 
obtained with the reporter mediated PB gene knockdown correlated with the viral knockdown 
assays with DF-1_PB or DF-1_PB-NP. The splicing and subsequent processing of two shRNAs 
from two alleles might have contributed to the strong RNAi response induced in the bi-allelic 
(DF-1_PB-NP) cell line. Although a reasonable level of NP gene knockdown was observed in 
the reporter assay, only a 3-fold reduction of viral titre was observed using the DF-1_NP cell 
line at 24 hr time point. Moreover, partial resistance to WSN infection with the DF-1_NP cell 
line was observed at 48 hr post-infection (Fig. 3.7.B). Similar findings were observed in a study 
by Chen et al. (2011) in their comparative analysis of shRNAs, in which the knockdown 
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efficiency of NP was slightly lower compared to PB or PA. The DF-1_MWH expressing three 
shRNAs elicited a very efficient knockdown effect indicating the fact that targeting the virus 
with multiple shRNAs is advantageous particularly when targeting a virus such as AI virus 
which has a high mutation rate. However, it is worth noting that the bi-allelic cell line 
expressing single shRNAs from the two PANK1 mRNA transcripts exhibited a stronger 
inhibitory effect than any of the mono-allelic cell lines including the mono-allelic DF-1_MWH 
(Fig. 3.7). One possible reason for this result is the fact that the bi-allelic cell line has 
transcription of shRNAs from two alleles; to produce higher levels of siRNAs and stronger 
inhibitory activity.  
From a biological perspective, these findings open the door to develop new proof of concept 
studies by precisely locating the anti-influenza shRNA molecules in other genes. For instance, 
positioning the shRNAs in an inducible genes (for example immune genes), that have the 
potential to transcribe and process the exogenous shRNAs at high levels along with the natural 
immune response to suppress viral infections. Furthermore, introduction into such genes is 
advantageous as immune genes are inactive during the embryonic development and thus could 
avoid any toxicity that has been associated with the use of constitutively expressing U6 
promoters. Future studies includes the possibility of integrating the MWH constructs into the 
chicken PGCs using new engineering technologies such as CRISPR/Cas9 system followed by 
PGC culture and re-implantation. The recent development of feeder-free PGC culture media 
could allow more robust approach to easily establish PGC lines with desired modification 
(Whyte et al., 2015), in this case the MWH insertion at PANK1 site. If successful, this provides 
the first demonstration of introducing “non-coding” shRNAs without any regulatory elements 
or markers, into an intronic location in chicken genome for ubiquitous anti-influenza RNAi 
expression.  
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CHAPTER 4: CHARACTERISATION OF HITCH-HIKING APPROACH 
USING TRANSPOSON MEDIATED GENETIC MODIFICATION. 
Abstract 
RNAi is known to be effective in regulating the gene expression in cell culture, however 
delivery or integration of these genetic constructs into a whole animals can cause serious 
toxicity issues. These toxicity issues were primarily believed due to the saturation of natural 
miRNA pathway by shRNA that resulted from using strong promoters (for example U6 & H1). 
The development of the hitch-hiking approach in the chapter 3; which avoids the use of these 
promoters and utilises the native miRNA processing machinery to express shRNAs provides 
an alternative approach. In order to test any in vivo toxicity issues with this alternative approach 
in chicken germ-line specific cells, hitch-hiker constructs were cloned into the Tol2 transposon 
vector to mediate the stable genomic integration. First, the short hairpin RNA expression and 
subsequent RNAi activity from the integrated Tol2_hitch-hiker construct was confirmed in DF-
1 cells by qRT-PCR and luciferase assay. Next, to assess any toxicity issues in the primordial 
germ cells (PGCs), one of characterised Tol2_hitch-hiker construct was injected into ED 2.5 
embryos targeting the circulating PGCs for stable integration. 9 out of 10 embryos that were 
analysed at ED 14 showed the expression of the GFP marker from Tol2_hitch-hiker construct 
in PGCs and giving a strong indication that the shRNA levels were tolerated by PGCs. A 
number of embryos injected with these constructs were hatched and the chicks raised to sexual 
maturity. The integration of Tol2_hitch-hiker construct was confirmed in the semen of G0 birds 
by qRT-PCR analysis.  
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4.1. Introduction    
Since the discovery of RNAi, it has emerged as a valuable alternative to mutagenesis or gene 
knockout strategies for the study of gene function. Furthermore, the relative ease of targeting 
genes (including exogenous) means that RNAi has not only revolutionized functional genomics 
but also has the potential to be used to treat animal and human disease (Clark and Whitelaw, 
2003; Kim et al., 2010; Zhang et al., 2012; Jiao et al., 2013). In cell culture, the induction of 
RNAi can be achieved by transient transfection of synthetic siRNAs (Elbashir et al., 2001; 
Hinton et al., 2014) or plasmids (Brummelkamp et al., 2002; Wise et al., 2007; Kim et al., 
2010). For some application such as generating transgenic animals with disease resistance 
against viral diseases, intracellular transcription of shRNA molecules is desired. These RNA 
transcripts form hairpin like structures and enter into RNAi pathway for sequential cleavages 
by RNAi enzymes, are processed into mature siRNA, and are loaded into the RISC complex to 
disrupt target mRNA or viral RNAs.  
Efforts to produce transgenic animals with stable integration of shRNA sequences have become 
a reality in several laboratories (Carmell et al., 2003; Cao et al., 2005; Coumoul et al., 2005; 
Hu et al., 2015). However, there are issues in vivo with reliable production of RNAi molecules 
that can effectively mediate gene target knockdown without causing toxicity. In addition, over 
expression of shRNAs can initiate induction of innate immune response that have the potential 
to alter global gene expression patterns causing cell death (Bridge et al., 2003; Akashi et al., 
2005; Hutson et al., 2012). Therefore, the use of strong exogenous promoters and the associated 
negative effects sometimes raise concerns about in vivo RNAi application (Boudreau et al., 
2009). Thus, it is a priority to thoroughly dissect the underlying mechanisms involved in RNAi 
toxicity and to develop new variations of the technology through in vivo studies to promote 
safe and successful application of this technology.  
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The utilisation of viral vectors to mediate stable transgenesis in chicken genome was 
demonstrated in several studies (Salter and Crittenden, 1989; Bosselman et al., 1990; McGrew 
et al., 2004; Motono et al., 2010). However, non-viral vectors offer advantages over viral 
vectors particularly in terms of perceived safety issues in agricultural production animal such 
as the chicken. The first successful transposon mediated production of a transgenic vertebrate 
was achieved with the sleeping beauty (SB) transposon (Ivics et al., 2009). A few years later 
the application of Tol2 (Macdonald et al., 2012) and piggy back (Macdonald et al., 2012; Park 
and Han, 2012) technologies to mediate stable transgenesis in cultured chicken PGCs were 
reported. In addition, the in vivo transfection of Tol2 plasmids to modify the genome of 
circulating PGCs in the blood stream of chicken embryo was also demonstrated (Tyack et al., 
2013). Transposons often allow for efficient chromosomal integration and sometimes could 
facilitate single-copy insertion events (Macdonald et al., 2012), and are thus recognised as a 
reliable tool to mediate transgenesis.  
The expression of shRNA by hitch-hiking on the native miRNA pathway is a novel approach 
with the potential to minimise the shRNA associated toxicities. Moreover, this approach may 
be favourable for generation of transgenic animals for use in the food chain due to the minimal 
size of the transgene without the addition of exogenous gene regulatory sequences. However, 
a stringent in vivo assessment of these constructs is required before realising the full potential 
of this approach. However, precise introduction of shRNAs into germ-line specific cells using 
PGE tools could present technical difficulties due to the complexity involved with the isolation 
of modified PGCs without any marker. In the current study, the Tol2-transposon system which 
facilitates random integration of the constructs into the genome at high efficiency was utilised 
to deliver the hitch-hiker constructs, enabling the analysis of shRNA expression and subsequent 
gene knockdown. Next, the constructs were delivered into chicken embryos to assess the in 
vivo toleration in the chicken PGCs. 
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4.2. Materials and methods.  
4.2.1. Construction of mini-Tol2 transposon with peGFP-Intron.  
To construct a vector that harbour intron-5/PANK1 and a mini-Tol2 transposon system, the 
core elements of peGFP-Intron plasmid (the section of EG-Intron-FP) were cloned into a vector 
containing the miniTol2 plasmid system that was previously described in Tyack et al. (2013). 
The insertion of the intron with acceptor and donor sites into the coding sequence of eGFP will 
facilitate the splicing of the intron from two exons of eGFP. In addition, the available RE sites 
(BamHI and KpnI; described in section 3.3.1 of chapter 3) downstream to the miR-107 
facilitated adding either single (PB or NP) or multiple shRNAs (loop or bulge).  
The miniTol2 system is classified as a two plasmid system (1) pT2-009 and (2) pT2-002. The 
pT2-009 plasmid contains the terminal Tol2 sequences with RE sites that enable the cloning of 
a GOI to integrate into the genome. While, the pT2-002 plasmid contains the coding sequence 
of the transposase gene. The transcription and translation of pT2-002 produces the transposase 
enzyme that mediates the transposition of miniTol2 into the genome of transfected cells.    
To clone the “EG-intron-FP” fragment into pT2-009, the peGFP-intron plasmid was digested 
with NotI and XhoI and the digested fragment was cloned into corresponding RE sites of pT2-
009, adjacent to the 1.7 kb hybrid promoter composed of the CMV immediate-early enhance, 
CBA promoter, and CBA intron1/exon 1 which is commonly called as the CAGGS promoter. 
The Poly-A sequence was PCR amplified using primers (Appendix B) from peGFP-N1 Intron 
vector and cloned into the Not1 RE site to generate the final construct. The construct was 
sequenced and it was confirmed that the correct insertions had occurred and that all the 
elements were in the correct orientations. The protocol described in chapter 3 was followed to 
clone the shRNA (single or multiple) into the BamHI and KpnI sites in the peGFP-Intron 
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plasmid. Fine structure of all the constructs were confirmed by DNA sequencing analysis prior 
to use in experiments.  
4.2.2. Formulation of miniTol2 plasmids for microinjection.  
The formulation of Lipofectamine 2000 CD with plasmid DNA was prepared by following 
previously described method by Tyack et al. (2013). Briefly, 0.6 μg of pMiniTol2-Intron-
MWH and 1.2 μg of pT2-002 were mixed in a tube containing 45 μL of OptiPRO SFM (Cat. 
No. 12309-019, ThermoFisher Scientific, USA). Similarly, 3 μL L 2000 CD (Invitrogen, USA) 
was added to 45 μL of OptiPRO and incubated for 5 min. The solutions were mixed and 
incubated at RT for 20 minutes to form L2000 CD-DNA transfection complex.      
4.2.3. Micro-injection into chicken embryos and Gonad assays. 
To perform microinjection of Tol2-intron and pT2-002 constructs, 50 fertilized specific 
pathogen free eggs were incubated to 2.5 days to reach the 15-16 Hamburger-Hamilton 
embryonic stage. The micro-injections were performed as previously described in Tyack et al. 
(2015). Briefly, sterile metal forceps were used to crack the pointed end of the recipient egg 
and to lift out a portion of the shell to make a small window. The viable ED 2.5 embryos were 
carefully microinjected with 1-2 μL of the transfection complex into the dorsal aorta of the 
embryo. The injected eggs were then re-sealed with sterile paraffin and placed in the incubator 
at 37oC. At ED 14 the gonads from 10 micro-injected chicken embryos were visualised under 
a fluorescence microscope.  
4.2.4. Characterisation of hatched chicks and semen screening.     
 Genomic DNA extracted from the blood of hatched G0 chicks was used to determine the sex 
of hatched chicks by qRT-PCR using W chromosome specific primers Fwd_W: 5’ 
GCTTCATGGAGGCAACTGAAAC and Rev_W: 5’ CACCAGCAATAGACTGCAAAGC. 
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Assessing the presence of the Tol2 integrated construct in the semen of G0 roosters was 
performed as described by Tyack et al. (2013).   
4.3. Results.  
4.3.1. Generation of Tol2-Intron modified DF-1 cells.  
Having shown expression of shRNAs (single or multiple) from the peGFP-Intron plasmid 
during transient transfection of DF-1 cells (chapter 3 results section), the next step was 
examining shRNA expression from a stably integrated peGFP-Intron plasmid introduced into 
the chicken genome using mini-Tol2 transposon system. The mini-Tol2 system is a dual 
plasmid based system and the transposition of Tol2 vector in the genome will occur only 
following the co-transfection of the two plasmids. The first plasmid contains the two Tol2 
terminal inverted repeats (TIRs) on either side of eGFP sequence containing Intron-5/PANK1 
gene under the control of the CAGGS promoter (designated as Tol2-Intron from now) 
(Fig.4.1.A). The second plasmid contains the coding sequence of the Tol2 transposase (pT2-
002) gene under the control of CAGGS promoter to express the transposase protein that 
mediates the transposition of Tol2-Intron into the genome of transfected cells. The DF-1 cells 
were transfected with Tol2-Intron with/without shRNAs (single and multiple) in the presence 
pT2-002 plasmid. GFP expression was confirmed at 24 hr post-transfection. This confirms 
functional transcription and splicing of the intron from the two eGFP fragments even after 
cloning into miniTol2 and the subsequent addition of shRNAs. To isolate cells containing the 
stably integrated transposon vector, the transfection positive cells were grown for up to 3 weeks 
and the GFP positive DF-1 cells were selected and sorted using FACS (Fig. 4.1.B). After 3 
weeks, the control groups that are transfected with Tol2-Intron alone were negative for GFP 
expression demonstrating that the transposition events did not occurred without the pT2-002 
plasmid. Using this approach, five transgenic DF-1 cell lines were generated and that includes; 
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Tol2-Intron, Tol2-Intron-PB, Tol2-Intron-NP, Tol2-Intron-bulge_MWH and Tol2-Intron-
loop_MWH.  
(A) 
 
 
(B) 
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Figure 4.1. Tol2-Intron vector construction and stable genetic modification.   
 
(A) Schematic of Tol2-intron construct used in the study. The core components in the construct; 
the CAGGS promoter (yellow), eGFP coding sequence (green), intron (purple), and Tol2 
inverted repeats (black) were shown. (B) DF-1 cells were transfected with Tol2-Intron 
constructs in the presence pT2-002 vector and visualized after 3 week post-transfection for 
stable GFP expression.  GFP positive cells were FACS sorted and cells were grown to expand 
the culture. The images were taken under fluorescence microscope with bright field and 
fluorescent filter at 20x magnification.   
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4.3.2. Characterization of shRNA expression in Tol2-Intron modified cells.  
To quantify the expression levels of PB, NP and NS in theTol2-Intron modified DF-1 cells, 
qRT-PCR analysis was performed by shRNA specific primers. As described in chapter 3, the 
shRNA expression was calculated as a fold difference by comparing it to the expression from 
transient BK plasmid. As seen in the figure 4.2.A, the expression of PB was confirmed in the 
cells modified with Tol2-Intron_PB by the observation of significantly higher levels of 
expression compared to the expression of transient plasmid PB_BK (P<0.0001). Likewise, 
significantly higher expression of NP shRNA was observed in the cells modified with Tol2-
Intron_NP compared to the plasmid based PB expression (P<0.0001).  To confirm the 
expression of PB, NP and NS shRNAs from the Tol2-Intron MWH cell lines, the expression 
levels were made relative to the plasmid based expression of low strength U6_BK_MWH 
plasmid described in chapter 3. As seen in the figure 4.2.B, the three shRNA levels from the 
Tol2-Intron MWH cell lines was significantly higher than the transient expression of 
U6_BK_MWH. Consistent with the peGFP-Intron plasmid transfection results in chapter 3, 
significantly higher levels of PB (black bars) expression were observed in the cells with 
bulge_MWH construct compared to loop_MWH (Fig. 4.2.B). In contrast, the levels of NP 
(white bars) and NS (line bars) were slightly higher in the cells integrated with loop_MWH 
compared to bulge_MWH (P<0.0001) (Fig. 4.2.B). As expected, no shRNA expression was 
detected in DF-1_WT cells.  
 
 
 
 
 100 | P a g e  
 
(A) 
 
(B) 
  
Figure 4.2. Characterisation of shRNA expression in Tol2-Intron modified DF-1 cells.  
The shRNA expression from Tol2 modified DF-1 cells with (A) single shRNA or (B) multiple 
shRNAs was characterized using qRT-PCR. The cells were harvested and small RNAs were 
extracted prior to cDNA synthesis. Levels of PB (black bars), NP (white bars) and NS (line 
bars) shRNAs were quantified using PB, NP and NS specific qRT-PCR primers. The shRNA 
expression from cells expressing single shRNA was normalised to 5S reference gene and made 
relative to BK_PB or BK_NP plasmid based expression (positive control). Similarly, the 
shRNA expression from cells expressing multiple shRNAs was normalised to 5S reference 
gene and made relative to transient expression of BK_MWH (positive control). Error bars show 
standard deviation (±SD). Asterisks indicate statistical significance: Results are representative 
of three separate experiments: ***P<0.0001, **P<0.001, *P<0.05.  
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4.3.3. Characterization miR-107 expression in Tol2-Intron modified cells.  
To determine the levels of miR-107 in the Tol2-Intron modified DF-1 cells, the levels of miR-
107 were examined by qRT-PCR analysis. Consistent with the plasmid based experiments in 
chapter 3, the integration of an additional copy (or copies) of intron-5 containing the miR-107 
into the chicken genome elevated the miR-107 levels in all of the Tol2 modified DF-1 cells. 
As seen in the figure 4.3, the levels of miR-107 in Tol2-Intron (without shRNAs) modified 
cells was up to 6-fold higher than DF-1_WT cells. Interestingly, the levels of miR-107 were 
decreased in the cells expressing shRNAs from the hitch-hiker construct compared to cells 
integrated with the Tol2-Intron by itself. As seen in the figure 4.3, a 2-fold reduction in miR-
107 levels was observed in the cells modified with Tol2-Intron-bulge-MWH compared to the 
cells modified with Tol2-Intron by itself.  Similarly, the elevated miR-107 levels were also 
found in the cells modified with either PB, NP or loop_MWH (Fig. 4.3). 
 
Figure 4.3. Characterisation of miR-107 expression in Tol2-Intron modified cells.  
The Tol2 modified DF-1 cells were characterized for miR-107 expression using qRT-PCR 
analysis. The cells were harvested and small RNAs were extracted prior to cDNA synthesis. 
The miR-107 expression was normalised to 5S reference gene and made relative to the levels 
of DF-1_WT. Results are representative of three independent experiments performed in 
triplicate. Error bars show ±SD. Asterisks indicate statistical significance: ***P<0.0001, 
**P<0.001 
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4.3.4. Characterization knockdown efficiency in Tol2-Intron modified cells.  
To assess the knockdown efficiencies of the integrated shRNAs, sections of the influenza genes 
(PB, NP & NS1) containing the target sites for the shRNAs were cloned into psiCHECK-2 
plasmids and dual Luciferase assays were performed. Figure 4.4.A shows sequence specific 
knockdown efficiency by DF-1_Tol2-Intron_PB cell line (black bars), which was 
demonstrated by the significant reduction of Rluc activity following the transfection with 
psiCHECK-2_PB plasmid. Similarly, the sequence specific knockdown by DF-1_Tol2-
Intron_NP cell line (Fig. 4.4.A, white bars) was demonstrated by the significant reduction of 
Rluc activity in cells transfected with psiCHECK-2-NP. The reduction of Rluc activity was not 
observed when the psiCHECK-2 (with PB or NP) plasmids were transfected into either DF-
1_WT or Tol2-Intron cells (with no shRNA). Next the knockdown activity of two MWH 
transgenic DF-1 cell lines was tested by transfecting the relevant psiCHECK-2 plasmids 
containing cloned sections of PB, NP and NS genes. As seen in the figure 4.4.B, the reduction 
of Rluc activity from psiCHECK-2_PB was significantly higher in the cells with Tol2-
bulge_MWH compared to Tol2-loop_MWH. In contrast, the reduction of Rluc activity from 
psiCHECK-2_NP (white bars) and psiCHECK2_NS (line bars) was observed in the cells with 
Tol2-loop_MWH compared to Tol2-bulge_MWH (Fig. 4.4.B). This is consistent with the 
pattern of expression detected by qRT-PCR.   
(A) 
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(B) 
 
Figure 4.4. psiCHECK-2 mediated knockdown analysis in Tol2-Intron DF-1 cells.  
 
The knockdown efficiency of transgenic DF-1 cells with (A) single shRNA or (B) multiple 
shRNAs in comparison with DF-1_WT cells was analysed using dual luciferase system. To 
analyse the knockdown effect of a section of PB (black bars), NP (white bars) and NS (line 
bars) genes, cells were transfected with psiCHECK-2 plasmids containing either corresponding 
or non-target segments of genes with appropriate control groups in triplicates. Cells were 
harvested two days post-transfection and knockdown efficiencies were calculated. Values 
represent mean ratios of Rluc: Fluc. Values are the mean ratios of Rluc: Fluc ±SD from n=3 
and representative of 3 independent experiments. Asterisks indicate statistical significance: 
***P<0.0001, **P<0.001 and *P<0.05.  
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4.3.5. In vivo transfection of PGCs and gonad assay.    
As reliable RNAi activity was observed for Tol2-Intron_Loop_MWH construct, the next step 
was to translate the technology to an in vivo system to assess if a transgenic chicken could be 
produced with this construct. For this purpose, the plasmid was microinjected into 50 ED 2.5 
embryos to transfect the circulating PGCs, prior to their migration to the gonads. The Tol2-
Intron_loop_MWH and pT2-002 were complexed in with L2000 and were intravenously 
injected into stage 14 HH (ED 2.5) embryos as illustrated in the figure 4.5.A. To analyse the 
integration of Tol2-Intron_MWH in the PGCs in gonads, ten eggs at ED 14 were opened and 
the gonads from the embryos were dissected and examined for fluorescence. One embryo found 
dead was presumably at ED7 or ED8. Based on the morphology of the gonads, we have 
determined that from a total of 9 embryos, six were females and 3 were males. Gonads were 
analysed under bright-field and fluorescent filters, and large numbers of cells (presumably 
PGCs) were observed emitting green fluorescence, which confirmed the presence of Tol2-
Intron_MWH (Fig. 4.5.B). Of the remaining embryos, 11 chicks survived to hatch. However, 
two chicks died before reaching 3 weeks of age (Table 4.1. Row No. 2 and Row No. 11).  
(A) 
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(B) 
 
 
Figure 4.5. Characterization of MWH construct in the gonads.  
(A) The procedure of in vivo transfection of circulating PGCs in ED 2.5 chicken embryo. To 
visually demonstrate the micro-injection procedure and subsequent distribution, a dye was used 
as a solution for the micro-injection of ED 2.5 embryo. The picture was a kind gift from Tim 
Doran’s group at CSIRO-AAHL. (B) Analysis of gonads of ED 14 embryos that were injected 
with L2000–Tol2-Intron complex. The gonads were analysed under bright-field and green 
fluorescence filter light at 100 x magnification. 
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4.3.6. Characterisation of hatched birds  
Of the 11 hatched chicks, one died before samples were collected to determine the sex of the 
birds. From the remaining ten chicks, blood was collected and the genomic DNA was extracted 
prior to performing qRT-PCR analysis, using W chromosome specific primers. A Ct value of 
less that 30 was obtained from the analysis of genomic DNA from 4 chicks (543, 544, 547, and 
548), confirming the presence of the W chromosome, indicating that the four chicks are 
females. Six chicks (545, 546, 549, 550, 551 and 552) did not show any measurable PCR 
product replication for the W chromosome primers, indicating that these birds are males (Table 
1, Column No. 2 and No.3). The males were raised to sexual maturity and semen from these 
roosters was used to screen for the presence of Tol2-Intron_MWH. To assess the presence of 
the transgene and get an estimate of levels in semen, the DNA extracted from the semen was 
used for qRT-PCR analysis for the presence of Tol2-Intron-MWH construct using Tol2 specific 
primers. The qRT-PCR yielded a Ct value of 31 for Tol2-Intron_MWH, while a Ct value of 26 
for the control genomic DNA gene was considered as base level to calculate the percentage 
transgenesis (Table 4.1 Column No. 5). The analysis was performed on two different semen 
samples from each rooster that were collected at least one week apart. As seen in the table 4.1 
column No. 7, the highest levels of Tol2-Intron_MWH DNA were found in the semen from 
roosters 551 and 552. These two male roosters were identified as the potential G0 founder 
roosters to breed for G1 germ-line transgenic offspring. The eggs derived after mating wildtype 
hens with the G0 chimera’s males are currently being screening to identify fully transgenic G1 
transgenic birds. The screening for GFP chicken was performed by illuminator and filter 
goggles which allow for visualization of the EGFP protein. To date, we have screened 225 G1 
embryos, including 128 dead in shell embryos and have not yet identified a GFP transgenic G1 
positive bird.   
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Table 4.1. The characterization of hatched chicks to determine the sex and subsequent 
analysis of transgenesis in the semen of roosters.  
(N/A represents not applicable) 
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4.4. Discussion   
 
The stable expression of shRNAs within the host cells to study gene function was one of the 
widely used in vitro technique by the scientific community (Abrahamyan et al., 2009; Kim et 
al., 2010; Choi et al., 2015). However, the situation is different with delivery or expression of 
shRNA in vivo. It is known that the expression of exogenous shRNA under a strong promoter 
may cause cellular toxicity, and therefore requires rigorous safety assessment when delivered 
into a whole animal (McBride et al., 2008; Grimm et al., 2010; Liu et al., 2013b). The hitch-
hiking on the native miR-107 pathway to express shRNA without any exogenous promoter is 
a novel approach developed in the chapter 3 of this thesis. However, this strategy requires 
precision placement of shRNAs into the PANK1 locus without any other DNA sequences such 
as marker genes. Although integration of just the hitch-hiker constructs (without any reporter) 
using ZFN induced DSB was achieved in DF-1 cells, the efficiency was very low and laborious 
process as previously discussed. Furthermore, during the period of these experiments, a report 
on homologous recombination of an GFP gene to knockout an endogenous gene in chicken 
PGCs was published and found that the HR efficiency was achieved at a rate of 1 positive clone 
for every 107 transfected PGCs (Schusser et al., 2013). This strongly suggests that this may not 
be a feasible approach to generate a transgenic chicken containing shRNAs at the PANK1 locus 
without any marker assisted selection to enable screening for transgene integration. Using the 
current technologies available, the selection of modified PGCs using PCR screening approach 
would be a large and difficult task. Therefore, the in vivo effect of integrated hitch-hiker 
constructs was first assessed by delivering the constructs using the much more efficient Tol2 
transposon system, before attempting to generate a transgenic chicken using the pure hitch-
hiker strategy.      
Built on earlier observations, the plan was to use the previously developed peGFP-Intron 
plasmid; in which intron-5 of the PANK1 gene was cloned into an eGFP sequence under 
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control of a CAGGS promoter for the in vivo toxicity assessment for hitch-hiker construct. This 
approach allows for simultaneous analysis of exogenous shRNA expression (one or multiple) 
from the intron, simply by screening transgenic cells for GFP expression. Similar to this, Shan 
et al. (2010) observed high levels miR155-based shRNA expression when expressed from an 
intron connected to the reporter gene compared to the shRNAs without any intron in cell lines 
(Shan et al., 2010). Likewise, Stegmeier et al. (2005) had previously developed a miR-30 based 
shRNA expression cassette in which the CMV promoter drives the expression of a reporter 
gene and shRNAs. Interestingly, they found reduced levels of GFP expression, since the 
shRNA processing interfered the production of GFP mRNA (Stegmeier et al., 2005). Based on 
these observations, the CAGGS promoter which can efficiently transcribe the eGFP-Intron 
transcript was used to processes high levels of cloned shRNAs.   
To date, the use of replication defective viral vector mediated gene transfer was the most widely 
used approach for shRNA transgenesis (Chang et al., 2005; Liu et al., 2013b). However, the 
emergence of replication competency from the genetic recombination between the integrated 
virus and helper sequences cannot be ruled out (Chong et al., 1998; Razi Soofiyani et al., 2013). 
Therefore, the use of viral vectors for gene transfer in a production animals like chickens may 
raise safety concerns if animals destined for the food chain. Previous research demonstrated an 
efficient genomic integration of transgenes when using the non-viral vector based Tol2 
transposon system for transgenic chicken production (Tyack et al., 2013).  
To test if the Tol2 transposon system would be effective at integrating the desired construct, 
the peGFP-Intron plasmids were generated by coupling the Tol2 system and incorporating one 
or multiple shRNAs adjacent to the miR-107. Upon transfection, this plasmid induced 
production of GFP, demonstrating the normal intron function without any disruption of the 
open reading frame (ORF). Furthermore, the transposition of Tol2-Intron constructs was 
confirmed by stable GFP production particularly following selection of cells using FACS. This 
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indicated that the use of the Tol2-Intron combination greatly facilitates the establishment of a 
simple and stable shRNA expression system using a hitch-hiking construct. Before taking steps 
towards making a transgenic chicken it was first important to study the stability, variability and 
functionality of shRNA expression. Following the integration of Tol2-Intron-shRNA 
constructs into the genome, the characterisation of RNAi activity was assessed by qRT-PCR 
and luciferase reporter mediated knockdown analysis. The results obtained using Tol2-Intron 
modified cells closely correlated with the plasmid and ZFN-modified DF-1 cell experiments in 
chapter 3. In particular, the PB shRNA was shown to have high levels of expression and that 
is consistent with expression in both the plasmid systems and when integrated into the genome 
regardless of when there is a single insertion or multiple insertions. Furthermore, the PB 
expression from bulge_MWH was relatively higher than loop_MWH, which corresponded 
with an observed reduction of Rluc activity in cells with bulge_MWH in comparison with cells 
modified with loop-MWH. Consistent to the plasmid transfection experiments, high levels of 
NP and NS shRNAs were observed in the cells modified with Tol2-Intron_MWH.   
The early embryonic toxicity associated with shRNAs has been reported in species such as 
mice (Cao et al., 2005), pigs (Dai et al., 2014) and chickens (unpublished data). This prompted 
the assessment of the toxicity associated with the hitch-hiker construct in PGCs by examining 
GFP fluorescence in gonad of chicken. The in vivo transfection of circulating PGCs and 
subsequent analysis of fluorescent PGCs in the gonads was previously described (Tyack et al., 
2013), and provide a clear indication that the PGCs tolerate the level of shRNA expression 
from hitch-hiking approach. Previous attempts in our laboratory (unpublished data) to generate 
transgenic chickens using a strong U6 promoter to drive expression of MWH constructs along 
with GFP as a marker found that the strong U6 promoters were toxic. This was concluded after 
it was observed that no GFP positive PGCs were able to migrate back to and colonize the 
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gonads. In contrast, shRNA constructs under an attenuated U6 promoter showed successful 
migration of GFP expressing PGCs to the gonad (unpublished data). 
In the current study, similar experiments were performed by co-injecting the Tol2-
Intron_loop_MWH plasmid and pT2-002 plasmid, the presence of stably expressing GFP 
PGCs in the gonads of 8 of the 9 chickens indicated the construct was not toxic in the PGCs 
during the early embryonic stages of chicken development. Consistent with the observation of 
GFP fluorescence in PGCs of ED 14 embryos, the qRT-PCR analysis with Tol2 specific 
primers on the semen was very encouraging from two of the G0 birds that were derived from 
these Tol2-Intron microinjections. Two roosters are currently set for mating and the offspring 
are being screened for fully transgenic G1 green chicks. Previous results from other projects 
using similar methods of sperm screening have found that estimated levels of 0.221% miniTol2 
positive sperm the can produce up to 1.55% G1 transgenic chicken; i.e. 3 transgenic chicks 
from 193 hatched chicks (Tyack et al., 2013). Once fully transgenic G1 chicks are identified, 
initial characterization experiments are planned to analyse the biological significance of the 
genomic integrated loop_MWH shRNA. Moreover, the G1 chicks will be raised to sexual 
maturity and mated with control chickens. This will enable transgenic green eggs that are 
collected from these mating’s to be used for in ovo influenza challenge to analyse the influenza 
resistance in these embryos.   
Although the in vivo shRNA expression analysis using Tol2-Intron hitch-hiker constructs was 
not the ultimate test, however this simple system allows for long term analysis of shRNA 
expression from the designed loop_MWH construct from a whole transgenic chicken. While 
ZFN-driven in vivo genome modification has been successful in several species (Meng et al., 
2008; Hauschild et al., 2011; Li et al., 2011a; Anguela et al., 2013), this application has not yet 
been demonstrated in chicken PGCs to engineer the genome for germ line transmission. 
Moreover, since the initiation of this study new genome engineering tools such as TALEN and 
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CRISPR have been shown to mediate more efficient genome editing of a diverse range of cell 
types and animal (Sander et al., 2011; Ding et al., 2013; Tan et al., 2013; Hai et al., 2014). Due 
to the time constraints during this study, the integration of marker-less hitch-hiker constructs 
into PGC lines has not been tested. However, a systemic evaluation of these emerging tools 
has been performed in chapter 5.   
 
 
 
 
 
 
 
 
 
 
 
 113 | P a g e  
 
CHAPTER 5: EVALUATION OF PRECISION GENOME 
ENGINEERING TOOLS IN CHICKEN PGCs. 
Abstract 
The advent of precision genome engineering (PGE) tools such as TALEN and CRISPR/Cas9 
systems have revolutionised the field of genetic engineering to a great extent, enabling precise 
changes to specific genomic elements. In an attempt to investigate the possibility of mediating 
PGE events in chicken cells, stably integrated GFP gene was chosen as the target gene in both 
DF-1 cell line and PGCs. First, GFP targeting TALEN and CRISPR/Cas9 expression plasmids 
were analysed in DF-1 cells for their ability to knockout expression of the GFP gene, this was 
followed by attempts to generated genomic fragment deletion and then finally HDR was 
stimulated to repair the DNA break with the DsRed coding sequence. Using the Surveyor assay, 
flow cytometry and PCR analysis, TALEN and CRISPR/Cas9 mediated GFP knock-out and 
DsRed knock-in was confirmed in DF-1 cells. Next, the genomic targeting of a single copy of 
the GFP gene, genomic fragment deletion and HDR of DsRed coding sequence was achieved 
in PGCs. Although, the GFP knock-out events were achieved at higher rates, the HDR of 
DsRed coding sequence into targeted GFP gene were observed at very low efficiency in PGCs. 
The CRISPR/Cas9 modified cells were confirmed for remigration into the embryonic gonad 
by PCR and microscopy analysis. Finally, the development of multiplex genome engineering 
by CRISPR/Cas9 system to enrich the modified cells by simultaneously targeting a reporter 
and an endogenous gene was demonstrated in DF-1 cells. The development of this new 
approach may open a new opportunities to the creation of gene edited chickens by cultured 
PGCs.  
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5.1. Introduction  
 
The world’s population is increasing at an accelerating pace and expected to reach 9 billion by 
2050. The substantial rise in population size, in conjunction with anthropogenic pressures will 
exacerbate the existing food productions systems (Borlaug, 2007; Godfray et al., 2010). From 
a food security perspective, providing sufficient, safe and nutritious food is a major challenge 
we will need to confront in the 21st century (Tester and Langridge, 2010; Tilman et al., 2011). 
Hence, it is critical to implement new bio-technologies to enhance the productivity and improve 
the animal welfare across the agriculture sector (Tester and Langridge, 2010), particularly 
livestock species (Fahrenkrug et al., 2010). With the advent of transgenic technologies, it is 
now possible to discover, expand and create quantitative and qualitative traits without affecting 
the overall genetic pool in a timely and more cost-effective manner, ultimately providing 
profound impact for sustainable animal agriculture (Pursel et al., 1989; Clark and Whitelaw, 
2003; Fahrenkrug et al., 2010).  
Chickens are excellent vertebrate animal models to study many research areas and one of the 
largest production system globally. The application of transgenic technology to manipulate the 
chicken genome could be an effective and alternative strategy to improve the trait (Sang, 2004a; 
Lillico et al., 2007; Motono et al., 2010; Schusser et al., 2013; Tyack et al., 2013). However, 
the efficient production transgenic chickens has lagged behind the mammalian species due to 
their differences in the reproductive system which present difficulties in accessing the zygote. 
Alternatively, the PGCs; progenitors of gametes are considered as an excellent target to 
develop for germ-line transmission (van de Lavoir et al., 2006). The manipulation of cultured 
PGCs using non-viral vectors such as Piggybac (Macdonald et al., 2012; Park et al., 2013) and 
Tol2 (Macdonald et al., 2012) technologies and transplanting PGCs back into embryos, was 
shown to have high germ-line transmission rates compared with any other techniques.    
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The development of PGE technologies such as ZFN (Kim et al., 1996), TALEN (Bedell et al., 
2012) and CRISPR/Cas9 system (Cong et al., 2013) offers precise and programmable editing 
of complex genomes at single-nucleotide resolution. The ZFN & TALEN technologies are 
protein based systems that combine engineered DNA-binding domains (either C2H2 zinc-finger 
motifs or TAL effector repeat domains) to the non-specific nuclease domain FokI to mediate 
the DNA break (Kim et al., 1996; Bedell et al., 2012). In contrast, the type II CRISPR/Cas9 
bacterial immune system has been programmed as a PGE tool by engineering the crRNA-
tracrRNA complex as a single-guide RNA (sgRNA); by which the Cas9 nuclease is directed to 
the target site to introduce the DNA break (Barrangou et al., 2007; Jinek et al., 2012; Mali et 
al., 2013b). The CRISPR/Cas9 offer tremendous advantages over ZFN and TALENs, as it 
requires only a 20 nt short RNA sequence, which is easier to generate than to TALE repeats or 
ZFN modules (Gaj et al., 2013). The distinct feature of these nucleases to introduce DSBs at a 
predetermined region and repair by either NHEJ or HDR mechanism to knock-out/in the genes 
has been demonstrated in a range of species (Rouet et al., 1994; Anguela et al., 2013; Gaj et 
al., 2013; Tan et al., 2013; Hai et al., 2014; Remy et al., 2014; Sakuma et al., 2014; Proudfoot 
et al., 2015).  
While the PGE tools have proven to be a valuable resources to generate genetically engineered 
animals in several species, these tools have rarely been reported in use with chickens (Park et 
al., 2014). Here, to study the practicability of CRISPR/Cas9 as a future candidate technology 
in chicken transgenics, a stably integrated GFP gene expressed ubiquitously in lines of chicken 
DF-1 cells and PGCs was targeted. This work undertakes a systemic evaluation and the proof 
of targeting using CRISPR/Cas9 in the chicken fibroblast DF-1 cell line and PGCs. 
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5.2. Materials and methods  
5.2.1. Plasmids and oligonucleotides  
The miniTol2_GFP (pT2-001) and Transposase (pT2-002) plasmid system used in the study to 
generate the DF-1_GFP and PGC_GFP were kindly provided by Tim Doran’s lab (Tyack et 
al., 2013). The Cas9-coding plasmid (hCas9; Plasmid No. 41815), gRNA_cloning vector 
(Plasmid No. 41824), sgGFP-1 in the cloning vector (Plasmid No. 41820) and pSpCas9 (BB)-
2A-Puro (Plasmid No. 48139) used in this study were purchased from Addgene, USA. The 
sgGFP-2 and sgPANK1 guide-RNAs targeting the corresponding genes were designed using 
http://crispr.mit.edu/, and cloned into pSpCas9 (BB)-2A-Puro/GFP plasmids by following the 
protocol described by (Mali et al., 2013b; Ran et al., 2013). The TALEN plasmids used in this 
study were previous described by (Reyon et al. 2012). The TAL2076 (TAL_Left) (Plasmid No. 
39446) and TAL2077 (TAL_Right) (Plasmid No. 39447) were purchased from Addgene. All 
the plasmids that were purchased from the Addgene were verified by diagnostic restriction 
enzyme cut and DNA sequencing to confirm the insert. The list of primers used in this study 
to generate CRISPR/Cas9 expression plasmids were listed in the Appendix B.   
The pDsRed-Express vector (Catalogue. No. 632535, Clontech Laboratories, Inc., USA) was 
used as the base vector to clone the homology arms. The CMV promoter to drive the expression 
of DsRed was PCR amplified from peGFP-N1 vector (Catalogue No. 6085-1, Clontech 
Laboratories, Inc.) and cloned into the BamH1 and KpnI sites of pDsRed vector. To generate 
HDR templates (DsRed100 and DsRed800) the homology arms were either ordered as oligos (for 
100 bp homology) or PCR amplified (for 800 bp homology) using the primers listed in 
Appendix B. The homology arms (either 50 bp or 400 bp on left) on the 5’ end were cloned 
into the HindIII and BamHI sites. Likewise, the homology arms (either 50 bp or 400 bp on 
right) were cloned into the NotI and EcoRI sites. The poly A region was PCR amplified from 
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peGFP-N1 plasmid and cloned into NotI site that was located downstream to the DsRed coding 
sequence.  
5.2.2. Cell culture and plasmid transfection.   
The chicken fibroblast DF-1 cells (ATCC No. CRL-12203) used in this chapter was previously 
described in section 3.2.1. The DF-1_GFP line used in this study was generated by using the 
plasmids reported in (Tyack et al., 2013). Briefly, 1 μg miniTol2_GFP and 2 μg of pT2-002 
complexed with 10 μL L2000 Transfection Reagent (Life technologies, catalogue number: 
11668-019) was used to transfect 3 x 106 cells. At 3 week post-transfection, the stably 
integrated GFP cells were sorted, expanded and used in experiments.  
For GFP knockout efficiency experiments, DF-1_GFP cells were seeded at 3 x 106 cells per 
well in 6 well plate for 24 hrs prior to transfection. All the plasmids used in this study were 
formulated by L2000 by following the manufacturer instructions. 8 μl of L2000 was used to 
make the complex with either TALEN (3 μg total; 1.5 μg TAL_Right & 1.5 μg TAL_Left) or 
CRISPR/Cas9 (3 μg total; 1.5 μg of sgGFP-1 & 1.5 μg of hCas9) with appropriate control 
groups. For Surveyor assay, the primers listed in Appendix B were used to amplify the region 
across targeted GFP region. The genomic deletion of eGFP coding sequence was performed by 
formulating the 8 μl of L2000 and the two sgRNAs (i.e. 1.5 μg sgGFP-1 in gRNA vector & 1.5 
μg sgGFP-2 in pSpCas9 (BB)-2A-Puro) to transfect 3 x 106 cells per well in a 6 well plate. A 
PCR was performed using primers flanking across (Appendix B) the targeted region to detect 
the successful deletion within the GFP gene.    
For DsRed knock-in experiments, the TALEN or CRISPR/Cas9 plasmids were co-transfected 
with the donor repair template (either CMV-DsRed100 or CMV-DsRed800) at a ratio of 1:1:2 (4 
μg DNA complexed with 10 μl of L2000; 1 μg: 1 μg: 2 μg; TAL_Right: TAL_Left:DsRed-
donor or sgGFP-1:hCas9:DsRed-donor). The controls groups were transfected by substituting 
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one of the core components of either TALEN or CRISPR/Cas9 plasmids with pUC-DNA. To 
isolate the DsRed modified cells, the transfection positive cells were enriched by FACS 
machine at 2 days post-transfection, and expanded in the culture for 3 weeks. To analyse the 
precise addition of DsRed gene at the targeted GFP site, the genomic DNA is used to perform 
a junction PCR (Appendix B). The genomic DNA from the treatment and control group cells 
was extracted using DNeasy Blood & Tissue Kit.  
5.2.3. PGC culture and transfection.     
The chicken PGC line used in this study was previously established in our laboratory and a 
kind gift from Tim Doran. The PGCs were maintained and sub-passaged with knockout (KO) 
DMEM (Life technologies, Cat. No.  10829-018) supplemented with buffalo rat liver (BRL)-
conditioned media, 7.5% (vol/vol) FCS (Tissue culture lab, AAHL), 2.5% (vol/vol) chicken 
serum (Irradiated 50 kGY) (Sigma, Cat. No. C5405), 5 mL Antibiotic/antimycotic (100x) (Life 
technologies Cat. No. 15240-62), 2-Mercaptoethanol (55 mM) (Life technologies, Cat. No. 
21985-023), GSEM Supplement (50x) (Sigma Cat. No. G9785), mSCF (10 ng/μL stock) (Cat. 
No. AF250-03), hFGF-2 (10 ng/μL stock) (Peprotech Cat. No. 100-18B) (100 μg). The 
cultured PGCs were subcultured onto mitotically inactivated STO (iSTO) cells in 5 to 6 day 
interval. The PGCs were cultured in an incubator at 37 °C with an atmosphere of 5% CO2 and 
60–70% relative humidity.  
The iSTO cells were maintained in DMEM, high glucose, GlutaMAX™ Supplement, HEPES 
(Gibco, Cat. No. 10564011) 500 mL, 10% (vol/vol) FCS (Tissue culture lab, AAHL), 1% 
(vol/vol) Antibiotic/antimycotic (100x) Gibco (Cat. No. 15240-62).      
The GFP_PGC line used in this study was generated by transfection of 1 X 105 cells with 1.5 
μg miniTol2_GFP and 2 μg of pT2-002 complexed with 10 μL Lipofectamine® 2000. After 3 
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weeks post-transfection, the GFP positive cells were FACS sorted and used to establish a pure 
GFP-PGC population that express GFP.  
For TALEN or CRISPR/Cas9 transfection into PGCs, approximately 5 x 105 PGCs were co-
transfected with ratios described in the section 5.2.2.    
5.2.4. Fluorescence measurement and data analysis. 
The genome edited DF-1 or PGCs were analysed after 3-4 weeks post-transfection by using 
Fluorescence Activated Cell Sorting (FACS) machine. Briefly, approximately 1 × 106 DF-1 
cells per each group (knock-out/in) were harvested at 3 weeks post-transfection, resuspended 
in FACS buffer (1% FCS in PBS). For GFP detection, the samples were run on using BD 
FACSAria II (BD Biosciences, USA) equipped with 488 nm laser with 530/30 emission filter. 
To simultaneously detect DsRed and GFP fluorescence, the samples were run on using BD 
FACSAria III (BD Biosciences, USA) equipped with 530 nm & 561 nm lasers with 530/30 
(GFP) & 582/15 (DsRed) emission filters. From each sample, 30,000 cells were acquired and 
gated for the analysis using standard forward/side scatter (FSC/SSC) parameters. The 
percentage numbers from FACS machine analysis were standardised to their corresponding 
negative controls as indicated for each graph.  
5.2.5. Surveyor assay and DNA sequencing analysis. 
The DNA cleavage activity on targeted (modified) DF-1 cells or PGCs derived as a result of 
imperfect repair of double-stranded breaks by NHEJ by either TALEN or CRISPR/Cas9 was 
analysed using Surveyor mutation detection kit by following the manufacturer’s. Briefly, 
Genomic DNA from control and treatment groups (exclusively non-green DF-1 or PGCs) was 
extracted from the sorted after 3 weeks post-transfection. The targeted site was amplified by 
using the primer set listed in Appendix B. The treatment sample was mixed with equal amounts 
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of control PCR product (wild type GFP) DNA to form the mismatches during the DNA 
hybridisation process, while the control DNA was hybridised to itself. The hybridisation 
program was run in thermocycler for: 95°C for 10 min; 95°C to 85°C with a decrement of 
2°C/s; 85°C to 25°C with a decrement of 0.3°C/s and 4°C hold.   
5.2.6. Junction PCR for DF-1, PGC culture.  
For DsRed insertion mapping, DsRed positive cells at 3 weeks post-transfection were sorted 
and genomic DNA was extracted using DNeasy Blood & Tissue Kit. The junction PCR reaction 
was performed using a 5′ primer that was specific DsRed sequence in the donor plasmid and a 
3′ primer that was located outside the homology region (Appendix B). The PCR amplicons 
were cloned into pGEM-T easy vector and sequenced. All methods used for PCR and 
sequencing were performed by following the standard protocols recommended by 
manufactures. The junction PCR details to detect insertion of shRNAs into intron-5/PANK1 
was previously described figure 3.3.A of chapter 3.   
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5.3. Results  
5.3.1. TALEN and CRISPR/Cas9 mediated PGE in DF-1 cells.    
To investigate the application of PGE tools in chicken cells, plasmids encoding the sequences 
of TALEN or CRISPR/Cas9 targeting the GFP gene were selected  and first validated in the 
chicken fibroblast DF-1 cell line that contained stably integrated with GFP coding sequence 
(designated as DF-1_GFP from now). If the TALENs or CRISPR/Cas9 systems were able to 
introduce the targeted DSBs at the GFP sequence, the repair by error prone NHEJ mechanism 
would generate the mutations that will interrupt the ORF of GFP coding sequence. Hence, the 
appearance of GFP negative cells in the treatment groups reflects the successful PGE activity. 
At 3 weeks post-transfection, the cells were examined under a fluorescence microscope and 
observed a small proportion DF-1_GFP cells in the treatment groups (TAL_Left + TAL_Right 
or sgGFP-1 + hCas9) had become ‘non-green’ cells, presumably due to the DSBs at the GFP 
(Fig. 5.1.A). In contrast, the control groups (transfected with pUC-DNA+TAL_Left or pUC-
DNA + hCas9 or) did not show any GFP loss in DF-1_GFP cells.  
Next, the targeted cells were analysed by FACS machine to determine the percentage of 
targeted cells. The CRISPR/Cas9 mediated knockout of GFP via the NHEJ pathway was about 
~13 - 17 %, which was higher than that of TALEN with an efficiency of ~9 - 11 % (Fig 5.1.B). 
To confirm that the presence of non-green DF-1s in the wells were due to the TALEN or 
CRISPR/Cas9 mediated genomic DSB, the genomic DNA was extracted to PCR amplify GFP 
region. The PCR products derived from both the control and treatment samples were used to 
analyse the mutations at the targeted site of GFP gene by using Surveyor assay. As seen in the 
figure 5.1.C, the presence of cleavage bands after Surveyor nuclease digestion was observed 
only when the both TALEN expression plasmids were used (Fig. 5.1.C, lane 2), but not in the 
control group with a single TALEN plasmid and pUC_DNA (Fig. 5.1.C, lane 1). Similarly, the 
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cleavage bands after surveyor nuclease digestion was observed only when the both hCas9 and 
sgGFP expression plasmids were transfected (Fig. 5.1.C, lane 4), but not in the control group 
transfected with hCas9 and pUC_DNA (Fig. 5.1.C, lane 3). Furthermore, the DNA sequencing 
analysis on the derived PCR amplicons have showed the expected indels (deletions/insertions) 
at the GFP gene using both TALEN and CRISPR/Cas9 systems (Fig. 5.1.D.) 
(A) 
 
(B)                                                                                
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Figure 5.1. TALEN and CRISPR/Cas9 mediated GFP gene knockout in DF-1 cells.  
 
DF-1_GFP cells were transfected with either TALEN (TAL_Right & TAL_Left) or 
CRISPR/Cas9 (sgGFP & hCas9) expression plasmids with appropriate control groups (pUC-
DNA + hCas9 or pUC-DNA+TAL_Left) (A) Assessment of loss of GFP expression at 3 weeks 
post-transfection in CRISPR/Cas9 treatment group by fluorescence microscopy (B) The GFP 
knockout efficiency of TALEN or CRISPR/Cas9 systems compared to control without an 
enrichment of transfected cells. Results are representative of 3 separate experiments. Results 
of representative of three separate experiments. (C) Surveyor assay on the genomic DNA of 
the cells after TALEN (lane 1; control & lane 2; treatment) or CRISPR/Cas9 (lane 3 and lane 
4) mediated GFP targeting. (D) DNA sequencing result of DF-1_GFP negative cells for 
TALEN (upper) and CRISPR/Cas9 (below). The letters in the red colour represents the target 
recognition site of TALEN or CRISPR/Cas9 systems. The letters highlighted in green colour 
besides protospacer represents the PAM site. A dash in the sequence represents the deletions, 
letters in blue colour represents the insertions.    
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5.3.2. CRISPR/Cas9 mediated genomic deletion in DF-1 cells 
Given the high observed targeting frequency of CRISPR/Cas9 system in DF-1_GFP cells using 
single sgRNA, the dual sgRNA strategy to delete approximately 200 bp of stably integrated 
eGFP coding sequence was examined. The pSpCas9-BB-2A-Puro plasmid contains one guide-
RNA (sgGFP-2) and hCas9 gene, the second guide RNA (sgGFP-1) used in this study was 
expressed in guide RNA cloning vector (Fig 5.2.A). The genomic deletion event requires the 
coordinated expression of two expression plasmids in the cells. At 3 weeks post-transfection, 
the GFP negative cells were sorted and genomic DNA was extracted for PCR and DNA 
sequencing analysis. The deletions were tested by conventional PCR using the primers flanking 
the target region (Fig. 5.2.B). The genomic DNA from the cells transfected with two sgRNAs 
with Cas9 has resulted in amplification of two bands (Fig. 5.2.C lane 3), in which the lower 
band represents the large deletion in the GFP gene. As expected, the control groups pUC DNA 
(Fig. 5.2.C, lane 1) or sgGFP-2-Cas9-Puro alone ((Fig. 5.2.C, lane 2) alone did not show any 
genomic deletion. The genomic deletion in the ~ 550 bp amplicon was also confirmed by DNA 
sequencing (Fig 5.2.D).  
(A) 
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(B)                                                                                 (C) 
    
 
(D) 
 
 
Figure 5.2. Deletion of genomic integrated GFP gene segment in DF-1 cells using the 
CRISPR/Cas9 system.  
DF-1_GFP cells were transfected with indicated sgRNA and Cas9 constructs or left 
untransfected (A) Diagram of the sgGFP-1 and sgGFP-2 plasmids used in the experiment. The 
sgGFP-2 also carries the CRISPR/Cas9 coding sequence expressed by the chicken beta actin 
promoter (Cbh) (B) Schematic diagram of the GFP gene (green) with sgRNA recognition sites 
of planned deletion of ~250 bp (blue) and the PCR primers that amplify across the targeted site 
(red arrows). (C) Diagnostic PCR detection of deletion in the GFP gene, negative controls 
using pUC DNA (lane 1), only one sgRNA and hCas9 (lane 2) and two sgRNAs with Cas9 
strategy (Lane 3). (D) DNA sequencing analysis of the lower band in the lane 3 derived after 
dual sgRNA targeting. The letters in red represents the sgRNA binding sites and the letters in 
green represents the PAM sequence of the sgRNAs.  
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5.3.3. TALEN and CRISPR/Cas9 mediated targeted gene insertion in DF-1 cells.    
To assess the targeted gene insertion in DF-1 cells, the GFP targeting TALEN or CRISPR/Cas9 
expression plasmids were used to evaluate precise insertion of the DsRed coding sequence at 
the DSB induced in the GFP gene. To determine whether the length of homology arms in the 
donor repair template plays a key role in the HDR events, two donor templates (DsRed100 or 
DsRed800) with homology regions of 100 and 800 bp respectively were constructed and 
analysed. DF-1_GFP cells were co-transfected with appropriate HDR template (Fig. 5.3.A & 
Fig. 5.3.B) in the presence or absence of TALEN or CRISPR/Cas9 expression plasmids. The 
control groups were transfected with pUC_DNA and DsRed fragments to normalise the DNA 
molar quantities. At 48 hr post-transfection, the transient DsRed expression was used as a 
marker to separate the transfection positive cells, as it is expected that TALEN and 
CRISPR/Cas9 plasmids are also co-transfected into these cells. At 3 weeks post-transfection 
the cells were visualised under fluorescence microscopy to assess the expression of DsRed 
positive cells, as result of HDR of DsRed donor fragment at the targeted GFP site. As seen in 
the figure 5.3.C, the targeted DSB at GFP site has enabled the HDR of DsRed donor fragment, 
demonstrated by transformation of the DF-1_GFP phenotype cells to DF-1_DsRed phenotype 
cells. No DsRed positive cells were found in the control groups. Subsequent FACS analysis 
showed that TALEN group generated 0.4 % cells using DsRed100, whereas 1.8 % positive 
DsReds cells were generated using DsRed800 donor repair template (Fig. 5.3.D). The 
CRISPR/Cas9 plasmids generated up to 0.6 % DsRed expressing cells using DsRed100 plasmid 
as HDR template (Fig. 5.3.E), but the highest numbers of DsRed positive cells were obtained 
with combination of CRISPR/Cas9 and DsRed800 donor template with of 2.1 % DF-1_DsRed 
cells.   
To confirm the targeted insertion, DsRed specific forward primer and a genomic reverse primer 
(located outside the exchange fragments) were used for junction PCR analysis. As seen in the 
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figure 3.2.F, the precision replacement of DsRed100 repair template using TALEN (lane 2) and 
CRISPR/Cas9 (lane 4), the expected PCR product of ~800bp was obtained. Similarly, the 
expected PCR products of ~1200 bp were obtained from the genomic DNA by co-transfection 
of DsRed800 with TALEN (lane 3) and CRISPR/Cas9 (lane 5) groups (Fig. 3.2.F). The genomic 
DNA of DF-1_GFP co-transfected with pUC-DNA and DsRed800 (negative control; Fig. 3.2.F, 
lane 1) did not produce any DsRed specific amplicons demonstrating that the HDR event did 
not occur in these cells. The PCR amplicons derived from genomic DNA of cells with DsRed 
gene integration cells were cloned into pGEM-T easy vector and the integration was confirmed 
by DNA sequencing analysis (data not shown).  
(A)                                                                                    (B) 
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Figure 5.3. TALEN and CRISPR/Cas9 mediated gene knock-in in DF-1 cells. 
DF-1_GFP cells were co-transfected with either TALEN or CRISPR/Cas9 expression plasmids 
with relevant HDR template. (A) & (B) The schematic of the strategy to knock-in the DsRed 
repair template (red) with 100 bp or 800 bp homology arms (green) at the targeted GFP site 
and their primer binding sites to determine the successful HDR. (C) Representation of HDR 
mediated DsRed gene knock-in expressing in the GFP negative cells derived from the 
CRISPR/Cas9 treatment group. The knock-in efficiencies of DsRed HDR templates using (D) 
TALEN & (E) CRISPR/Cas9 into the targeted GFP gene. The percentage modified cells 
derived after co-transfection of DsRed100 and DsRed800 with TALEN (black bars) and 
CRISPR/Cas9 (white bars) plasmids. The values are the data derived from the FACS analysis 
indicating the percent modified DsRed positive cells at 3 weeks post transfection. The data 
represents three independent experiments (F) Junction PCR detection on the genomic DNA 
extracted from DsRed positive cells by using the DsRed specific forward primer and reverse 
primer outside the homology region. The amplicons in the lane 2 (TALEN) and lane 4 
(CRISPR/Cas9) represents the successful amplification of integrated DsRed100 HDR template. 
The amplicons represents in the lane 3 (TALEN) and lane 5 (CRISPR/Cas9) represents the 
successful amplification of integrated DsRed800 HDR template. 
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5.3.4. TALEN & CRISPR/Cas9 mediated GFP knockout in chicken PGCs.   
The precision engineering of chicken genome CRISPR/Cas9 system in germ-line specific (the 
primordial germ cells; PGCs) cells has not yet been reported. To investigate if the TALEN and 
CRISPR/Cas9 technologies can induce precise indels in PGCs, the stably integrated GFP gene 
was selected as the target. In contrast to the GFP KO experiment in DF-1 cells, a reporter gene 
(DsRed reporter plasmid; no homology) was co-transfected with the TALEN or CRISPR/Cas9 
to enrich transfection positive PGCs. At 3 day post-transfection, the transfection positive cells 
(based on DsRed expression) were separated by FACS sorting and expanded in the cell culture. 
After 2 weeks of cell culture expansion, a small proportion of the green PGCs in the treatment 
wells were found to be non-green (Fig. 5.4.A), indicating that both the TALEN and 
CRISPR/Cas9 systems were able to create site specific DSBs in chicken PGCs. The control 
group did not show any GFP KO events. As seen in the figure 5.4.B, the FACS plots showing 
the GFP negative were derived from the TALEN or CRISPR/Cas9 treatment wells which had 
undergone multiple rounds of transfection enrichment procedures and 5-6 weeks expansion, 
then pooled in culture. As a consequence of this process, the knockout efficiency could not be 
determined in these PGCs. The genomic DNA from the targeted cells (green + non-green) was 
used for Surveyor assay. As seen in the figure 5.3.C, cleavage bands after surveyor nuclease 
digestion was observed in treatment groups of TALEN and CRISPR/Cas9 system, but not the 
control groups. Furthermore, the DNA sequencing analysis on the PCR amplicons confirmed 
the site specific DSB of GFP (Fig. 5.1.D).   
To examine the re-migration ability of the CRISPR/Cas9 modified PGC into the embryonic 
gonads, the non-green PGCs derived from the experiments were sorted, expanded in culture 
and injected into ED 2.5 chicken embryos. Although TALEN and CRISPR/Cas9 systems have 
shown the successful targeting of GFP gene in PGCs, the remigration test was performed only 
on the non-green cells derived from CRISPR/Cas9 system. The injections were performed by 
 131 | P a g e  
 
using approximately 1500 non-green PGCs into each embryo, and the embryos were left 
incubated to ED 14. Out of 9 embryos injected, 4 embryos survived to ED14 and the gonads 
from these embryos were harvested to extract the DNA. The PCR was performed by using the 
GFP specific primers, by which, only after the successful remigration of “non-green” PGCs 
will amplify the GFP PCR product. As seen in figure 5.4.E, the amplification of GFP region 
was observed in gonads of all the four embryos (lane 1 to lane 4). The positive control of GFP 
was located in lane 5, in which the GFP positive DNA was used. The genomic DNA extracted 
from non-transgenic cells (negative control; lane 6) did not show any PCR amplification. The 
mutations in the GFP sequence from these PCR products were further confirmed by the DNA 
sequencing analysis.     
(A) 
 
 
(B) 
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Figure 5.4. TALEN and CRISPR/Cas9 mediated GFP gene knockout in PGCs. 
 
(A) GFP-PGCs were transfected with either TALEN or CRISPR/Cas9 expression plasmids 
targeting GFP with appropriate controls. The loss of functional GFP expression at 3 weeks 
post-transfection was found in treatment groups, but no effect in control group. The picture is 
a representation from CRISPR/Cas9 treatment group. (B) FACS plots for the GFP gene 
knockout efficiency from the pool of cells derived from several transfection experiments (C) 
Surveyor assay on the genomic DNA extracted from the cells after TALEN (lane 1; control & 
lane 2; treatment) or CRISPR/Cas9 (lane 3; control and lane 4; treatment) mediated GFP 
targeting. (D) DNA sequencing result of GFP-PGCs negative cells genomic DNA for TALEN 
(upper) and CRISPR/Cas9 (below). The letters in the red colour represents the target 
recognition site of TALEN or CRISPR/Cas9 systems. The letters highlighted in green colour 
besides protospacer represents the PAM site. A dash in the sequence represents the deletions 
and letters in blue colour represents the insertions. (E) The PCR amplification of GFP sequence 
from the non-green PGCs injected into embryos that were derived after the remigration (lane 
1 to lane 4). The genomic DNA of GFP-PGCs was used as positive control (lane 5) and no 
template negative control (lane 6).   
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5.3.5. Defined genomic deletion in PGCs using CRISPR/Cas9 system.   
Having successfully demonstrated the GFP gene knock-out using a single sgRNA in PGCs, the 
ability to induce defined genomic deletion using two guide RNAs was examined (Fig. 5.2.B). 
The GFP-PGCs were co-transfected with the two CRISPR/Cas9 plasmids illustrated in the 
figure 5.2.A along with a DsRed reporter gene (no homology arms) to separate the transfection 
positive cells. The transfection and enrichment procedures were repeated between 3 to 5 times 
to achieve reasonable number of cells. After 3-4 weeks post-transfection, a small proportion of 
the GFP-PGCs had transformed into non-green PGC phenotype. (Fig. 5.4.A). The non-green 
PGCs in the treatment group were sorted using FACS, and the genomic DNA was used to 
perform a diagnostic PCR across the targeted region. Consistent to the experiment in DF-1 
cells, the PCR resulted in the amplification of two bands the wild type (upper) and 
CRISPR/Cas9 targeted amplicon (lower) with ~250 bp deletion in the GFP region. The PCR 
performed on the genomic DNA extracted from a pure population of non-green PGCs under 
the same PCR condition and concentration as previously used, produced a very faint mutant 
amplicon (550 bp), indicating the fact that the two DSB events occurs at low frequency in 
PGCs (Fig 5.2.C & Fig. 5.5.A). The amplicon generated by double sgRNA targeting was 
further analysed by DNA sequencing and confirmed defined deletion of GFP fragment in PGCs 
(Fig 5.5.B).      
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Figure 5.5. CRISPR/Cas9 mediated genomic deletion in cultured PGCs.  
(A) Diagnostic PCR detection of deletion for ~250 bp fragment in the GFP gene. The upper 
band in gel represents WT or single cut, while the lower band represent the deletion using 2 
sgRNAs lane 1, 2 & 3; PCR product derived from the genomic DNA of non-green PGCs 
derived in 3 individual transfection experiments with sgGFP-1 (cloning vector) and sgGFP-2 
(pSpCas9-2A-Puro). Lane 4; the positive control of DF-1 cells carrying the deletion. Lane 5; 
negative control from untargeted GFP gene in PGCs and lane 6; 1 kb plus ladder. (B) Sequence 
comparison of GFP gene with PCR products derived in the lane 3 to confirm the deletion. The 
DNA sequence derived from the lower band was aligned with WT GFP sequence. The letters 
in the red colour represents the target recognition site of two sgRNAs targeting GFP. The letters 
highlighted besides protospacer in green colour represents the PAM site. A dash in the 
sequence represents the deletions and letters in blue colour represents the insertions. 
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5.3.6. Precision gene insertion in cultured PGCs using CRISPR/Cas9.  
Encouraged by demonstrating the ability to introduce targeted indels in cultured GFP-PGCs 
using CRISPR/Cas9, the possibility of mediating the HDR events was examined. To analyse 
the HDR mediated knock-in, the DsRed800 donor template and CRISPR/Cas9 expression 
plasmids were co-transfected into PGC_GFP. The transfection positive cells were separated by 
FACS machine after 2 days post-transfection based on the transient DsRed expression from 
DsRed800 (Fig. 5.6.B, middle FACS plot). As the transfection and targeting efficiencies in 
PGCs is relatively lower than DF-1 cells, multiple rounds of transfection and FACS enrichment 
experiments (approximately 20-25 times) were performed to analyse the HDR events. The 
PGCs were analysed for NHEJ and HDR events under the fluorescence microscope regularly. 
As expected, the control group does not show any GFP negative or DsRed positive expression 
after 3 weeks post-transfection. Although, a few cells were observed that were ‘non-green’ and 
morphologically dissimilar to PGCs in both treatment and control groups, they are most likely 
to be dead cells that perished during the process of transfection and sorting.   
The transient DsRed expression in the control groups was lost after 3-4 week post transfection. 
At 4 weeks post-transfection, very small population (1-5 cells) of non-green cells that stably 
express DsRed expression were observed (Fig. 5.6.A), demonstrating the HDR mediated 
knock-in of DsRed gene. Although the transfection was performed at various experimental 
conditions with increased DNA concentration, the efficiency of HDR events did not increased 
and that was very low than expected. In addition, the low number of DsRed positive cells that 
were obtained in this process were not sufficient to calculate the percentage of HDR events. 
However, during the process of sorting the cells, an estimation of approximately 1 DsRed 
positive cell for every 104 targeted non green cells (GFP targeted cells) were obtained. 
Moreover, the number of PGCs that survive after the sorting procedure are quite low and the 
complexity involved in the passaging of PGCs has presented numerous difficulties in attempts 
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to generate pure population of DsRed positive cells. After a series of failure attempts to 
generate the pure population DsRed positive PGCs, the combination of GFP negative (only 
NHEJ) and DsRed positive (NHEJ + HDR) were sorted to attain sufficient number of cells and 
cultured in 6 well plates prior to extract the genomic DNA (Fig. 5.6.B). The diagnostic PCR 
using DsRed specific primer (fwd) and a primer outside the 3’ homology arms (Rev) has 
derived the expected PCR amplicon only from the cells sorted mixed population of DsRed 
positive (Fig. 5.6.C, lane 3). The mixed population of PGCs containing few numbers of DsRed 
positive cells were transplanted into day 2.5 embryos to analyse their migration ability to the 
gonads. Approximately 4000-5000 PGCs were injected into each embryo to maximise the 
chances of migration of DsRed positive PGCs from the mixed population. Out of 15 embryos 
injected, 11 embryos survived to ED 14, and only 3 embryos were positive for DsRed in the 
gonads (Fig 5.6.D). These results suggest that there is a need to develop new strategies to 
enhance the HDR efficiency in cultured PGCs.  
(A) 
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 138 | P a g e  
 
(B) 
(C) 
 
(D) 
 
 
 139 | P a g e  
 
Figure 5.6. CRISPR/Cas9 mediated gene knock-in in PGCs and remigration test.  
 
(A) Microscopy assessment GFP-PGCs showing the PGE event in a diving cell (white arrows) 
at the GFP locus by precisely knocking-out the GFP gene and HDR mediated DsRed gene. 
Magnification of 100X was used for the image. (B) FACS plots derived at various stages of 
PGC manipulation, Plot 1 showing the GFP expressing cells with no modification. Plot 2 shows 
the successful co-transfection of CRISPR/Cas9 and DsRed plasmids by analysing the transient 
DsRed expression to sort the transfection positive cells. Plot 3 was shows the CRISPR/Cas9 
modified DsRed+ (top quadrant). (C) Diagnostic PCR analysis using DsRed specific forward 
primer and reverse primers located outside the homology region to analyse the HDR integration 
of DsRed800 at the targeted GFP site. The genomic DNA of GFP_PGCs (negative control; lane 
1), DsRed800 plasmid alone (negative control; lane 2) and DsRed positive PGCs after HDR of 
targeted GFP site (test; lane 3). The PCR amplification was performed for 45 cycles.                  
(D) Microscopy analysis of one of the positive gonads of ED 14 embryo from the PGC 
remigration experiment showing the DsRed and corresponding bright field images. The picture 
of the gonad was taken at the magnifications of 100X.   
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5.3.7. Multiplex genome engineering using CRISPR/Cas9.   
First, the genomic deletion of 60 bp sequence of PANK1 gene (details in chapter 3) in DF-
1_WT cells was performed by the transfection of either single sgRNAs (to create indels) or 
two sgRNA in pSpCas9-2A-GFP plasmid. The transient GFP expression from pSpCas9-2A-
GFP plasmid was used to select the transfection positive cells assuming that the Cas9 protein 
and guides targeting PANK1 gene were co-expressed from this plasmid. The transfection 
positive cells are expanded and analysed for genomic targeting by Surveyor assay (for single 
sgRNA) and PCR analysis (for genomic deletion by two sgRNAs). Unexpectedly, the Surveyor 
assay and PCR analysis on the genomic DNA of transfection positive cells (either single or 
double sgRNAs) did not show any positive results (data not shown). The specific reasons for 
the failure was not determined (Fig. 5.7.A).  
Second, to selectively enrich the mutant cells with PANK1 gene modification, the multiplexing 
of CRISPR/Cas9 system was attempted by simultaneously targeting the endogenous PANK1 
gene and the stably integrated GFP gene in DF-1_GFP cell line. To perform the multiplex 
genome engineering, the sgGFP-1 guide RNA that was effectively targeting the GFP gene was 
cloned into the guide RNA cloning vector that does not contain the Cas9 gene. In contrast, the 
sgPANK1 sequences (sgPANK1-1 or sgPANK1-2) were cloned into pSpCas9-2A-Puro vector 
that contain the Cas9 protein coding sequence (Fig. 5.7.B). The DF-1_GFP cells were co-
transfected with sgGFP-1 and sgPANK1 (single or double) constructs, and the presence of 
“non-green” cells was examined using fluorescence microscopy analysis. At 10 day post-
transfection, a proportion of DF-1_GFP cells were transformed into “non-green” cells. The 
presence of “non-green” cells in the treatment wells have confirmed the successful 
CRISPR/Cas9 mediated knock-out of GFP gene by coordination between the sg-GFP-2 
(without Cas9) & sg-PANK-1 (with Cas9) expression plasmids. Therefore, the transfection, 
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transcription and targeting of the Cas9 can be estimated by the visual screening of GFP loss, 
there by enriching these cells to analyse the PANK1 gene modification.  
To confirm the induction of indels in the PANK1 gene using multiplex approach, the green and 
non-green cells derived after the transfection were separated by FACS machine and expanded 
in cell culture for 1 week prior to the genomic DNA extraction. The genomic deletion in the 
PANK1 gene by two PANK1 guide RNAs (sgPANK1-1 and sgPANK1-2) and sgGFP-1 was 
examined by both Surveyor assay (5.7.D, lane 5 and lane 6) and PCR analysis across the 
deletion site (Fig. 5.7.C, lane 4 and lane 5) on green/non-green cells. However, the indels at 
PANK1 gene from the genomic DNA of green/non-green cells derived from the transfection 
of a single guide RNA (sgPANK1-1 or sgPANK1-2) was examined and confirmed by Surveyor 
assay (Fig. 5.7.D, lane 1 to lane 4). The PCR amplification of targeted PANK1 region of non-
green cells that were co-transfected with sgGFP-1 and two PANK1 guide RNAs has produced 
the expected mutant band (deletion of ~ 60 bp) (Fig. 5.7.C, lane 5). This was not seen in the 
green cells (Fig. 5.7.C, lane 4) or cells transfected with a single guide RNA (Fig. 5.7.D, lane 2 
and lane 3). Similarly, using the PCR products derived from the genomic DNA of cells 
transfected with single or double sgRNAs, the presence of cleavage bands after surveyor 
nuclease digestion was observed in PCR products of non-green cells (Fig. 5.7.D, lane 2, 4 and 
6), but not in the green cells (Fig. 5.7.C, lane 1, 3 and 5). The difference in the size of cleavage 
bands was due to the fact that the sgRNAs will bind at different sites within the targeted region 
of the PANK1 gene (Fig. 5.7.A).   
To enable the insertion of HDR template (pUC_Intron_MWH) into the targeted PANK1 site, 
DF-1_GFP cells were transfected with sgGFP-1, sgPANK1-1 and HDR template to examine 
the possibility of targeted insertion using multiplex approach (Fig. 5.7.E). The green/non-green 
cells derived after the transfection were separated, expanded and the genomic DNA was 
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subjected to PCR analysis using the PCR strategy-1 described in section 3.3.A of chapter 3. As 
expected, the PCR analysis on these cells did not detected any knock-in of HDR template in 
either DF-1_WT cells (Fig. 5.7.E lane 1) or green cells from experiment (Fig. 5.7.E lane 3). 
However, the precise insertion of HDR template was confirmed in the “non-green” cells 
derived after co-targeting the PANK1 gene along with GFP (Fig. 5.7.E, lane 4). The PCR 
product was subjected to DNA sequencing analysis and confirmed the targeted insertion. These 
results suggests that the co-targeting a reporter gene to analyse the functional knock-out/in of 
gene of interest could enhance the enrichment of targeted cells.   
(A) 
 
 (B) 
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Figure 5.7. Multiplex genome engineering of GFP and PANK1 gene.  
 
DF-1_GFP cells transfected with sgGFP-1 and corresponding sgPANK1-Cas9 constructs (A) 
Picture of target binding sites of sgPANK1-1 and sgPANK1-2 sequences derived from 
CRISPR guide RNA designing tool. The selected guide RNA sequences and the scores were 
highlighted in blue colour box. (B) The expression of Cas9 and sgPANK1 guide RNAs in 
pSpCas9-2A-Puro plasmid while the sgGFP-1 in guide RNA cloning vector (without Cas9). 
The function of sgGFP-1 relies on the successful transfection/transcription of the pSpCas9-2A-
Puro plasmids. (C) The schematic representation of genomic deletion at PANK1 gene by 
multiplex genome engineering approach. The PCR amplicons derived from the genomic DNA 
of untransfected DF-1_WT (lane 1), genomic DNA of green cells (lane 2) and non-green cells 
(lane 3) derived after the transfection of sgGFP-1 and only one PANK1 sgRNA. The genomic 
DNA extracted from green cells (lane 4) and non-green (lane 5) cells derived after the 
transfection of sgGFP-1 and two PANK1 guide RNAs. The lower band in the lane 5 represents 
the mutant band derived after double cut while the upper band represents the wildtype band. 
(D) The schematic representation of introducing targeted indels at the PANK1 gene using 
multiplex genome engineering. The stars (red, blue and purple) indicates the corresponding 
surveyor nuclease results transfected with sgRNAs. Surveyor assay results on sorted green cells 
(lane 1, 3, 5) and non-green cells (2, 4, 6) derived after co-transfection of sgGFP-1 with 
sgPANK1-1 (red colour stars; lane 1 & 2), sgPANK1-2 (blue colour stars; lane 3 & 4) and both 
sgPANK1-1_2 (purple colour stars; lane 5 & 6). (D) The schematic representation of precise 
insertion of HDR template into the PANK1 gene using multiplex genome engineering. DF-
1_GFP cells were co-transfected with sgGFP-1, sgPANK1-1_Cas9 and miR-30_MWH to 
introduce shRNAs into PANK1 locus. To confirm the integration, the PCR strategy-2 analysis 
(described in chapter 3, Fig. 3.3.A) was performed on the cells (green/non-green) derived after 
14 days post-transfection. The genomic DNA of DF-1_WT (lane 1), positive control for the 
integration (DF-1_MWH from chapter 3) and genomic DNA of green cells (lane 3) derived 
from multiplexing experiment. The genomic DNA of non-green cells derived after 
multiplexing strategy using GFP and PANK1 to integrate HDR template (lane 4). 
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5.4. Discussion  
Although a proof of principle study has demonstrated the TALEN mediated gene knockout in 
chickens (Park et al., 2014), a systematic and comparative evaluation of emerging PGE tools 
has yet to be reported. In an attempt to estimate the efficiencies of emerging PGE tools, a 
comparative study was conducted targeting a stably integrated GFP gene in cultured chicken 
DF-1 cells and PGCs. As chicken PGCs are known to have low transfection rate, slow doubling 
time and difficult maintain in culture (Macdonald et al., 2010), the study first focused on 
targeting a stably integrated GFP gene in DF-1 cells that maintain a high transfection rate to 
determine the efficiency of different PGE tools. The GFP knockout by both TALEN and 
CRISPR/Cas9 system was achieved at range of 10-15% without any pre-enrichment for 
transfection positive cells. The GFP gene targeted in this study was introduced into the chicken 
genome using transposable elements. Hence, the targeting efficiencies may be substantially 
different when targeting biallelic endogenous genes (Sander et al., 2011; Sakuma et al., 
2014).Taken together, the GFP knockout efficiency using TALEN or CRISPR/Cas9 in DF-
1_GFP cells was observed at higher rates. In contrast, the GFP knockout experiment in GFP-
PGCs appeared to be less efficient than DF-1 cells. However, the indels created in the 
integrated GFP gene provide proof of CRISPR/Cas9’s functionality in chicken PGCs, which 
opens the door to examining other target genes.  
Several groups have reported germ-line transmission of small indels created by ZFNs (Cui et 
al., 2011), TALENs (Park et al., 2014) or CRISPRs (Chen et al., 2014) through NHEJ mediated 
events in a wide range of species. However, indels that cause a frameshift mutation in a gene 
often produce only partial abolition of functional protein synthesis and genotyping of these 
indels in cells is labour intensive and costly. Alternatively, a pair of DSBs to produce a genomic 
deletion of a coding region or chromosome region to create a large deletion is an ideal approach 
to ensure the complete inactivation of the gene (Chen et al., 2014). For some commercial 
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applications where the use of marker genes is not possible, deletion of genomic loci that can 
be detected by simple PCR genotyping, which allows for easy screening and generation of 
knockout PGC lines or chickens is of particular interest. This study provides the first evidence 
for a large genomic deletion in chicken PGCs (Fig. 5.5.A) and signifies a major step towards 
the goal of being able to target many key genes. 
 The high efficient DSB induction in DF-1 cells at the GFP gene has enabled the testing of 
HDR mediated gene insertion. HDR mediated knock-in of genes is a complex genomic event 
and involves many proteins with different enzymatic activities (Smithies et al., 1985; Rouet et 
al., 1994; Johnson and Jasin, 2001), and thus rely on factors such as availability and design of 
donor template used for HDR. Previous studies have reported that the length of homology arms 
in a donor template plays a significant role when using transgenes that are 1.5 kb or longer 
(Orlando et al., 2010). Although, small DNA inserts containing minimal homology arms have 
the potential to recombine (Zhang et al., 1998). It is essential to increase the length of homology 
arms to compensate for the insert size (Li et al., 2014). 
In an attempt to use the optimal DsRed donor plasmid and PGE system in cultured PGCs, two 
DsRed donor plasmids in conjunction with different PGE combinations was performed in DF-
1 cells to determine the knock-in efficiencies. The data has revealed that donor plasmids with 
longer homology arms tend to integrate at higher rates than those with shorter homology arms 
in a circular donor template. In addition, linearization of either the DsRed100 or DsRed800 
plasmids significantly decreased the transfection efficiency and yielded low numbers of 
transient DsRed DF-1 positive cells (data not shown). The optimization HDR studies in DF-1 
cells showed a higher knock-in efficiency was obtained by using a CRISPR/Cas9 based system 
with an HDR donor plasmid with longer homology arms.  Thus, this was the combination used 
to test PGE in PGCs.  
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The application of PGE technology to manipulate the genomes of agricultural relevant avian 
species is just the beginning. This is particularly so in chickens, where the establishment of 
PGC cultures and subsequent injection of modified PGCs into receipt embryos is possible 
(Schusser et al., 2013; Park et al., 2014). An elegant chicken PGC knockout/knock-in 
experiment by Schusser et al. (2013) demonstrated the application of classical HR mediated 
knock-in of an eGFP gene at a targeted locus by using long homology arms, and achieved at a 
rate of 1 targeted clone for every 107 transfected PGCs. However, the recent evidence of the 
efficiency of TALEN mediated gene targeting and NHEJ mediated gene repair in chicken 
PGCs by Park et al. (2013) has prompted to test the HDR mediated knock-in, which has proven 
to be more efficient compared to the classical HR in many species (Gaj et al., 2013; Chu et al., 
2015). In this study, the HDR mediated knock-in of DsRed800 donor template at the GFP DSB 
was achieved at a much lower efficiency than expected.      
Prior research as well as the data gathered in this study suggests that there are two major 
limitations preventing HDR events in PGCs are 1) Since the metabolic growth rate and cell 
division of PGCs is relatively slow compared to other cells, the cell likely spend significant 
amounts of time in G1 phase, but not S phase. Therefore, the HDR-mediated gene repair 
process could be slower in PGCs compared to more active cell types, as it was shown 
previously that the HR mechanism is active in the dividing cells in S phase of mitosis 
(Maruyama et al., 2015). This distinct feature of PGCs proliferation is a potential disadvantage 
for efficient HDR events. 2) The low transfection efficiency of PGCs may have a significant 
effect on gene targeting. Increasing the availability of donor template for HDR by improving 
the efficiency of DNA delivery into PGCs could change this. Moreover, the current study has 
utilised only ~ 800 bp homology arms for the DsRed template, and that could possibly be the 
one of the major reasons for the obtained poor knock-in efficiency. As the length of homology 
arms play a crucial role to repair the genomic DSBs (Inbar et al., 2000), the utilisation of longer 
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homology arm could improve the HDR efficiency in PGCs. Due to the time constraints to the 
thesis, the demonstration of HDR events using longer homology arms was not performed.  
The GFP gene targeted in this study was originally integrated into the DF-1 cells and PGCs 
using Tol-2 transposons, thus they were inserted into random places in the genome, and it is 
possible that multiple copies of the GFP gene were integrated (Macdonald et al., 2012). Hence, 
the GFP integration site and copy number may potentially impact the HDR frequency with the 
DsRed repair plasmid depending on the access of the HDR template and repair machinery to 
the targeted location in the genome. The HDR efficiency obtained in this study is likely to vary 
from efficiencies obtained when targeting unique endogenous sites in the chicken genome.   
In remigration studies using the previously engineered GFP negative-DsRed positive knock-in 
PGCs, 3 out of 11 live embryos showed DsRed positive PGC remigration. As expected, the 
number of DsRed PGCs found in the gonads was lower as the injection were performed with 
mixed population of non-green and DsRed positive PGCs. In addition, in a review by (Collarini 
et al., 2015) speculated that the long-term maintenance of PGCs in culture can have effects on 
their migration and differentiation into gametes. This idea may be applicable to the current 
study to explain the poor remigration of the DsRed PGCs in embryos, as it took more than 7 
months to establish the few DsRed knock-in PGCs in culture using the CRISPR/Cas9 system.  
The poor knock-in efficiency in PGCs and the problems associated with some guide RNAs 
used in the experiments has promoted to development of new concepts and alternative methods 
to enrich the modified cells. The guide RNA sequences that were designed to target the intron-
5/PANK1 expressed in pSpCas-2A-GFP plasmid did not show positive results using normal 
transient transfection experiments. Since no successful targeting was observed in the PCR 
detection assay or Surveyor assay, it is difficult to explain the reasons behind the experiment 
failure. As a way to maximise the population of positively targeted cells to use in the PCR 
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analysis, co-targeting of GFP and PANK1 with corresponding sgRNAs was performed and 
achieved surprising results. As the sgGFP-1 guide RNA sequence was located in a vector that 
does not contain Cas9, the function of sgGFP-1 guide RNA relies on efficient co-transfection 
and transcription plasmid containing the Cas9 gene and PANK1 guide RNAs (Fig. 5.7.B). 
Therefore, the presence of non-green cells after the co-transfection confirms the expression and 
activity of Cas9 and ‘gene of interest’ guide RNAs; in this case the PANK1 gene (Fig. 5.7.C, 
D & E). The ability to use visual screening by GFP knockout to selectively enrichment a major 
the modified cells can offer tremendous advantage when working with inefficient guide RNAs, 
and could be applied for other targets. In addition, the enrichment of modified cells by co-
targeting can be a very useful tool for selection in cells that have low transfection efficiencies. 
Indeed, this approach has recently been adopted and successfully demonstrated in cultured 
PGCs within the laboratory, however that data has not been presented in this thesis.           
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CHAPTER 6: GENERAL DISCUSSION 
6.1. Summary  
 
The overall aim of this thesis was to improve shRNA expression in vivo by taking a novel 
approach to drive shRNA expression by utilising the recent advances in the field of genome 
engineering. To achieve the aims, critical experimentation was performed by bringing together 
diverse technologies such as RNAi, miRNA biology, the Tol2 transposon system, and PGE 
tools to hitch-hike exogenous shRNAs onto the miRNA processing machinery for the control 
of gene expression. Moreover, this thesis has also explored the possibilities of introducing 
precise deletions/insertions in chicken germ-line specific cells by emerging PGE technologies 
such as TALEN or the CRISPR/Cas9.  
RNAi is an eukaryotic cellular mechanism that is mediated by the RISC complex to exhibit 
targeted silencing of mRNA (including exogenous RNA sequences) initiated by double 
stranded RNA. The small RNAs such as siRNAs or miRNAs are considered as the key effector 
molecules for the RNAi mechanism. Over the last two decades, key developments in the area 
of RNAi research have not only made this technology a powerful experimental tools, but also 
a potential therapeutic strategy to treat genetic (Olson et al., 2012) and viral infectious diseases 
(Golding et al., 2006; Liu et al., 2009; Hu et al., 2015), including AI virus (Hinton et al., 2014). 
Although RNAi has been widely used in several in vitro studies, very few in vivo studies have 
been performed and those which been have had limited success.  
The suppression of AI virus transmission in chickens was demonstrated by delivering “Decoy 
RNAs” encoding anti-influenza sequences into the chicken genome (Lyall et al., 2011b). Since 
this was reported, there has been much interest in developing influenza resistant chickens using 
RNAi as an alternative approach. However, the production of transgenic chickens that 
constitutively express shRNA molecules against influenza virus has not yet been demonstrated. 
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Our laboratory has been focussed in the development of transgenic chickens with RNAi 
constructs against avian influenza. During the process of this development, the shRNA-
associated toxicity was observed in the chicken PGCs of the developing embryo when strong 
U6 promoters were used to drive the shRNAs. Importantly, decreased toxicity was observed 
when RNAi constructs with attenuated promoters were used in subsequent experiments. 
Furthermore, the number of G1 off-spring derived from the G0 chickens bearing strong pol III 
promoter was relatively low compared to the number of off-spring bred from the G0 chimeric 
chickens bearing attenuated promoters (personal communication with Dr. Tim Doran). This 
strongly indicates a direct association between the level of activity of the exogenous promoter 
and its associated toxicity in the germline specific cells.   
These results, and in conjunction with other reports in mice (Grimm et al., 2006) and pigs (Dai 
et al., 2014) has prompted to search for a more reliable approach that could overcome the 
mechanistic hurdles and  help the advancement of RNAi as a potential disease control strategy 
in chickens.  
6.2. Hitch-hiking on native miRNA expression to express anti-influenza 
shRNAs.    
The work thus far described strived to establish novel shRNA expression strategies based on 
our understanding of miRNA biogenesis. It is known that endogenous miRNAs are expressed 
at a level which is not toxic but still has biological impact. This thesis aimed to investigate if it 
is possible to achieve these naturally occurring levels of an exogenous shRNA by hitch-hiking 
shRNA expression on with miRNA expression by precisely positioning the sequences 
alongside of natural miRNAs. It is known that 30% of genes are regulated by intronic miRNAs 
(Filipowicz et al., 2008), therefore a highly expressed intronic miRNA, miR-107 which is 
located in the intron-5 of the PANK1 gene, was chosen (Glazov et al., 2008). The initial proof 
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of concept studies were performed by using the peGFP-Intron plasmid that was developed in 
our laboratory. A question remained as to which backbone structure would be effective in terms 
of processing and thus RNAi induction. Therefore, the anti-influenza siRNA sequences were 
embedded and tested in classic Brummelkamp and miR-30 structures. The utilization of anti-
influenza siRNA sequences embedded in the miR-30 structure demonstrated the highest levels 
of knockdown when corresponding segments of different influenza genes (PB, NP and NS) 
were transfected in psiCHECK-2 plasmids. Furthermore, the expression and functional 
knockdown of psiCHECK-2 reporters and virus replication by multiple shRNAs (MWH) 
expressed from two distinct (bulge & loop modification) designs was done by hitch-hiking with 
the intronic miRNA.  
Previously, the rationale for optimisation of shRNA expression strategies has been the 
development of either low strength pol II promoters (Giering et al., 2008) or by embedding the 
siRNA sequences in a miRNA structures (McBride et al., 2008). In this way, it is estimated 
that the low strength promoters does not cause high risk, whilst the processed effector siRNAs 
from miRNA based structures have less likelihood to saturate the miRNA pathway. These 
approaches can have issues as the levels of shRNA produced can be too low to mediate an 
effective knockdown. Furthermore, several reports have shown that replacement of pre-
miRNA loop sequences with the classic shRNA sequences may considerably increase 
processing efficiency (Hinton et al., 2008; Schopman et al., 2010; Gu et al., 2012). 
Nevertheless, these optimisation systems have all been based on the use of exogenous 
promoters that can have potential side effects. Boudreau et al. (2009) speculated that the key 
issues such as dosing of vectors that carry shRNAs, processing efficiency and promoter 
strength are the rate limiting factors to solve the technical problems associated with shRNAs. 
However, in their own study they found that the lowering any of these rate-limiting factors has 
significant effect on gene silencing efficacy.  
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6.3. Precision engineering and characterisation of anti-influenza shRNAs 
in DF-1 cells.  
The major aim of this thesis was to achieve stable shRNA expression by precisely engineering 
the chicken genome with shRNA molecules (a very small amount of exogenous DNA ~100 
bp) adjacent to a universally expressed miR-107 located in the intron-5 of PANK1 gene. Many 
projects use antibiotic selection or linked reporters such as EGFP to follow the integration of 
transgenes. However, to minimize any negative effects caused by inserting a large piece of 
DNA into the PANK1 gene, reporter genes were not included into the HDR construct. The only 
possible way to identify and generate the transgenic cell lines was by limiting dilution and PCR 
approach. This conventional methodology is a very slow process in terms of identifying the 
genuine clones of transgenic cell lines (Appendix A, Fig. A.3 and A.4). Inefficient ZFN 
targeting activity and repairing the double strand break made it quite rare that a genuine cell 
clone could be found with the junction PCR approach. Although laborious, the outcomes of 
this research were unique and a significant step forward compared to conventional transgenic 
RNAi, as the shRNAs were precisely modified adjacent to a native miRNA in the intronic 
region without disturbing the processing of the protein coding sequences.  
The natural levels of shRNA expression obtained with this approach will not only assist with 
decreasing the risk of shRNA-associated toxicities, but also should mediate efficient RNAi 
knockdown. This is in contrast to conventional RNAi strategies that utilise Pol-III promoters 
to drive the expression of shRNAs. Due to the ubiquitous presence of pol III activity in variety 
of cells, these promoters often lack control over the timing and location of in vivo shRNA 
expression. As miRNA mediated RNAi is believed to play a key role in a number of diverse 
cellular functions, the optimisation of artificial RNAi induction strategies is critical to avoid 
shRNA-associated toxicity. The PANK1 gene encodes member of the pantothenate kinase 
family which are known to be involved in the biosynthesis of coenzyme A (CoA) (Rock et al., 
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2002). Since CoA is an essential cofactor that mediates several oxidative and synthetic 
metabolic reactions, the changes in the gene expression after shRNA insertion could affect 
metabolism. Hence, this provides additional support for the hypothesis that any negative effects 
to gene expression after engineering the shRNA into the PANK1 locus would be deleterious 
and thus naturally counter selected.   
While the expression of three shRNAs from the mono-allelic loop_MWH transgenic DF-1 cells 
was confirmed, effective knockdown of influenza of virus was observed in the bi-allelic 
transgenic cell line with a single shRNA on two alleles. The reasons behind this result could 
be the due the strong expression of single PB shRNA from one allele coupled with the NP 
shRNA expression from the other allele (i.e. a double promoter dose). Moreover, several 
reports have shown that the knockdown of either the PB or the NP gene is sufficient to inhibit 
the replication of influenza virus (Chen et al., 2011; Hinton et al., 2014).  
This thesis demonstrates the ability to achieve precise insertion of shRNAs in the genome, and 
the expression of exogenous shRNAs under the control of an endogenous promoter, by hitch-
hiking the processing onto the processing of a miRNA. The biological activity of these 
integrated hitch-hiker constructs at the PANK1 locus provides proof of the hitch-hiking 
concept that supports exploration of other optimal intronic location of genes that are highly 
expressed in the chicken genome, with the aim to achieving robust knockdown of target genes.   
6.4. Characterisation of hitch-hiking approach using Tol2 transposon 
mediated transgenesis.  
There are significant hurdles to the application of RNAi in vivo, of which the most difficult 
might be whether shRNAs validated in vitro will exhibit similar efficacy and also not cause 
any in vivo toxicity. Our laboratory has previously demonstrated the production of transgenic 
chickens by in vivo transfection of Tol2 constructs targeting the circulating PGCs in ED 2.5 
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chicken embryos (Tyack et al., 2013). Utilizing this technology, the peGFP-Intron plasmid 
coupled with a Tol2 vector was used to mediate the stable integration of Tol2_hitch-
hiker_MWH construct into the chicken genome as a step towards in vivo analysis. Although 
this is an artificial form of the hitch-hiking concept, this simple approach with the eGFP marker 
has enabled the examination of PGC tolerance to the MWH construct with simple evaluation 
of these constructs in the gonads of a developing embryo.  
Genomic modification of PGCs with a precise insertion of a shRNA sequence without any 
marker assisted selection is likely to present significant difficulties in the clonal isolation of 
properly modified PGCs. Moreover, there is no publication that has demonstrated the 
possibility of marker-less gene knock-in using either classic HR or HDR by PGE tools in 
chicken PGCs. The results obtained in chapter 4 not only demonstrated the expression of 
shRNAs from the Tol2-Intron construct, but also confirmed that the expression levels from this 
construct do not cause in vivo toxicity as judged by the PGC–gonad recolonization assay. The 
use of the Tol2 construct to deliver the hitch-hiker constructs into the genome simplified the 
screening approach with the presence of GFP gene with-in the construct. This construct could 
be a useful alternative to the “pure hitch-hiker” strategy to quickly analyse and develop 
transgenic chickens bearing the shRNAs-of-interest.      
6.5. Evaluation of emerging PGE tools in chicken PGCs.  
Several groups have reported the production of transgenic chickens using recombinant viral or 
non-viral vectors to transfer functional genetic elements (McGrew et al., 2004; Lee et al., 2007; 
Lyall et al., 2011b; Tyack et al., 2013). However, the integration events mediated by both viral 
and non-viral vectors can pose some issues, and particularly some viral vectors tens to integrate 
with the preference of transcriptionally active areas of the genome (Wu et al., 2003). This 
feature means that there may be other unexpected, unwanted or undesirable effects on unrelated 
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gene expression when inserting a transgene. This may complicate interpretation of 
experimental results. In the context of making an animal destined for food production it will 
be certainly bring complication for the regulation and public acceptance.         
As shown in chapter 3 the pure hitch-hiker approach, for antiviral transgenes, the only method 
of identifying the transgene is by laborious PCR assay. It is therefore very important to know 
what frequency of transgene integration occurs through the required HDR events in PGCs i.e. 
will it be one in thousand, one in every hundred, one in every ten in transfected PGCs. In the 
thesis a method was devised to determine the efficiency of the genome integration which relies 
on having a chicken PGC line expressing GFP (and therefore green) and performing PGE to 
exchange the GFP with the DsRed gene. This is quicker and easier than other targets with the 
potential to generate numbers for the frequency of replacement and thus the efficiency of HDR 
PGE in PGCs. At the start of this PhD, ZFN was the only extensively used engineered nuclease 
for PGE activities. However, revolutionary developments including TALEN and 
CRISPR/Cas9 systems have come to the forefront of PGE technology in recent years. To ensure 
that this thesis could explore these emerging technologies for avian transgenesis TALEN and 
CRISPR/Cas9 plasmids encoding the targets for GFP and PANK1 gene have been developed.  
While transgenic chickens have been generated in labs around the world including our own, 
thus far there is only one publication using PGE in chickens (Park et al., 2014). That study used 
the very fastidious and laborious culture of PGCs and generated a single change with no 
phenotype observation, using a costly screening process. Previously, our laboratory has 
demonstrated a very simple technique of modifying the circulating PGCs in the blood stream 
by in vivo transfection of Tol2 constructs, and has shown the successful germ-line transmission 
of these constructs. This technique has provided new options and opportunities in avian 
transgenics and also may become an alternative approach to the use of cultured PGCs for many 
applications. At the first step, a series of experiments using different experimental conditions 
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with PGE tools were performed to assess the targeted gene knock-in/out by the in vivo 
transfection approach. To achieve this objective, the GFP was chosen to target, by injecting the 
constructs into ED 2.5 green chicken embryos and repair of DSB by HDR template containing 
the DsRed coding sequence. Unfortunately, no positive results were obtained with this 
approach (data not shown in the thesis). However, the same constructs have been shown to be 
effective in creating indels in PGCs in culture. This suggests that the in vivo transfection 
method requires a better optimised protocol and more effective enrichment to detect indels 
generated by PGE tools.   
The present study has systemically evaluated the PGE activity of TALEN and CRISPR/Cas9 
system in DF-1 and PGCs in cell culture. The superior performance that was observed with 
CRISPR/Cas9 to create indels is presumably due to its high efficient DNA unwinding activity 
(Anders et al., 2014) compared to FLASH assembly TALEN scaffold that was used, and its 
ability to bind the methylated DNA (Deng et al., 2012). Newer technologies like the second-
generation Goldy-TALEN scaffold (Bedell et al., 2012), could change this calculation though 
this was not compared directly in this study.  
6.6. Multiplex genome engineering to enrich the modified cells.   
The multiplexing strategy that was developed in this thesis, using eGFP gene knock-out to 
report the genomic DSB event in an endogenous gene provides a creative gene knock-out 
approach in chickens without any need of HDR in PGCs. The enrichment of knock-out cells 
based on parallel eGFP knock-out offers a great advantage over current transfection enrichment 
as it confirms only transfection has taken place. Indeed, this multiplexing KO strategy has been 
adopted and evaluated for two other endogenous targets with-in our laboratory, and 
demonstrated to be highly effective and reproducible technique in PGCs (data not shown in 
this thesis).  
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The development of constructs such as all-in-one CRISPR which deliver up to 7 sgRNAs 
(Sakuma et al., 2014), will be very useful for multiplexing of different targets to enrich the 
modified PGCs. However, one disadvantage of this approach is that it requires the GFP reporter 
to be integrated into the genome, and therefore will not be suitable for some commercial 
applications. Although Park et al. (2014) have demonstrated the successful germ-line 
transmission of TALEN induced mutation of an endogenous gene in chickens, the data 
presented here provides the first confirmation of CRISPR/Cas9 induced mutations in chicken 
PGCs. Moreover, this thesis provides the first evidence of deleting a section of coding region 
of genomic integrated GFP in chicken PGCs. The results discussed in chapter 5 highlights the 
great potential of PGE tools, particularly the CRISPR/Cas9 system, which promises to open 
new frontiers in avian transgenics, developmental models and for poultry health and 
production.  
6.7. Application of PGE technology in animal agriculture.  
Today, food security is recognised as a global issue due to the ever growing population, and is 
perhaps one of the highest priority in developing countries. Global food insecurity puts 
significant pressure on agriculture production systems, particularly livestock systems. 
Although selective breeding of livestock animals has significantly contributed to genetic 
improvement of modern farm animals, the process is still very slow, inefficient and often 
retains detrimental recessive genes within the genetic pool. The advent emerging PGE tools 
such as TALEN or CRISPR/Cas9 offers an unprecedented opportunity for precision genetic 
improvements in a single generation.  
The information available for the chicken genome is abundant and accurate for many genes 
providing the background necessary to exploit these new tools. The activity and specificity of 
emerging PGE tools such as TALEN and CRISPR/Cas9 are being improved at a rapid pace. 
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For instance, techniques such as direct delivery of mRNA (Tan et al., 2013) and proteins (Kim 
et al., 2014) of genes encoding PGE tools can eliminate the unwanted integration of expression 
plasmids into the host genome. All of this represents a paradigm shift away from the old 
methods of transgenesis with random genomic integration to an era of precision genetics. 
Despite many technological advances, the consumer scepticism on the safety of the technology 
used to produce the GM animals is arguably a fundamental concern for the acceptance of GM 
food as a food source.  
Recently, an extensive review by Van Eenennaam and Young (2014) has provided valuable 
insights into current standing on GE technology for food sources across various countries and 
its implications globally. The review has highlighted a comprehensive data set spanning almost 
2 decades on the consumption of GE plants by several animal species, which demonstrated that 
there have been no observable detrimental effect on animal health profiles (Van Eenennaam 
and Young, 2014). It is imperative to explore the future directions to maintain the similar 
standards of safe and effective application of emerging PGE tools. 
There is a great potential for PGE modified chickens to have a beneficial impact on future food 
security through improved production and greater resilience to disease. It is hoped that the 
findings made during this project will contribute to further improvement of the efficiency of 
genome engineering activities with chicken PGCs and will lead to innovative CRISPR/Cas9 
based applications.  
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6.8. Future directions  
The successful demonstration of the hitch-hiking approach for active RNAi in DF-1 cells and 
CRISPR/Cas9 functionality in cultured PGCs could provide the following future directions for 
this work.   
ShRNA expression by hitch-hiking with miR-107 provides proof of concept to explore a range 
of other highly expressed miRNAs in the chicken, and possibly in other animal models. 
Another interesting study to attempt would be to analyse the shRNA expression by positioning 
them in intronic regions of genes expressed with tissue specificity. If successful, this approach 
could open the doors to control the expression of exogenous shRNAs with high tissue 
specificity. This concept could be extended to use intronic regions of immune genes. Since the 
expression of immune genes is up-regulated significantly to mediate innate and adaptive 
defence, positioning of anti-viral shRNAs in the introns of these genes could enhance defence 
against virus infections. Steps towards this are underway using an intron in IFN gamma to 
express an exogenous shRNA.  
The demonstration of the presence Tol2-hitch-hiker constructs in the sperm of G0 chimera 
chickens in chapter 4 has encouraged us to breed a fully transgenic G1 chicken bearing this 
construct for characterisation in the future. The G1 founder chickens will be raised to sexual 
maturity for wild type mating’s to produce transgenic green embryos that will be tested for 
expression of multiple shRNAs. The transgenic eggs can be used to analyse their resistance to 
influenza infection in ovo. Based on the results, the chickens could further be tested to 
characterise the influenza resistance/resilience in adult birds.  
The demonstration of multiplex genome engineering using CRISPR/Cas9 in DF-1 cells by 
simultaneously targeting the GFP and PANK1 genes in Chapter 5 has provided a strong 
foundation for the possibility to generate a “pure” hitch-hiker bird. Using green PGCs, co-
targeting of GFP and PANK1 to introduce loop_MWH construct into PGCs by HDR could 
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enrich the modified cells based on the “loss of GFP reporter” selection, and subsequently allow 
production of the pure hitch-hiker bird. This would provide an opportunity to test the 
hypothesis that embryonic toxicity will be alleviated, to study any long term effects of 
constitutive RNAi expression and ultimately test any improved resilience to influenza virus 
infection.   
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APPENDIX A 
 
 
 
Figure A.1. ZFN mediated PGE of PANK1 gene. Schematic representation of intron-5 region 
of PANK1 target sequence where the ZFN pair bind and create the DSB. The sequence of miR-
107 (annotated at 1281 bp to 1361bp) and the ZFNs target sequence (highlighted in oval shape). 
 
Exon 5 Exon  6 Intron 5 
ZFN target 
site miR107  
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Figure A.2 Targeted insertion of shRNA at intron-5: ZFN mediated targetted DSB creation 
adjacent to miR-107 using a pair of ZFNs. Schematic of Homology directed repair (HDR) 
template (miR-30_NP or miR-30_PB cloned into pUC-Intron) to mediate the precise insertion 
at the ZFN targeted site.      
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Figure A.3. Experimental outline of limiting dilution procedure.   
DF1 cells were seeded at 4 x 106 cells in a 6 well plate, transfected with ZFN pair and HDR 
template at indicated concentrations. On day 3, DNA is harvested and PCR was performed 
with either PB or NP specific primer (exogenous primer) or a primer upstream from ZFN cut 
side (not present in donor template). If genomic insertion of donor template occurs, a weak 
band (approximately 1000 bp) can be expected in PCR on the DNA extracted from cell pool. 
Since a very low number of cells will be modified in the total population, a limiting dilution of 
cells was performed to select clonally the genuine cells that carry the HDR template. Cells 
from 6 well plates were seeded at 50 cells/mL and diluted across in a 96 well plate. After 3 
weeks of expansion, the cells were transferred to a 24 well plate and expanded for 1-2 weeks. 
A junction PCR is performed on 24 well plate clones, assuming some of those colonies are 
transgenic cells and the colonies with precise insertion were subjected to additional rounds of 
screening to establish pure cell population.   
 
 
 
50 
cells   
25 
cells   
12 
cells   
6 cells   1-3 cells   
Step 2 
 Limiting dilution  
to isolate  
 Clonal population  
3 weeks expansion  
Step 1 
Transfection 3 × 106 cells.   
(ZFN pair + Intron-shRNA) 
 
Step 3 
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(C) 
 
Figure A.4. Clonal isolation of ZFN modified cell lines.  
 
The isolation of pure population of ZFN modified DF1 cells. The isolation of genuine ZFN 
modified (A) DF1_NP and (B) DF1_PB cell lines. The PCR strategy-2 using the primers 
spanning across the site has produced two PCR amplicons demonstrating the targeted insertion 
of miR-30_NP shRNA in DF1_NP (7 clones) and miR-30_PB shRNA in DF1_PB (16 clones). 
The upper band (500 bp) represents the WT band, while the lower band (300 bp) represents the 
mutant band with shRNA insertion. The PCR strategy-1 using  Screen_7_Fwd and Rev_NP 
and Screen_7_Fwd and Rev_PB has derived the expected PCR amplicons only in the genomic 
DNA of corresponding ZFN modified cells, but not in the DF1_WT cell line.  (C) The isolation 
of bi-allelic modified DF1_PB-NP cell line. The PCR strategy-2 has produced a single PCR 
amplicon (300 bp) demonstrating the targeted insertion of miR-30_NP and miR-30_PB shRNA 
on two allelles in 5 DF-1 ZFN modified clones. The PCR strategy-1 using Screen_7_Fwd and 
Rev_NP and Screen_7_Fwd and Rev_PB has derived the expected PCR amplicons using the 
genomic DNA of DF1_PB-NP, but not in the DF1_WT cell line.  
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Table A.1. The list of primers used in this study.  
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